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Introduction  
and  
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Chapter 1
Introduction
This thesis focuses on different aspects of vulvar Paget disease (VPD). 
After a review of the history of this rare disease, the anatomy of the vulva 
is explained, followed by the pathogenesis and treatment of vulvar carci-
nomas. Concluded by an outline of this thesis on VPD.
The history of vulvar Paget disease
Sir James Paget (1814-1899), was the surgeon of the English royal family. 
He had a great interest in pathology. Together with Rudolf Virchow, he is 
considered to be one of the founders of modern scientific medical pathol-
ogy. 
In 1877, he was the first to describe a chronic inflammation of the bone, in 
which the formation and breakdown of the bones was disturbed, causing 
multiple deformities.1 This disease is nowadays well known as Paget’s dis-
ease of the bone, or osteitis deformans. After osteoporosis, it is the second 
most common disease of the bones in the elderly.2
In 1874, Sir James Paget published a paper on a nipple ulceration.3 He 
had seen 15 women, with a chronic, eczema-like nipple ulceration, that 
all developed a malignancy of the mammary glands afterwards. He raised 
the question whether this skin eruption was a precursor for an underlying 
malignancy or invaded into the breast. Nowadays, we call this skin dis-
ease Paget’s disease of the breast, or mammary Paget disease (MPD), and 
is diagnosed when Paget cells are seen in the epithelium. Of all patients 
with MPD, 55% have an underlying invasive ductal carcinoma of the 
breast, and 35% has the premalignancy called ductal carcinoma in situ 
(DCIS).4 DCIS is premalignant but aggressive, and therefore it is treated as 
a malignancy. MPD, with or without an underlying carcinoma or DCIS, is 
treated according to guidelines for breast cancer in general.
In response to Sir Paget’s paper on MPD, Crocker reported a case of peno-
scrotal Paget disease in 1889.5 Two years later the first case of vulvar  Paget 
disease was reported by a French dermatologist, William Dubreuilh.6 Ever 
since, when located elsewhere than the breasts, the skin disease is called 
extramammary Paget disease (EMPD). Alternative names are related to 
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specific locations of the skin disease: for example VPD, or penoscrotal 
Paget disease. EMPD, irrespective of location, is also diagnosed when the 
same Paget cells as in MPD are seen in the epithelium.
Breast cancer, or a premalignancy such as DCIS, are commonly seen in 
MPD. VPD has comparable signs and symptoms as MPD, and in both dis-
eases Paget cells are present in the epithelium. Therefore, from the first 
report of VPD, it is thought that these diseases are related. It still remains 
unclear how these diseases are related, and even if they are related. The 
tissue of the breast resembles the tissue of the vulva, suggesting a similar 
pathological mechanism causing both diseases. However, EMPD has also 
been reported in the hair-bearing skin of the axilla and ear canal. Thus, 
EMPD can also be seen in different parts of the hair-bearing skin.
Little is known about VPD, as it is extremely rare. The exact incidence is 
unknown, nor is the natural course of disease. To optimise care for pa-
tients with VPD, it is necessary to understand the disease better.
The vulva
The vulva is the external part of the female reproductive tract. The basic 
anatomy of the vulva is presented in figure 1.7 
The orifices of the urethra and vagina are located in the centre of the vulva; 
the vestibule. The vestibule is lined by the clitoral frenulum, labia minora, 
medial labia majora, and the fourchette. The vagina is separated from the 
vulva by the hymen. The major labia are hair-bearing on the lateral side 
and fuse into the mons pubis on the anterior side, and into the perineum 
on the posterior side. The tissue in between the major and minor labia is 
called the interlabial sulcus. The anus and the perianal skin are strictly 
not part of the vulva, but may be involved in genital skin disease.
The outer part of the vulva consists mainly of keratinised squamous epi-
thelium. The so-called Hart’s line separates the keratinised epithelium 
of the outer part of the vulva from the inner non-keratinised epithelium. 
The urethra in females does not contain typical transitional cells as the 
urethra in males does, but consists of glycogen rich stratified squamous 
epithelium like the vagina and ectocervix.
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The mons pubis, the lateral part of the labia majora and peri-anal skin 
are hair-bearing and besides hair follicles, also contain pillosebaceous 
glands and adnexal glands: eccrine or apocrine sweat glands and seba-
ceous glands. The medial part of the labia majora does not contain hair 
follicles, but does contain sebaceous glands along Hart’s line. 
The vulvar vestibule contains three main types of mucinous glands: Bar-
tholin’s glands, also known as the major vestibular glands, the minor 
vestibular glands, and Skene’s ducts. Bartholin’s glands are located on 
either side of the distal vaginal orifice. The epithelium contains mucus-se-
creting columnar cells, secreting in Bartholin’s duct. Bartholin’s duct is 
lined by transitional epithelium, adjacent to columnar epithelium, which 
is adjacent to the non-keratinised stratified squamous epithelium of the 
vulvar vestibulum. The minor vestibular glands are multiple simple tu-
Figure 1 Basic anatomy of the vulva
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Vulvar Cancer
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bular glands lined with mucus-secreting columnar epithelium, blending 
into the stratified squamous cells of the vulvar vestibule. Skene ducts are 
located bilaterally and immediately posterolateral of the urethra. These 
glands (counter parts of the male prostate) are lined with pseudo-stratified 
mucus-secreting columnar epithelial cells, and the ducts with transitional 
type cells adjacent to the stratified squamous cells at the duct’s orifice.
Vulvar cancer
Clinical characteristics
All cells in the human body have a malignant potential, including those 
of the vulva. Figure 2 presents an overview of the different types of vul-
var malignancies. Actual data on the incidence of the different types is 
unknown. It is thought that about 90% of the vulvar malignancies are 
epithelial, of which 80% are of the squamous cell type. In the Netherlands, 
Figure 2 Flow-chart of different types of vulvar malignancies
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little over 400 women are diagnosed with a vulvar malignancy every year, 
representing +/- 5% of all gynaecological malignancies.8 
About 8% of the vulvar malignancies are the basal cell carcinomas (BCC).9 
BCC is a relatively common malignancy with good prognosis and little 
risks for metastases. BCCs occur over the entire body; about 2% are lo-
cated on the vulva. 
Pathogenesis of vulvar carcinoma
In vulvar squamous cell carcinoma (VSCC) the pathogenesis is quite es-
tablished. Two different pathways can be recognised: the human papil-
loma virus (HPV) positive and HPV negative pathway. Most cases, about 
80%, are HPV negative and are thought to arise from differentiated vulvar 
intraepithelial neoplasia (dVIN), a premalignancy often seen in the auto-
immune disease Lichen Sclerosus. HPV positive VSCC are often preceded 
by the premalignancy high grade squamous intraepithelial lesion (HSIL), 
previously known as usual VIN (uVIN).10
The pathogenesis of BCCs is unclear. It is currently thought they originate 
from pluri-potent cells in the basal layer of the epidermis, or pilloseba-
ceous unit.11
Glandular malignancies are a separate entity, and are most commonly called 
adenocarcinomas. The vulvar adenocarcinoma is rare, so little knowledge 
is available. ‘Adenocarcinomas’ originate from the glandular epithelium or 
mucosal tissues, for example of the vulva, breast or intestine. Adenocarci-
nomas originating from a specific gland or tissue type may be considered as 
a separate entity, with a specific name. The most common cause of a vul-
var adenocarcinoma is supposedly the rare skin disorder VPD. Other types 
of primary vulvar glandular malignancies are Bartholin gland tumours, 
Skene gland tumours, mammary-like-gland tumours and sweat gland tu-
mours.12-14 These glandular malignancies are rare, and may seldomly be 
seen by a pathologist. The origin of these glandular malignancies of the 
vulva is unknown: there are no specific genetic, microbiological or other 
causes identified for the development of a vulvar glandular malignancy. 
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Treatment of vulvar carcinoma
In the Netherlands, care for patients with a vulvar carcinoma is centralised 
since 2009. All cases should be treated in tertiary centres by gynaecologic 
oncologists, except for BCC. In general, surgery with or without adjuvant 
treatment is the treatment of choice. Because vulvar glandular malignan-
cies are extremely rare, there is no specific guideline for these types of 
malignancies. Therefore, these are treated according the (local) guidelines 
for VSCC.
Outline of thesis
This thesis investigates glandular malignancies of the vulva, with specific 
attention to VPD, a skin disorder which is considered to be an adenocar-
cinoma in situ with a malignant potential. Little research on this disease 
has been performed in the last decades. In the recent years, care for pa-
tients with vulvar disease has been improved due to specialised vulvar 
clinics and new treatment methods. This thesis aims to improve care for 
patients with VPD by evaluating the most evident clinical challenges.
We investigated the incidence and survival of glandular malignancies of 
the vulva in the Netherlands in chapter 2, with the use of pathology re-
ports of all cases in the Netherlands between 2000 and 2015, supple-
mented with data from the National Cancer Registry. 
One of the main origins of vulvar glandular malignancies is VPD. VPD 
may be of a primary cutaneous origin, or secondary to an intestinal or 
urological malignancy. In chapter 3 we reviewed literature on the clinical 
symptoms, diagnosis, treatment and survival of VPD patients. This raised 
some additional questions, which we explored in further chapters.
To understand the clinical course of VPD, we reviewed the medical charts 
of all patients in eight tertiary university medical centres. Chapter 4 gives 
an overview of most common clinical aspects of the disease, and the im-
pact of VPD on survival.
In chapter 5 we investigated whether patients with VPD have a higher 
risk of developing other malignancies associated with the disease once di-
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agnosed with VPD. We used the histology reports of all patients diagnosed 
with VPD in the Netherlands between 2000 and 2015. We investigated 
whether the risk was increased and whether routine screening is neces-
sary in the work-up of patients with non-invasive cutaneous VPD. 
The origin of VPD remains uncertain. It is speculated that primary VPD 
originates from the skin adnexa, mammary-like-glands or Toker cells. 
Non-cutaneous VPD may be secondary to intestinal or urological malig-
nancies, but where the typical Paget cells arise in these malignancies is 
unknown. In chapter 6 we reported an extremely rare case of retrograde 
cervical spread of VPD secondary to an intestinal malignancy. We geneti-
cally proved all lesions originate from the same tumour with p53 analysis. 
In skin samples of primary VPD, we often see an immune infiltrate. This 
may be a component in the development of clinical symptoms, or may play 
a role in new treatment options. Therefore we investigated which immune 
cells are present in the immune infiltrate in non-invasive primary VPD in 
chapter 7 and compared our findings to those in vulvar HSIL and healthy 
controls. 
In chapter 8 we present the protocol of a clinical trial investigating topical 
5% imiquimod cream for non-invasive VPD. 
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Abstract
Aim: There is limited knowledge in the field of glandular vulvar malig-
nancies. The aim of this study is to describe the incidence and survival of 
women with glandular vulvar malignancies.
Methods: We searched PALGA, a nation-wide database registering all his-
to- and cytopathology in the Netherlands, for all cases of glandular vul-
var malignancies between 2000 and 2015. Additional data were retrieved 
via the Netherlands Cancer Registry. Incidence rates were calculated per 
1,000,000 women per year. Five-year net survival rates were calculated.
Results: We identified 197 patients with a glandular vulvar malignancy. 
Of these patients 55% had a primary malignancy while 45% had second-
ary malignancies: expansion of another tumour in 17%, and metastases 
or recurrences of another malignancy in 28%. There is a great variety 
of different diagnoses of primary vulvar malignancies: 11 different types 
were identified. We found an overall incidence rate of glandular vulvar 
malignancies of 0.9 – 2.5 per 1,000,000 women per year. Five-year net 
survival for patients with a primary malignancy was 68.5%. Most of the 
secondary vulvar malignancies originated from (ano-)rectal malignancies.
Conclusion: Glandular vulvar malignancies are extremely rare and pri-
mary tumours are slightly more common. Overall survival of patients with 
primary glandular vulvar malignancies is comparable to patients with a 
vulvar squamous cell carcinoma, with five-year survival around 70%. The 
great variety in diagnoses combined with the low incidence should lead 
to routine pathologic revision and treatment in specialised gynaecologic 
oncology centres. 
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Vulvar Cancer
Epithelial Non-epithelial
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Glandular type:
- Adenocarcinoma
- Adenoid cystic carcinoma
- Adenosquamous carcinoma
- (Micro-) invasive vulvar Paget disease
- Mammary Like Gland tumours
- Neuroendocrine malignancy
- Signet ring cell carcinoma
- Skin appendages malignancy
Background
In the Netherlands the incidence of vulvar cancer was 4 per 100,000 wom-
en in 2015,1 representing 7% of all gynaecological malignancies. Primary 
vulvar malignancies can be divided into epithelial and non-epithelial ma-
lignancies, figure 1 presents an overview of the different types. More than 
80% of the cases are of the squamous cell type.2,3 Vulvar melanomas and 
basocellular carcinomas are less common.3 Epithelial carcinomas of the 
extremely rare adenotype are called glandular tumours altogether and 
consist of several diagnoses. 
Figure 1 Overview of different types of primary vulvar cancer.
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The most common and ambiguous term for a glandular vulvar malignancy 
is vulvar adenocarcinoma. Invasive vulvar Paget disease (VPD) and Bar-
tholin’s gland tumours are the most common adenocarcinomas. Tumours 
of the skin appendages and mammary-like-gland (MLG) tumours are ex-
tremely rare.4,5 Besides these primary adenocarcinomas, several case re-
ports are published about patients with secondary vulvar metastases of 
other primary malignancies, such as: breast,6 colon,7 lungs,8 or other gy-
naecological malignancies.9-11
In contrast to vulvar squamous cell carcinomas (VSCC), with a human 
papilloma virus related and a lichen sclerosus related pathway, the onco-
genesis of glandular vulvar malignancies is unknown. Furthermore, there 
are no recent data on the incidence rates, nor on the survival rates of pa-
tients with these glandular vulvar malignancies. 
In the Netherlands, centralization of care for patients with VSCC in spe-
cialised oncology centres was implemented in 2000 with beneficial effects 
on survival.12 The national guideline states all vulvar malignancies except 
vulvar basal cell carcinomas should be treated in specialised oncology cen-
tres.13 Due to its rarity, there is no disease specific guideline for manage-
ment of glandular malignancies of the vulva in general; patients with glan-
dular vulvar malignancies are treated according to the guidelines for VSCC. 
This national study aims to present the incidence rate and survival of pa-
tients with various types of glandular vulvar malignancies.
Methods
Patient selection
We performed a search in the PALGA database, a nationwide network 
and registry of histo- and cytopathology in the Netherlands (~17 million 
inhabitants). The PALGA network has national coverage since 1991. We 
selected all women with a diagnosis of an invasive glandular malignancy 
of the vulva between 2000 and 2015 (ICD-O: C51.0-9). We excluded cases 
with a benign diagnosis, basal cell carcinoma, Merkel cell carcinoma, car-
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cinosarcoma, (myo-)epithelial carcinoma, or spindle cell carcinoma. Cases 
in which the diagnosis was not specified, e.g.: carcinoma, undifferentiated 
carcinoma, were also excluded. 
We matched the cases of invasive glandular vulvar malignancies to the 
Netherlands Cancer Registry (NCR) based on age, and date of diagnosis for 
additional clinical data. We retrieved data on morphology, TNM classifi-
cation, FIGO stage, differentiation grade, and treatment. The Netherlands 
Comprehensive Cancer Organization (IKNL) maintains the NCR by docu-
menting all primary malignancies in the Netherlands, and has national 
coverage since 1989. Information on the vital status and date of death is 
obtained by annual linkage to the Municipal Personal Records Database, 
and was available up to 1 February 2016.
Tumour characteristics are reported according to the International Classifi-
cation of Diseases for Oncology (ICD-O) and the Tumours Node Metastasis 
(TNM) classification guidelines.14 The quality of the NCR is ensured by regu-
lar consistency checks, and completeness is estimated to be at least 95%.15,16 
Statistical analysis
Incidence rates were calculated for the most common diagnoses per 
1,000,000 women per year. The number of inhabitants was obtained from 
Statistics Netherlands, and categorised per year and 5 year age category.17 
To obtain an estimation of the probability of survival of glandular vulvar 
tumours in the absence of other causes of death, we calculated net sur-
vival using the Porhar-Perme estimator, since this has been shown to be 
an unbiased estimator of net survival. Results of this estimator can be 
interpreted as survival in the hypothetical world where it is not possible to 
die from other causes. This allows the data to be compared with data from 
other countries.18 Actuarial survival time was calculated from the date 
of diagnosis to the date of death or February 1st 2016, whichever came 
first. We analysed survival of two different groups: early stage defined as 
FIGO Stage I or II, and advanced stage defined as FIGO stages III and IV. 
Difference in survival rate between groups were analysed visualised with 
the 95% confidence intervals (CI). All analyses were performed using Mic-
rosoft Office Excel 2007, STATA software (STATA Corporation, 2002) and 
SPSS for Windows, version 20.
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Results
Population 
We identified 197 patients with a glandular malignancy of the vulva in 
the Netherlands between 2000 and 2015. Overall, 108 patients (54.8%) 
had a primary glandular vulvar malignancy and 89 (45.2%) had a vul-
var malignancy secondary to another malignancy. Secondary glandular 
vulvar malignancies can be divided into expansive growth of an internal 
malignancy, or a metastasis of another malignancy, see figure 2. Addition-
al clinical data for 71 (65.7%) of the patients with a primary tumour was 
available through the NCR. 
See table 1 for an overview of the different primary glandular vulvar ma-
lignancies. Each year, an average of seven primary glandular malignan-
Figure 2  Distribution of diagnoses.
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cies of the vulva were diagnosed. Furthermore, an average of six cases of 
secondary malignancies were diagnosed each year. These data represent a 
crude incidence rate of 0.47 to 1.3 per 1,000,000 women per year for pri-
mary, and 0.47 to 1.2 for secondary glandular vulvar malignancies. The 
overall median age at diagnosis was 69 years (range 26-97).
Primary glandular vulvar malignancies
The median age of patients with a primary glandular malignancy was 71 
(range 26-93) at time of diagnosis. FIGO stage was reported for 54 (50%): 
39 patients (72.2%) had early stage disease, and 15 had advanced stage 
disease. Treatment was available for 80 patients (74.1%) with a primary 
glandular malignancy: 56 underwent surgery (51.9%), 17 (15.7%) received 
(neo-)adjuvant radiotherapy or chemotherapy besides surgery. Four pa-
Primary malignancies Secondary metastasis / 
recurrence
Secondary expansion
Adenoid cystic 
carcinoma
11 (10%) Adenocarcinoma 
NOS
2 (3.6%) Anal malignancy 1 (3.0%)
Adenosquamous 
carcinoma
2 (1.8%) Breast malig-
nancy
2 (3.6%) Endometrial 
malignancy
2 (6.0%)
(Micro-) invasive 
VPD
33 (30.1%) Cervical malig-
nancy
3 (5.3%) PUIN 1 (3.0%)
MLG-tumour 5 (4.6%) Coecal carci-
noma
1 (1.8%) Rectal carcino-
ma
17 (51.5%)
Mucinous ade-
nocarcinoma
3 (2.8%) Endometrial 
malignancy
9 (16.0%) Signet ring cell 
carcinoma
1 (3.0%)
Neuroendocrine 
tumour
6 (5.5%) Lung malig-
nancy
3 (5.3%) Transitional cell 
carcinoma
1 (3.0%)
Signet ring cell 
carcinoma
1 (0.9%) Neuroendocrine 
carcinoma
1 (1.8%) Urethral adeno-
carcinoma
3 (9.1%)
Transitional cell 
carcinoma
2 (1.8%) Ovarian carci-
noma
3 (5.3%) Urothelial cell 
carcinoma
7 (21.2%)
Tumour of the 
skin appendages
21 (19.3%) Signet ring cell 
carcinoma
2 (3.6%)
Vulvar adeno-
carcinoma
24 (22.0%) Rectal carcino-
ma
22 (39.3%)
Renal cell carci-
noma
1 (1.8%)
Urothelial cell 
carcinoma
7 (12.5%)
TOTAL 108 56 33
Table 1 Overview of specific diagnosis.
NOS: not otherwise specified, MLG: mammary-like-gland, PUIN: Pagetoid Urothelial In-
traepithelial Neoplasia, VPD: vulvar Paget disease.
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tients (3.7%) received radiotherapy only, two patients (1.9%) received 
other, not specified, treatment, and one patient (0.9%) did not have any 
treatment. 
Of the 108 patients with a primary vulvar malignancy, 10 (9.3%) had 
breast cancer before or after the diagnosis of their vulvar malignancy. 
Ten patients (9.3%) were diagnosed with intestinal malignancies before or 
after the diagnosis of their vulvar malignancy, and 3 (2.8%) with a uro-
logical malignancy. Twenty-two patients were diagnosed with other malig-
nancies, the most frequent tumours were squamous cell carcinoma of the 
skin (5), endometrial cancer (5), and cervical cancer (3).
Table 2 reports the clinical characteristics of patients diagnosed with the 
most common primary glandular vulvar malignancies: (micro)invasive 
VPD, adenocarcinoma NOS (not otherwise specified), malignancy of the 
skin appendages, or adenoid cystic carcinoma. Invasive VPD was reported 
in 22 cases, and micro-invasive VPD in 11 cases. In two cases of invasive 
VPD characteristics of a vulvar squamous cell carcinoma were mentioned 
in the histology report. Twenty-six patients were diagnosed with an adeno-
carcinoma NOS, in four cases there was evidence of VPD or characteristics 
of a VSCC in the tumour. In six cases of adenocarcinoma NOS Bartholin’s 
gland was reported to be the origin of the malignancy. Of the 21 reported 
malignancies of the skin appendages, five were specified as malignancies 
(Micro-) 
invasive VPD 
(n=33)
Adenocarci-
noma NOS 
(n=26)
Skin ap-
pendages 
(n=21)
Adenoid cys-
tic carcinoma 
(n=11)
Median age (range) 74 (50-89) 71.5 (43-89) 65 (26-92) 68 (30-78)
FIGO stage, n (%):
- Early (I or II)
- Advanced (III or IV)
- Unknown
11 (33.3%)
3 (9%)
19 (57.7%)
4 (15.4%)
4 (15.4%)
18 (69.2%)
11 (52.4%)
2 (9.5%)
8 (38.1%)
6 (54.5%)
2 (18.1%)
3 (27.4%)
Primary treatment, n (%):
- Surgery
- Surgery + RT/CT
- RT
- Other
- None
- Unknown
21 (63.6%)
4 (12.1%)
0
0
0
8 (24.3%)
7 (26.9%)
3 (11.5%)
2 (7.7%)
1 (3.8%)
1 (3.8%)
12 (46.3%)
14 (66.7%)
0
0
0
0
7 (33.3%)
4 (36.4%)
4 (36.4%)
0
1 (9%)
0
2 (18.2%)
Table 2 Clinical characteristics of most common primary glandular vulvar malignancies.
VPD: vulvar Paget disease, NOS: not otherwise specified.
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of the sebaceous glands, 10 of the apocrine or eccrine sweat glands, and 
one of the hair follicle. In eight of the eleven adenoid cystic carcinomas, 
Bartholin’s gland was specifically reported as the origin of the malignancy. 
Survival
Five-year net survival for primary glandular vulvar malignancies was 
68.5% (95%CI 50.9-80.7%). For early stage disease it was 69.9% (95%CI 
44.1-85.5%), whereas it was 36.1% (95%CI 12.1-61.2%) for advanced 
stage disease, see figure 3. The FIGO stage of 54 (76%) of the patients 
was available. Most deaths (78.6%) occurred in the first two years after 
diagnosis. 
Secondary glandular vulvar malignancies
Tumour expansion to the vulva
Overall, 33 cases were reported as an expansion of another malignancy to 
the vulva. The median age of the patients at time of diagnosis was 68 years 
(range 44-97). The vulvar lesions expanded from an intestinal tumour in 
19 patients, a urological malignancy in 12, and another gynaecological 
malignancy in 2 patients. 
Figure 3 Five-year net survival, early versus advanced stage disease. 
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Most lesions were reported to be located at the labia: 14 cases. In eight 
patients the vulvar lesion was located at the perineum and in four at the 
peri-anal skin, these 12 lesions expanded from an intestinal malignancy. 
Vulvar expansion of urological malignancies was seen around the urethra 
in five of the 12 cases (41.7%) that originated from a urological malignancy. 
In 13 cases (39.4%), the pathology report suggested the presence of an 
internal malignancy, or the internal malignancy was diagnosed by histo-
logical examination of the vulvar lesion. 
In 16 patients (48.5%), the vulvar lesion was diagnosed either before or at 
the same time as the internal malignancy. In eight cases, the vulvar lesion 
was diagnosed within half a year (24.2%), and in two cases within a year 
(6.1%) after diagnosis of the internal malignancy. In four patients (12.1%) 
the vulvar lesion was diagnosed more than a year after the initial diagno-
ses, in these cases the vulvar lesion was an expansion of a recurrent uro-
logical or intestinal malignancy. Two cases (6.1%) were diagnosed more 
than two years after the initial diagnosis, and it can be debated whether 
the vulvar lesion should have been reported as a recurrence or metastasis 
rather than an expansion.
Tumour metastasis or recurrence to the vulva
Overall, 56 cases were reported as distant metastases of other malignan-
cies to the vulva. The pathology reports lacked standardised terminology 
to be able to distinguish vulvar metastases from vulvar recurrences of oth-
er malignancies. We defined metastasis as a vulvar lesion diagnosed at the 
same time as the primary malignancy. Vulvar lesions that were diagnosed 
after the primary malignancy are reported as vulvar recurrences. The me-
dian age at time of diagnosis of the vulvar lesion was 66 (range 33-89). 
Most lesions originated from intestinal malignancies: 25 (44.6%), lesions 
originated from gynaecological malignancies in 15 (26.8%), and urological 
malignancies in eight (14.3%) patients. Other malignancies metastasised 
to, or recurred at the vulva in six (10.7%) patients, and from an unknown 
primary malignancy in two (3.6%) patients. Most vulvar metastases and 
recurrences originating from an intestinal malignancy were located at the 
perineum or peri-anal skin: 21 cases.
In six cases (10.7%) the vulvar lesion was diagnosed at the same time as 
the internal malignancy, or revealed the presence of another malignancy. 
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These cases were metastases from endometrial cancer (2), ovarian cancer 
(1), lung cancer (1), urothelial carcinoma (1), and of an unknown origin 
(1). Four vulvar recurrences (7.1%) were diagnosed within half a year, and 
eight (14.3%) within a year. The other 38 patients (67.9%) had a vulvar 
recurrence more than 12 months after the diagnosis of the primary tu-
mour. The median time between the primary diagnosis and diagnosis of 
the vulvar recurrence for these patients was 39.5 months (range 14-298 
months).
Twelve patients had one or more recurrences, besides the vulvar metas-
tasis, of their internal malignancy. The internal malignancy metastasised 
only to the genital skin in 38 patients. Others had metastases to the gen-
ital skin and the pelvis (3), lung (2), pleura (2), peritoneum (1), retro peri-
toneum (1), or intestine (3). 
Discussion
To our knowledge, this is the first population-based study with national 
coverage to present the incidence and outcome of rare glandular vulvar 
malignancies over a significant time period. Most studies on rare diseas-
es entail small single-institute case series or retrospective institutional 
reviews, lacking power to present accurate incidence rates. Based on na-
tional data of 15 years, the incidence of glandular vulvar malignancies can 
be estimated at 0.9 to 2.5 per 1,000,000 women per year. Primary glan-
dular tumours are slightly more common than secondary glandular vul-
var tumours: 54.8% versus 45.2%. The most common primary diagnoses 
were (micro)invasive VPD, adenocarcinoma NOS, malignancy of the skin 
appendages, and adenoid cystic carcinoma. Secondary glandular vulvar 
malignancies were most commonly caused by expansion, metastases, or 
recurrences of intestinal malignancies. 
The five-year net survival of primary glandular vulvar malignancies was 
68.5%, which is comparable to the five-year survival in patients with the 
more common VSCC in the Netherlands.19-21 In VSCC, prognosis is influ-
enced by stage of disease. We therefore also analysed survival data for 
FIGO stages ≤ II compared to FIGO stage > II. Five-year net survival in 
early stage disease was 69.9% and 36.1% in advanced stage, which is also 
comparable to survival rates in VSCC.22 However, due to missing data of 
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the FIGO stage in a quarter of the patients and the small sample size, this 
analysis should be interpreted with caution. Sufficient data on the cause 
of death lacked; therefore we were unable to calculate the disease specific 
survival.
In secondary vulvar malignancies, the pathology report suggested or re-
vealed the presence of another malignancy in about half of the cases. The 
importance of adequate pathological diagnosis is emphasised. 
As glandular vulvar carcinomas are rare, expertise is necessary. The 
hodgepodge of diagnoses indicates the extreme difficulty of accurately di-
agnosing vulvar pathology. Because of the rarity of these diagnoses, pa-
thologists seldomly encounter these kind of cases. Therefore it may be 
assumed that interobserver variability is extremely high. Many publica-
tions have paid attention to the difficulty of diagnosing glandular vulvar 
lesions, and notice many different entities are reported.23,24 However, there 
is still little knowledge on the possible oncogenesis of all different lesions. 
The heterogeneity of glandular skin malignancies, especially of the skin 
adnexa and the so-called mammary like glands, is pointed out in sever-
al previous publications.25,26 The clinical characteristics of these different 
diagnoses vary, and influence the treatment options and prognosis of the 
patient. Therefore, there is high need for a collaboration between pathol-
ogists specialised in dermato- and/or gynaecopathology. A standardised, 
and perhaps simplified, classification of these lesions, might prevent the 
development of an abundance of pathological diagnoses. Revision of the 
pathological sample as well as treatment should take place in a special-
ised gynaecologic oncology centre.
In conclusion, though the overall sample size of our study is relatively 
small, we present an overview of the population-based incidence of glan-
dular vulvar malignancies. Because of the great variety in diagnoses, it is 
difficult to define any clinical implications at this moment. Vulvar glandu-
lar tumours are rare with an incidence of 0.9 to 2.5 per 1,000,000 women 
per year. About half of the cases are primary vulvar glandular malignan-
cies, the other half is secondary to other internal malignancies. Survival 
of patients with a primary glandular vulvar malignancy is comparable to 
survival of patients with a VSCC. To improve health care for patients with 
these rare malignancies, more research into the oncogenesis and biologi-
cal characteristics should be conducted. Revision of histological samples 
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by an expert (gynaeco-) pathologist should be standard care. Patients with 
these rare malignancies should be treated at specialised gynaecologic on-
cology centres. 
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Abstract
In this review, we provide an overview of the clinical aspects, histopathol-
ogy, molecular genetics, and treatment options for Vulvar Paget’s Dis-
ease (VPD), a rare skin disease, most commonly found in postmenopausal 
Caucasian women. The underlying cause of VPD remains not well un-
derstood. VPD is rarely associated with an underlying urogenital, gastro-
intestinal or vulvar carcinoma. In approximately 25% of the cases, VPD 
is invasive; in these cases, the prognosis is worse than in non-invasive 
cases. Recurrence rates in invasive VPD are high: 33% in cases with clear 
margins, and even higher when surgical margins are not clear, regard-
less of invasion. Historically, surgical excision has been the treatment of 
choice. Recent studies show that imiquimod cream may be an effective 
and safe alternative.
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Introduction
Sir James Paget (1814–1899) was a surgeon with a special interest in 
pathology and physiology. In addition to his work as a surgeon for the 
English royal family and his practice in London, he wrote ‘Lectures on 
Surgical Pathology’, a work that established him as one of the founders 
of modern pathology along with Rudolf Virchow.1 Sir James Paget is best 
known for his paper describing a nipple ulceration that was associated 
with an underlying breast carcinoma.2 That paper reported a series of 
15 cases of chronic skin eruption of the nipple and areola, a condition 
that is now referred to as mammary Paget disease. In 1889, shortly after 
James Paget’s report, Crocker described the first case of Paget disease on 
extramammary skin, a case involving penoscrotal Paget disease.3 In 1901, 
Paget disease of the vulva was described for the first time by a French der-
matologist, William Dubreuilh.4 Mammary and extramammary Paget dis-
ease are characterised by the presence of intraepithelial mucin-producing 
neoplastic cells known as Paget cells. However, the exact origin of these 
cells remains unclear.5 This review presents an overview of the current 
literature on invasive and non-invasive VPD, including its epidemiology, 
clinical aspects, histopathology, treatment options, and survival.
Methods
Data sources
Relevant publications were identified by a computer search in the PubMed 
database (date of last search April 9th 2015). We searched the database us-
ing combinations of the following terms: ‘Paget’s disease’, ‘Paget disease, 
extramammary’ or ‘Paget’ in title and text. Subsequently, these terms were 
combined with ‘vulva’, ‘vulvar’, ‘vulval’, ‘genitalia’, ‘perianal’ or ‘anogenital’. 
The button ‘related articles’ in PubMed and reference lists from selected ar-
ticles were used to identify additional papers. Also, gynaecologic oncology, 
pathology and dermatology handbooks were used. Overall, 852 studies were 
found, 324 studies were not available in full-text and after assessment of all 
titles and abstracts, 298 were considered relevant. Main reasons for exclu-
sion were: extramammary Paget disease in males, or locations other than 
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the vulva. The remaining publications on VPD were considered for inclusion 
in this review if they reported one of the topics mentioned in this review. Of 
these 298 studies 230 reported clinical or histopathological data of patients 
with VPD, including 79 case-reports and 53 case series with <10 patients. 
We prepared tables of clinical data based on studies that included 10 pa-
tients or more, to ensure the size of the tables remained manageable. Stud-
ies that reported on both male and female patients with EMPD were consid-
ered for inclusion. However, we only used data of female patients with EMPD 
located on the (ano)genital skin, unless there was no data on VPD available.
Terminology
In this review, the terms mammary Paget disease (MPD) will be used for 
Paget disease of the breast, and extramammary Paget disease (EMPD) will 
be used for other locations, including the anogenital skin in males. The 
term vulvar Paget disease (VPD) will be used for a disease location in the 
genital area in females, including the perineal and perianal skin.
Clinical characteristics
Epidemiology
Only one study presents the occurrence of MPD versus EMPD: 90% of 
all cases of Paget disease are MPD and 10% of all cases of Paget disease 
are EMPD.6 The overall European incidence of EMPD is 0.7 per 100,000 
persons per year, and is slightly higher for women than men. A study in 
16 European countries reported 871 cases of invasive EMPD in 13 years, 
including 231 male and 640 female patients.7 Of the 640 female patients, 
disease was located at the vulva in 533 patients (83%), 3 cases were re-
ported as ‘Paget disease of the female genital tract, not otherwise specified’ 
(0.5%), and 21 cases were reported as ‘Paget disease of the anal canal 
and perianal skin’ (3%). VPD is reported to occur most often in postmeno-
pausal Caucasian women. In the Asian population, EMPD is seen mostly 
in males,8 but there is considerable literature describing VPD in Asian 
women.9-14 However, the exact incidence of VPD is unknown.
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EMPD may be associated with underlying vulvar adenocarcinoma. Inva-
sive VPD represents 1%–2% of all vulvar carcinomas.15 A Dutch epidemi-
ology study including 226 cases of EMPD over a 13-year period found that 
178 (79%) cases were invasive and 48 (21%) non-invasive. When the data 
were categorised by location, invasive VPD (n=59) was reported twice as 
often as non-invasive VPD (n=32).16 These data were taken from the Neth-
erlands Cancer Registry, which may have resulted in underreporting of 
non-invasive disease. Most clinical studies used Wilkinson’s classification, 
and report invasion in 16-19% of the cases, and a vulvar adenocarcinoma 
in 4-17% of all cases.17-19 Moreover, VPD might not be recognised and thus 
be underreported if no skin biopsy is performed to confirm the diagnosis.
Origin of extramammary Paget disease
The origin of EMPD has not been clarified, although there are currently 
three theories. The first suggests that EMPD has an intraepidermal ori-
gin from adnexal structures, like apocrine glands, multipotent stem cells 
in the epidermal basal layer or infundibular stem cells of the hair folli-
cle.15,20,21 EMPD is typically located in the hair-bearing skin of the axilla or 
genital area which supports the disease origins from adnexal structures. 
Although, VPD can also occur in the modified mucosa of the interlabial 
sulcus, or, in advanced cases, in the glycogenated mucosa without adnexal 
structures,22-24 which supports another theory suggesting that Paget cells 
originate from mammary-like glands, which are located in the interlabial 
sulci.25 A more recent theory is that Toker cells are precursor cells in MPD 
as well as in EMPD and VPD.26,27 Toker cells have a single round nucleus 
and pale cytoplasm and are usually found in the nipple and areola.28,29
Signs and symptoms
In the majority of patients, VPD causes symptoms such as irritation, 
itching, and burning. VPD can be asymptomatic in some patients: about 
5%–15% of patients have no symptoms at the time of diagnosis.30,31 Upon 
physical examination, VPD presents as an erythematous plaque with typ-
ical white scaling known as “cake-icing scaling”. It is a clinical chameleon 
as it can present with a variety of colours and macular or plaque-like pre-
sentation. The plaque may be ulcerated and crusted with a papillomatous 
Paget’s disease of the vulva
37 
surface, as shown in Figures 1 and 2. The symptoms experienced by the 
patient are not always related to the extent of the visible lesion. 
Studies have shown that symptoms are typically present for an average 
of almost 2 years before the diagnosis is made, due to both patient and 
doctor delays.31-33 There is limited knowledge regarding the natural course 
of VPD, as most study reports describe patients who have undergone sur-
gery. The ‘Radiumhemmet series’ of 28 women describes 4 patients with 
untreated VPD. Of these four women, two women were inoperable and two 
women refused surgery. Both inoperable patients died of other causes. 
One of the two women who refused surgery died of a squamous cell car-
cinoma (SCC) of the vagina, and the other patient had progressive VPD.34 
Diagnosis
In cases of suspected VPD, an accurate medical history should be tak-
en, including a history of vulvovaginal complaints and gastrointestinal 
and urological symptoms. In addition, a full gynaecological examination 
Figure 1 Peri-anal Paget’s disease. 
Poorly demarcerated erythematous perianal 
plaque with small erosions and white scaling.
Figure 2 Vulvar Paget’s disease. 
White hyperkeratotic plaque with 
typical ‘cake-icing’ scaling with 
small superficial erosions on the 
right labium majus.
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should be performed that includes vulvar, vaginal, and rectal examina-
tions. All raised, pigmented, or otherwise suspicious lesions should be ad-
dressed appropriately by a thorough report, digital photography, and his-
tological examination. Digital photographs can help monitoring the course 
of the disease. Invasive disease should be excluded, preferably by vulvar 
mapping, including multiple biopsies of the involved and surrounding un-
involved skin. In case of a small unifocal lesion, it can be considered to 
perform a single biopsy, in which the visible lesion is completely excised. 
The diagnosis is confirmed by the histological presence of Paget cells. 
Differential diagnosis
In addition to eczema and vulvovaginal candidiasis, the differential diag-
nosis of VPD consists of psoriasis, lichen simplex chronicus, lichen scle-
rosus, lichen planus, differentiated vulvar intraepithelial neoplasia (VIN) 
or usual VIN (synonymous: high grade squamous intraepithelial lesion, 
or HSIL), SCC, histiocytosis, condylomata acuminata and melanoma. In 
addition to these clinical diagnoses, a histological differential diagnosis 
of intraepithelial Pagetoid cells can include the following: melanoma (in 
situ), pagetoid spitz naevus, sebaceous carcinoma, clear cell papulosis, 
eccrine porocarcinoma, cutaneous T-cell lymphoma, and Langerhans cell 
microabscess.33,35,36
Classification
The World Health Organization (WHO) defines VPD as ‘an intraepithelial 
neoplasm of epithelial origin expressing apocrine or eccrine glandular-like 
features and characterised by distinctive large cells with prominent cy-
toplasm, referred to as Paget cells’.37 In the International Society for the 
Study of Vulvovaginal Disease (ISSVD) Terminology and Classification of 
Vulvar Dermatologic Disorders (2011), VPD is assigned to the morpholog-
ical group 2, described as ‘Red lesions, patches and plaques’ and to sub-
group B, ‘Red patches and plaques (no epithelial disruption)’.38
In 2001, Wilkinson et al. proposed a histopathological classification of 
VPD that distinguishes primary/cutaneous VPD (type 1) from secondary/
non-cutaneous VPD.39,40 
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As shown in table 1, secondary VPD originates from a malignancy of the 
gastrointestinal tract (type 2) or the urogenital tract (type 3).41 In cases of 
pagetoid extension of an urothelial carcinoma, the term pagetoid urothe-
lial intraepithelial neoplasia (PUIN) may be used. The current literature 
often refers to Wilkinson’s classification, which is mainly based on the 
histopathological features of VPD. 
However, this classification is no longer supported by the most recent WHO 
Classification of Tumours of Female Reproductive Organs (4th edition).37 
Moreover, it is a matter of debate whether non-cutaneous EMPD should be 
regarded as a form of VPD. Some consider it a direct extension (‘pagetoid 
spread’) of an intestinal or urothelial malignancy and use immunohisto-
chemistry to distinguish primary from secondary VPD.42 There are no ac-
curate data regarding the distribution of types 2 and 3 versus type 1 VPD. 
Together with Wilkinson’s classification, the subdivision of cutaneous and 
non-cutaneous EMPD is regularly used in current literature.
Cutaneous VPD (type 1) is further subdivided according to the presence or 
absence of dermal invasion: type 1a (intraepithelial disease), is reported to 
account for 75%–81% of all primary VPD cases, type 1b in 16%–19% and 
type 1c in 4%–17% of all cases.17-19 In contrast, 60% or more of patients 
with MPD have an underlying breast malignancy.43 It is hypothesised that 
Paget cells migrate from the epidermis to the dermis in type 1b and that 
in type 1c the Paget cells have migrated into the epidermis (“pagetoid 
spread”) from an underlying vulvar adenocarcinoma.
Most studies do not report the definition of ‘invasive VPD’ or ‘vulvar ade-
nocarcinoma’ that was used. Some described dermal invasion as ‘invasion 
>1 mm’. Curtin et al. defined vulvar adenocarcinoma as invasive ade-
nocarcinoma of sweat gland origin.44 Lee et al. defined invasive VPD as 
Primary VPD  
(cutaneous)
Type 1a Cutaneous vulvar non-invasive Paget’s disease
Type 1b Cutaneous vulvar invasive disease: dermal invasion of Paget 
cells
Type 1c Cutaneous vulvar disease as a manifestation of an underly-
ing vulvar adenocarcinoma
Secondary VPD 
(non-cutaneous)
Type 2 VPD originates from rectal or anal adenocarcinoma
Type 3 VPD originates from urogenital neoplasia
Table 1 Classification of vulvar Paget disease by Wilkinson.39,40 
EMPD: Extramammary Paget’s disease.
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Paget disease with in situ involvement of the underlying sweat glands and 
defined vulvar adenocarcinoma as an invasive adnexal adenocarcinoma.45 
Because most studies lack clear definitions of invasive VPD and vulvar 
adenocarcinoma, we are unable to present an overview of the incidence 
distribution of non-invasive VPD, invasive VPD, and VPD with an under-
lying adenocarcinoma. 
Associated malignancies
Patients diagnosed with EMPD are reported to have a higher risk of de-
veloping a second primary cancer, especially the first year after diagnosis 
(standardised incidence ratio of 1.39 with a 95% CI of 1.11 to1.73).7 VPD 
is reported to be associated with other malignancies in 11%–54% of the 
cases, including malignancies of the breast, vagina, cervix, uterus, ovary, 
gallbladder, and liver.19,45-47 However, some studies consider an underly-
ing vulvar, rectal, or urothelial carcinoma to be an associated malignancy, 
whereas others reserve this term for distant malignancies. Data need to 
be interpreted with caution, since most studies reporting on associated 
malignancies had no adequate age matched control groups. 
A total of 15 studies with 10 or more patients, reported intestinal or uro-
logical malignancies in patients with VPD.14,31,34,48-59 Of the 456 included 
patients 10 (2.2%) had intestinal malignancies, and 18 (3.9%) had uro-
logical malignancies. Five patients were reported to have VPD and a si-
multaneous bladder carcinoma (1.1%) and 3 patients (0.7%) had an anal 
carcinoma that occurred simultaneously with VPD.48,52,54,59 Twenty-six 
studies with 10 patients or more reported that 51 (3.2%) of the included 
1598 patients had a history of breast cancer.14,17-19,31,33,34,45-47,49-53,55,56,58-66 
The time relative to the diagnosis of VPD varied greatly. Based on current-
ly available literature it is not proven that there is a clinical relationship 
between VPD and breast cancer.
Excluding other malignancies
There is no current consensus if women with VPD should be screened for 
associated malignancies, or which additional tests should be performed. 
Because of the presumed association of VPD with locoregional and distant 
Paget’s disease of the vulva
41 
malignancies, guidelines advise excluding the presence of other malig-
nancies, although the proposed policies vary. The Royal College of Obste-
tricians and Gynaecologists states that “the gastrointestinal and urinary 
tracts and the breasts should be checked”,67 and that “women with VPD 
should have prolonged follow-up in a multidisciplinary vulvar clinic or by 
a gynaecological oncologist”.68 The U.S. Department of Health & Human 
Services advises, “evaluate the breasts, genitourinary, and gastrointesti-
nal tract (level C evidence: consensus and expert opinion)”.69 
Histopathological diagnosis
Histological characteristics
Histologically, VPD is characterised by the presence of large oval or poly-
hedral intraepithelial cells that have pale cytoplasm and large nuclei with 
prominent nucleoli, these cells are the so-called Paget cells. Paget cells 
can be visualised using haematoxylin and eosin (HE) staining. They are 
arranged either singly or in clusters throughout the epithelium to a vari-
able extent, and may form a lumen or gland-like structures. Sometimes 
reactive changes are seen in the surrounding epithelial surface, such as 
acanthosis, papillomatosis, and hyperkeratosis; these changes in them-
selves are not sufficient for diagnosis. A lichenoid inflammatory infiltrate 
can be seen in the underlying papillary dermis. The scattered Paget cells 
are diagnostic, but they are interspersed within the normal epithelium 
and can be difficult to detect at times (figures 3 and 4). 
In the pathologic assessment of VPD, it is important to exclude invasive 
growth. This is challenging because it is not uncommon for VPD to extend 
into the adnexal structures. An additional problem is the frequent pres-
ence of a dense infiltrate that can obscure the epithelial/stromal interface. 
Invasion is characterised by the presence of dyscohesive neoplastic Paget 
cells infiltrating the underlying dermis or submucosa (figures 5 and 6). In 
case of invasion, the pathologist is required to report the depth of inva-
sion, as this has proven prognostic significance and determines the type 
of treatment.70,71 
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Figure 4 A: Non-invasive vulvar Paget’s disease (HE, 100x), B: CK7 stained cells (100x). 
Large pale solitary cells and cell nests are present throughout the thickened hyperplastic 
epidermis. With CK7 it is clearly depicted that there is no invasive growth in the underly-
ing vulvar stroma. 
Figure 3 Non-invasive vulvar Paget’s disease (HE stain, 100x). 
Solitary cells and large cell nests are present in the lower parts of the epidermis (arrows). 
The Paget cells have pale cytoplasm and large rounded atypical nuclei. There is no inva-
sive growth.
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Figure 5 A: Micro-invasive vulvar Paget’s disease (HE, 100x) B: Detail (HE, 200x). 
Some large atypical pale cells and cell nests are present in the basal layers of the vulvar 
epithelium. At magnification it is shown that two small cell clusters have invaded the un-
derlying vulvar stroma (arrows). The invasive growth is less than 1 mm. 
Figure 6 A: Invasive Paget’s disease with underlying anogenital invasive adenocarcino-
ma (HE, 100x), B: CK7 stained cells (100x). 
At left a poorly differentiated adenocarcinoma is present directly under the hyperplastic 
thickened vulvar epithelium. With CK7 immunostaining it is depicted that tumour cells 
spread alongside the basal parts and rete ridges of the vulvar epithelium.
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Immunohistochemistry
A number of immunohistochemical stains can be used to distinguish cu-
taneous VPD from its histological mimics. Paget cells can be highlighted 
by PAS reaction and/or by immunohistochemistry, as they are usually 
positive for cytokeratin (CK) 7 and carcinoembryonic antigen (CEA).36,72,73 
They do not express markers of squamous cell differentiation, such as 
p63 and p40, and these markers can therefore be used to exclude squa-
mous intraepithelial lesions such as uVIN, also known as HPV-induced 
HSIL with a pagetoid growth.74,75 However, VPD may over express p16 and 
mimic uVIN (or: HPV-induced H-SIL), which strongly over express p16 as 
well.76,77 In addition, Paget cells do not express melanocyte markers, such 
as Mel-A, HMB45 or S100, and this can help distinguish VPD from (in 
situ) melanoma. Paget cells may express androgen receptors, but in gen-
eral are negative for estrogen and progesterone receptors.78-81
Immunohistochemistry can also be helpful in determining the primary 
location of an underlying adenocarcinoma. For example, pagetoid ex-
tension of urothelial cancer will likely express CK20, uroplakin-III, and 
GATA-3,36,81 whereas CK20, CDx2, and MUC2 positivity might indicate an 
underlying anorectal adenocarcinoma.36,73,82 It is therefore recommended 
that a combination of these markers be used in cases in which pagetoid 
extension from an underlying adenocarcinoma is suspected.83 Because 
of the rarity of a co-existent intestinal and/or urological we suggest this 
may be performed in cases in which the patient has a clinical suspicion 
of an underlying intestinal and/or urological tumour. See table 2 for an 
overview of the expression patterns of common markers.
Tumour microenvironment
Studies of the local tumour microenvironment of VPD are limited, and have 
not investigated the types of cells present in the immune infiltrate. Only 
specific markers have been investigated, such as regulatory T-cells (Tregs) 
that suppress effector T-cells. Tregs express Foxp3, CD4, and CD25 (or IL-
2-Rα), and high numbers of Tregs are associated with adverse clinical out-
comes in several types of cancer.84-86 A study of Tregs in 44 cases of VPD 
showed that Tregs are frequently found at the epidermal-dermal junction 
whereas the surrounding healthy skin is negative for Tregs.59 That study 
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also described a correlation between the number of FOXP3+ Tregs and 
positive surgical margins and recurrence.59 The percentage of Tregs is 
significantly higher in non-invasive EMPD than in invasive EMPD, while 
CD163+ macrophages are detected more frequently in invasive EMPD.84
Genetic profile 
Given the rarity of VPD, there are limited data on genetic alterations in 
VPD, and this field is therefore largely unexplored. Her2/Neu amplifica-
tion is probably the most studied genetic alteration in VPD, likely because 
of its therapeutic potential and its association with mammary Paget dis-
ease. HER-2/Neu overexpression is found in 70%–100% of MPD cases.87,88 
However, the reported frequency of Her2/Neu amplification in EMPD var-
ies significantly.89,90 Small series and case reports have investigated var-
ious genetic abnormalities: mutations in the PIK3CA (Phosphatidylinosi-
tol-4,5-Bisphosphate 3-Kinase, Catalytic Subunit Alpha) gene, divergent 
DLC1 (Deleted in Liver Cancer 1) methylation, single nuclear polymor-
phism in the XRCC1 (X-ray repair cross-complementing protein 1) gene, 
chromosome 7 gains and X chromosome losses have been described.91-93 
However, the clinical significance of these abnormalities remains to be 
determined. 
CEA p63 CK7 CK20 Uro-III GATA-3 CDx2 MUC2 GCDFP-15
Primary  
cutaneous VPD 
(type 1)
+ - + - - - - - +
Secondary to 
intestinal  
malignancy
(type 2)
+ - - + - - + + -
Secondary to  
urological malig-
nancy
(type 3)
+ + +/- + + + - - -
Table 2 Overview of common expression patterns in vulvar Paget disease.
CEA: carcinoembryonic antigen, CK: cytokeratin, Uro-III: uroplakin-III, MUC2: mucin 2, 
GCDFP-15: Gross cystic disease fluid protein.
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Treatment
Traditionally, the treatment of choice for VPD is surgical excision.
Surgery
Surgical treatment of VPD consists mainly of wide local excision, with 
or without inguinofemoral lymph node dissection.31,33,94 A inguinofemoral 
lymphadenectomy is indicated in cases showing invasive VPD (>1 mm). 
The main clinical challenge of wide local excision is obtaining clear sur-
gical margins; it is unclear what the surgical margin should be in VPD, 
as Paget disease spreads microscopically throughout the epidermis. This 
makes it difficult to determine the complete extent and spread of the le-
sion.95 Paget cells may be difficult to recognise on frozen sections: frozen 
section evaluation in EMPD is reported to have a false negative rate rang-
ing from 10.4% to 13.2%.96,97 The relationship between surgical margin 
status and recurrence rates remains unclear. 
In Mohs microsurgery (MMS) the vulvar lesion is excised through the epi-
dermis and dermis, and 100% of the peripheral margins are examined im-
mediately.98 Excision is repeated, enlarging the circumference each time, 
until the margins are clear. MMS was reported to be used for VPD for the 
first time in 1991,99 after 90 years of surgical treatment consisting of wide 
local excision or (hemi-)vulvectomy.
For large lesions, different plastic surgery methods for reconstruction of 
large vulvovaginal defects have been reported and include local fasciocu-
taneous flaps, gluteal fold flaps, pudendal thigh flaps, and gracilis myocu-
taneous flaps.100-103
Sentinel lymph node
There are no studies on the accuracy of sentinel lymph node (SLN) biop-
sies in invasive VPD. The current literature describes SLN only sporadical-
ly in cases with microinvasive VPD,104 and in cases with suspected lymph 
node metastases.105,106 However, based on current knowledge of surgery 
for vulvar SCC, microinvasion is not an indication for SLN, and uni- or bi-
lateral inguinofemoral lymphadenectomy is indicated in cases of invasive 
VPD (>1 mm) with clinically suspected lymph node involvement. 
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Complications of surgery
Vulvar surgery is associated with significant morbidity. Local vulvar com-
plications consist mainly of infection, hematomas, and wound breakdown, 
with incidence rates for wound breakdown ranging from 9%–45%.107-109 
According to quality of life assessments, extensive surgery, such as radical 
vulvectomy, tends to cause more discomfort than wide local excision.110 
The incidence of complications after inguinofemoral lymphadenectomy 
ranges from 17.5%–84%. Early complications (<1 month after surgery) 
are mainly lymphocyst formation, wound breakdown, and infection of the 
wound. Late complications (≥1 month after surgery) include lymphedema, 
leg pain, and erysipelas.109,111-113 
Psychosexual complications
There are no studies concerning the psychosexual effects of vulvar surgery 
in VPD. One study showed that women with a history of vulvar excision 
for VIN more frequently reported sexual function impairment and worse 
quality of life than healthy women.114 However, two other studies showed 
no significant differences in quality of life and sexual function between 
patients surgically treated for VIN, Bowen’s disease, or VPD and a healthy 
population.115,116 In patients who underwent vulvar surgery for vulvar car-
cinoma or carcinoma in situ, there was no correlation between the extent 
of the surgery, the type of vulvectomy, and sexual dysfunction severity. 
Elderly women were more likely to stop sexual activity after such surgery, 
and women with high depression scores more often had sexual aversion 
disorder, increases in body image disturbance, and sexual dysfunction.117 
Following vulvar surgery for VIN, older women had lower quality of life 
and lower sexual function according to the Female Sexual Function Index 
questionnaire compared to younger women.114 
Non-surgical treatment
Surgery for VPD is not always possible or desirable due to the location or 
size of the lesion or due to patient factors or preferences. In addition, re-
currence rates after surgical treatment are high and morbidity is impres-
sive.30,33 There is thus a pressing need for alternative treatment options 
for VPD.
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Topical imiquimod cream
Imiquimod is registered for the treatment of condylomata acuminata, su-
perficial BCCs, and actinic keratosis. It has also shown to be effective in 
the off label treatment of usual VIN in randomised controlled trials.118,119 
Imiquimod, a toll-like receptor (TLR) 7 agonist, is an immune response 
modifier. It triggers immune cells to produce cytokines, including inter-
feron-α, interleukin 1, 6, and 8, and TNF-α.120 It also indirectly stimulates 
the production of pro-inflammatory T helper type 1 cytokines. In the skin, 
imiquimod activates Langerhans cells, which enhance antigen presenta-
tion to T cells. 
A few observational studies and case reports have shown imiquimod to 
be effective for the treatment of perineal, scrotal, and inguinal Paget dis-
ease.121 Topical imiquimod cream for the treatment of recurrent VPD was 
first described by Wang et al. in 2003,122 and subsequently around 25 
retrospective case series were published on the use of topical imiquimod 
cream in non-invasive VPD. The treatment schedules differed widely in 
these studies, ranging from daily application to application three times a 
week. The duration of the treatment ranged from 5 to 26 weeks, and fol-
low-up ranged from 2 to 55 months. In these studies, a total of 64 women 
with VPD were treated with imiquimod cream; 56 (88%) had an objective 
clinical response, 43 (67%) had a complete response, and 13 (21%) had 
a partial response. Only 8 women were reported to have residual disease 
after treatment.57,123-143 Figure 7 shows a patient from our clinic who has 
obtained a complete response with topical 5% imiquimod treatment.
Figure 7 Extended vulvar Paget’s disease before (A), during (B), after (C) treatment with 
topical 5% imiquimod cream.
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A recent observational study examined the effectiveness of imiquimod 
cream in 10 patients with non-invasive VPD.144 The patients were treated 
for 5 to 7 months. Nine patients had a complete response, and one patient 
had a partial response. Local skin reactions like pain and ulceration were 
reported in this cohort without systemic reaction. We found 16 publi-
cations reporting adverse events in 59 patients.57,125-127,129-134,136-138 A local 
adverse reaction, such as pain, ulceration, or inflammation, was reported 
in 16 patients.57,122,129-134,136,137 Five patients reduced the application fre-
quency or stopped for one or more weeks because of these adverse reac-
tions.122,126,143 In most cases, the severity of adverse effects as reported by 
the patient was reduced after 4 or 5 weeks of treatment. The recurrence 
rate after treatment with topical imiquimod cream for VPD is unknown. 
Overall imiquimod seems to be effective, but treatment schedules differ 
greatly between the studies, and there may be a high risk of publication 
bias.
Chemotherapy
Chemotherapy for metastatic EMPD has been reported in one small study 
(n=7).145 The clinical response of 4 patients after FECOM therapy (com-
bination therapy with 5-fluorouracil, epirubicin, carboplatin, vincristine, 
and mitomycin C) at 4-week intervals showed a partial response according 
to RECIST (Response Evaluation Criteria in Solid Tumors). One case re-
port describes a patient with untreated non-invasive VPD who was treated 
with radiotherapy and FEC100 (fluorouracil, epirubicin, and cyclophos-
phamide) followed by 3 courses of docetaxel for a lobular breast carci-
noma. The VPD clinically disappeared after chemotherapy, but recurred 
2 years later.146 Another case report describes the clinical response and 
regression of lymph node metastases in a patient with Her2-Neu-over-
expressing VPD after treatment with trastuzumab in combination with 
paclitaxel.147 
One study describes the topical use of bleomycin for 2 weeks with a rest-
ing period of 4 to 6 weeks in 7 patients with non-invasive VPD. Four pa-
tients had a complete response: three after 2 two-week courses and one 
patient needed 4 courses but had a recurrence after 30 months The other 
three patients could not be evaluated: one patient died of intercurrent dis-
ease, in one patient therapy was stopped due to adverse events, and one 
patient refused further therapy after a partial response.148
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Other topical treatment
Topical corticosteroids are not proven to be effective for VPD. The current 
literature includes case reports of women who were treated with topical 
corticosteroids without success for an irritative vulvar skin lesion. Treat-
ment failure led to further examination of the initially misdiagnosed lesion 
and resulted in a VPD diagnosis.130,131,149,150 Based on clinical experience, 
topical application of lidocaine (as a cream or ointment) can relieve pain, 
and emollients with zinc oxide can prevent secondary infection of the le-
sion. There is no literature available on the symptomatic treatment of 
VPD.
Radiotherapy
Radiotherapy has been used as a primary treatment option for patients 
with invasive and non-invasive VDP who were not eligible for surgery or 
who refused surgery, as a treatment option for patients with recurrence 
after surgery, and as adjuvant postoperative therapy.151,152 Son et al. de-
scribed a case series of 3 patients with VPD that included 1 patient with 
invasive VPD.152 All 3 patients had a clinical complete response. Karam 
et al. performed a large retrospective study of 1,439 patients with EMPD, 
781 of whom had VPD. In total, 92 patients received radiotherapy, but 
these were not analysed by sex or by lesion location.151 The invasion depth 
was not reported. Adjuvant postoperative radiotherapy was given to 51 
patients (55.4%), and 40 patients received radiotherapy as primary treat-
ment. A dose of 40 to 50 Gy is recommended for intraepithelial EMPD 
and 55 to 65 Gy is recommended for invasive EMPD or for an associated 
adenocarcinoma.153-155 Long-term follow-up shows that recurrence rates 
after radiotherapy are less than 20%.152 Lower doses may be less effective 
and may thus have a higher recurrence rate.156 One case report described 
the use of high-dose-rate superficial brachytherapy, also known as ple-
siotherapy, for VPD. A total dose of 54 Gy was administered in 3 weekly 
fractions for 4 weeks. The patient had a complete response and was free 
of disease during 18 months of follow-up.157
Photodynamic therapy
Photodynamic therapy (PDT), also known as photochemotherapy, is mainly 
prescribed by dermatologists.158 A photosensitizer such as 5-aminolevulin-
ic acid (5-ALA) or methyl 5-amnoplevilunate (MAL) is applied to the lesion. 
After an incubation period of several hours, the photosensitizer is washed 
off and the lesion is irradiated with visible red light, destroying prolifer-
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ating tumour cells that have absorbed the photosensitizer.159,160 PDT has 
shown clinical efficacy for treating superficial cutaneous (pre-) malignan-
cies such as superficial BCCs, actinic keratosis, and usual VIN.161 PDT can 
be painful and can cause inflammation. 
Several case reports have evaluated PDT for VPD. Three case reports of 
three patients all reported complete responses to PDT therapy.159,162,163 The 
reports described using topical antibiotics, tretinoin 0.05%, and vitamin E 
ointment at the lesion site. The patients received 2 to 3 sessions of 5-ALA 
or MAL PDT, and all were free of disease for the follow-up periods of 3 to 
6 months.162,163 As side effects, one case reported minimal pain and mild 
erythema for several days after a session. She had a partial response and 
refused surgical treatment. During the 3-year follow-up period, there was 
no invasion of the lesion.159 Raspagliesi et al. reported a case series of 7 
patients who were treated with PDT; 4 had a complete response, 1 had a 
partial response, and 2 patients had stable disease after 1 to 5 months of 
follow-up. The patients, who were premedicated with benzodiazepine and 
NSAIDs, received 3 sessions of MAL PDT with a 3-week intervals. Two pa-
tients reported having pain for several days after the treatment.160 
Laser therapy
CO2 laser therapy has been used as a treatment for recurrent VPD after 
surgery. One case report described the use of 30W CO2 laser therapy for 
recurrence after multiple extended surgeries. Invasion was not reported. 
After the laser treatment, there was no recurrence during the 12 months 
of follow-up, and the clinical response was satisfactory.164 Laser therapy 
has also been used in combination with PDT and surgery. One case series 
describes additional 10W CO2 laser vaporization after surgery. One pa-
tient had a vulvar adenocarcinoma and was primarily treated with a radi-
cal vulvectomy. The other patients underwent wide local excision prior to 
laser therapy. All patients were free of disease 4 months to 4.5 years after 
treatment.165 A trial that included 3 patients with recurrent VPD after sur-
gery subsequently treated the patients with CO2 laser therapy and 5-ALA 
PDT. Invasion was not reported. All patients showed complete response 
during 12 months of follow-up, although 1 died due to other causes.166
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Recurrence rates
Reported local recurrence rates after surgical treatment of VPD vary from 
34%–56%.30,33 Recurrences have also been reported in reconstructive skin 
grafts and flaps.167-169
Table 3 presents an overview of the local recurrence rates of invasive and 
non-invasive VPD in surgically treated patients.
Author Number of patients with local 
recurrence in non-invasive VPD
Number of patients with local 
recurrence in invasive VPD
Black 200755 17/28 (60.7%) 0
Cai 201361 7/22 (31.8%) 1/5 (20%)
Crawford 199949 5/10 (50%) 3/10 (30%)
Creasman 1975170 0/7 (1†) 0/5 (3†)
Curtin 199044 6/28 (21.4%) 2/5* (2†) (40%)
De Magnis 201331 13/30 (43.3%) 2/4 (50%)
Fanning 199933 30/84 (35.7%) 3/12 (25%)
Feuer 199046 7/14 (50%) 2/3 (1†) (66.7%)
Goldblum 199762 4/13 (30.8%) 1/6 (16.7%)
Gregori 197863 2/13 (15.4%) 0
Jones 1979171 7/32 (21.9%) 4/9 (44.4%)
Lee 197745 1/5 (20%) 2/7 (28.7%)
Liu 201414 7/23 (30.4%) 4/8 (50%)
Mendivil 201218 8/13 (61.5%) 1/3 (33.3%)
Scheistrøen 1997172 6/15 (40%) 2/4 (50%)
Shaco-Levy 2010173,174 15/46 (32.6%) 3/10 (30%)
Tebes 200253 4/14 (28.6%) 2/6 (33.3%)
Zollo 200066 5/15 (33.3%) 2/6 (33.3%)
TOTAL 144/402 (35.8%) 34/103 (33.0%)
Table 3 Local recurrences after surgical treatment. 
VPD: vulvar Paget disease. *1 patient had metastases in LN. †Number of patients that died 
of Paget disease.
Some studies report high recurrence rates regardless of the surgical mar-
gin status,53,55,175 whereas others found a significant correlation between 
negative margins and lower recurrence rates.52 Table 4 presents an over-
view of studies that looked at associations between recurrence rates and 
surgical margin status. 
Gunn et al. performed a topographical study of VPD in 1980.95 Four spec-
imens from affected vulvas were examined, and it was found that the 
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Author Number of patients with recur-
rence in patients with positive 
surgical margins
Number of patients with 
recurrence in patients with 
negative surgical margins
Black 200755 14/20 (70%) 3/8 (37.5%)
Cai 2013*61 N/A (38.5%) N/A (18.8%)
Crawford 199949 7/13 (53.8%) 1/7 (14.3%)
Curtin 199044 2/6 (33.3%) 3/11 (27.2%)
De Magnis 201331 10/15 (66.7%) 5/19 (26.3%)
Lee 197745 0/1 (0%) 3/11 (27.3%)
Liu 201414 9/15 (60%) 11/31 (35.5%)
Mendivil 201218 5/11 (45.5%) 4/5 (80%)
Scheistrøen 1997172 1/8 (12.5%) 0/6 (0%)
Shaco-Levy 2010173,174 20/50 (40%) 3/17 (17.6%)
Tebes 200253 6/16 (37.5%) 2/7 (28.6%)
Zollo 200066 1/6 (16.7%) 5/12 (41.7%)
TOTAL† 75/161 (46.6%) 40/134 (29.8%)
Table 4 Local recurrences in relation to margin status after surgical treatment of vulvar 
Paget disease. 
N/A: not available. *Percentages available only. †Excluding Cai 2013.
histological presence of disease extended far beyond the visible lesion. 
This may contribute to the difficulties in obtaining a clear margin. Mul-
tifocality of the disease may also play a part in recognising the extend of 
the disease.
The type of surgery may also influence the recurrence rate. It is well known 
that Paget cells are present in hair follicles and bulbs, which can be found 
deeper into the adipose tissue of the mons pubis and labia minora. A 
skinning vulvectomy may leave diseased hair bulbs in the patient, and it 
is known that laser ablation does not reach this deep as well. 
There are no data available on the recurrence rates according to type of 
VPD, invasion depth or location of the disease. Topical treatment of VPD 
is relatively new. Therefore, publications on this topic do not report suffi-
cient follow up for recurrence rates. Other treatment modalities have been 
described in such small sample sizes, that we are unable to explore this 
topic.
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Author Death of disease 
in patients with 
non-invasive EMPD
Death of disease in 
patients with mi-
croinvasive EMPD 
(≤1 mm)
Death of disease 
in patients with 
invasive EMPD (>1) 
and/or malignancy
Crawford 199949 0/11 0/7 1/3 (33.3%)
Creasman 1975170 1/10 (10%) N/A 3/5 (60.0%)
Curtin 199044 0/28 N/A 2/5 (40.0%)
De Magnis 201331 1/29 (3.4%)† 0/3 0/2#
Feuer 199046 0/14 NA 1/3 (33.3%)
Ito 201271 0/18 0/9 5/8 (62.5%)
Jones 201151 0/38 N/A 2/5 (40.0%)
Mendivil 201218 0/15 N/A 0/1
Niikura 200617 0/18 N/A 0/4
Shaco-Levy 2010173,174 0/46 N/A 1/10 (10%)
Zollo 200066 0/19 N/A 1/9 (11.1%)
TOTAL 2/246 (4,9%) 0/19 16/55 (29.1%)
Table 5: Overview of literature reporting patients who died of Extramammary Paget’s 
disease. 
When studies reported cases with invasion ≤1 mm, they are reported separately in the 
‘micro-invasion’ column. Otherwise we assumed cases with invasion ≤1 mm are classified 
as ‘non-invasive’. EMPD: Extramammary Paget disease. N/A: not available. †Patient that 
died of disease was also diagnosed with vulvar squamous cell carcinoma. #Both patients 
had non-invasive VPD with a vulvar adenocarcinoma.
Prognosis and follow up
The overall 5-year survival rate for EMPD in male and female patients is 
75%–91%.7,70,71 Patients with invasive Paget disease or with an associated 
malignancy seem to have significantly shorter survival. As a comparison, 
the overall 5-year survival rate for vulvar cancer is reported to be 70%.176 
Hatta et al. reported on 76 male and female patients with EMPD and 
found that 5-year survival was 100% in the 43 patients with intraepithe-
lial disease and 88.2% in the patients with microinvasion to the papillary 
dermis. Eleven patients with deep invasion did not survive for 5 years.70 
Ito et al. reported 30 patients with EMPD and showed that survival was 
100% for intraepithelial disease and dermal invasion ≤1 mm. The 5-year 
survival rate for patients with dermal invasion >1 mm was 15%.71 Table 
5 presents an overview of studies that report the number of patients who 
died from EMPD based on invasion depth. 
Based on the currently available literature, the risk of developing inva-
sive VPD disease or metastases after treatment for non-invasive VPD is 
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very low (table 6). Fanning et al. describe 2 patients with extra-vulvar 
adenocarcinoma metastases after initial non-invasive VPD.33 Jones et al. 
describe 2 patients with metastases, but do not specify the location and 
histological type171. Lesions with nodules, elevated CEA, deeper invasion 
depth, and lymph node metastases all correlate with a shorter survival 
time and patients with intraepidermal disease or microinvasion had sig-
nificantly longer survival time than patients with invasive EMPD.70,71
Conclusion and discussion
VPD is a rare skin disease that typically occurs in elderly women. Its ori-
gin remains unclear. Wilkinson’s classification is used most frequently to 
distinguish primary or cutaneous VPD from secondary VPD; the latter is 
associated with an intestinal or urological malignancy. This separation, 
however, has been omitted in the 2014 WHO classification.37
The majority of patients with VPD have non-invasive cutaneous disease. 
About 20% of the cases involve invasive VPD, and 5.7% are associated 
with an underlying vulvar adenocarcinoma. There is no consensus on how 
to distinguish between invasive VPD, VPD with an underlying associated 
intestinal/urological malignancy, or vulvar adenocarcinoma. Intestinal 
and urological malignancies might spread to the vulva in a pagetoid pat-
tern, or Paget cells might cause an underlying malignancy.
Author N Number of patients with 
invasive VPD after treatment 
for initial non-invasive VPD
Number of patients with me-
tastases after treatment for 
initial non-invasive VPD
Baehrendtz 199434 28 3 0
Black 200755 28 1 0
Fanning 199933 88 1 2
Goldblum 199762 19* 1 0
Jones 1979171 39 0 2
TOTAL 202 6 (2.9%) 4 (1.9%)
Table 6 Overview of number of patients with invasive vulvar Paget disease or metasta-
ses after treatment for initial non-invasive vulvar Paget disease. 
N: Total number of patients with non-invasive vulvar Paget disease, VPD: vulvar Paget 
disease. *Includes 5 cases of micro-invasion (< 1 mm), the patient with an invasive recur-
rence did not have micro-invasive disease at time of first diagnosis. 
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VPD is reported to be associated with other malignancies, in our review 
we found that 3.2% of patients with VPD were reported to have been diag-
nosed with breast cancer, 2.2% with an intestinal malignancy, and 3.9% 
with an urological malignancy. Based on these low figures, we want to 
raise the question on the association with breast, intestinal, and uro-
logical malignancies, as there are no studies with age matched control 
groups. We especially question the association with concurrent intestinal 
and urological malignancies, as they are reported in 1.1% of VPD patients 
and in 0.7% respectively. Therefore screening for all associated malignan-
cies might be superfluous. However, as 12% of women will develop breast 
cancer during their lifetime, we do think that all women with VPD should 
undergo mammography, which is an easy and affordable test.177 More re-
search on this topic should be conducted to support a screening protocol.
A diagnosis of VPD is confirmed by the presence of Paget cells on histolog-
ical examination. Immunohistochemical markers can be used to differen-
tiate between cutaneous and non-cutaneous VPD, and may serve as a de-
cision aid in the work-up of patients with VPD. Invasive disease should be 
excluded by accurate histological examination or by vulvar mapping. The 
risk of progression into invasive VPD or to metastasis after treatment for 
non-invasive VPD is low (2.8% and 1.9%, respectively), and the prognosis 
of non-invasive VPD is excellent. We therefore suggest that aggressive sur-
gical treatment can be avoided in cases of non-invasive VPD. There seems 
to be a place for topical treatment, and sometimes more symptomatic 
treatment could be considered. Because of the lack of literature on SLN in 
VPD, there is no place for SLN procedures in VPD. In case of invasive VPD 
>1 mm, standard treatment of the groin area should consist of uni- or 
bilateral inguinofemoral lymphadenectomy.
The risk of recurrence after standard surgical treatment is high i.e. about 
35% for non-invasive VPD. The use of topical imiquimod cream for the 
treatment of VPD shows promising results in small case series, but more 
research is needed before definite conclusions can be drawn. One ongo-
ing study on this topic is registered at clinicaltrials.gov (NCT00504023); 
which is currently not recruiting. Our group has started an observational 
trial in 20 patients with non-invasive VPD and is currently recruiting pa-
tients (NCT02385188).
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Patient suspected for
VPD
Consultation:
Accurate medical history,
including vulvovaginal,
gastrointestinal and urological
symptoms
Examination:
Gynaecologic examination,
including rectal examination,
PAP smear and vulvar biopsy
Histopathological examination
of skin sample, including:
CK7/CK20/Uroplakin-III to
distinguish cutaneous from
non-cutaneous VPD
Cutaneous VPD Non-cutaneousVPD
Mammography
Perform vulva
mapping
Invasive Non-invasive
Treat as VSCC:
Surgery
Symptomatic
approach:
Follow-up, medical
or surgical
Mammography
and cystoscopy
and/or
colonoscopy
Screening
negative Screening positive
Individualised therapy, taking into account:
Location and extent of malignancy,
location and extent of vulvar lesion, patient factors
Figure 8 Flowchart for diagnostic procedures and treatment of patients with VPD. 
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Based on the results of this review, we suggest that the work-up of VPD 
patients should include a consultation that addresses symptoms that 
could indicate an underlying intestinal or urological malignancy. A full 
gynaecological examination should be performed, including rectal exam-
ination. A pap smear can be performed if no recent results are available, 
and a vulvar biopsy should be performed to confirm the VPD diagnosis. 
The immunohistochemical expression pattern can be used to distinguish 
primary from secondary VPD. Screening for an associated locoregional 
malignancy should be performed in non-cutaneous VPD, or if the patient 
has symptoms of a malignancy elsewhere. Even though the risk of pro-
gression into invasive VPD is small, invasion should be excluded in all 
patients by vulvar mapping.
Given its aggressive clinical behaviour, invasive VPD should be treated 
similarly to vulvar SCC. However, patients with non-invasive VPD can be 
treated with a symptomatic approach that should be individualised. In 
case of non-cutaneous VPD with an underlying intestinal or urological 
malignancy, individualised therapy should be provided. The location and 
extent of the malignancy and skin lesion should be taken into account 
along with symptoms and patient factors. We therefore propose a flow-
chart, based on the information reported in this review, which is intend-
ed to function as a supportive decision aid (figure 8). The treatment of 
patients with VPD should be individualised, taking into account the size 
and location of the lesion, the symptoms it causes, and individual patient 
factors. 
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Abstract
Background: Vulvar Paget disease (VPD) is a rare skin disorder, consid-
ered premalignant. 
Objective: To assess the clinical course, treatment schedules and the 
effect of invasion and treatment on recurrence and survival in patients 
with VPD.
Methods: Data on women with VPD were retrieved from the medical files 
and pathology reports in all Dutch tertiary university medical centres. 
Disease free survival (DFS) and 5-year disease specific survival (DSS) were 
estimated using Kaplan-Meier curves.
Results: Data of 113 patients diagnosed between 1991 and 2016 were 
analysed. Seventy-seven percent had non-invasive VPD. Most women un-
derwent surgery (65%). Recurrences were reported in 40%. Of women with 
non-invasive VPD 8% developed invasion. There were no disease specific 
deaths reported in women with non-invasive VPD. The 5 year DSS was 
over 98% in non-invasive and micro-invasive VPD, but significantly worse 
in invasive VPD: 50% (p<0.0005). 
Limitations: The main limitations of this study are its retrospective char-
acter and that original pathology samples were not available for reassess-
ment. 
Conclusions: VPD is extremely rare and recurrence rates are high. Most 
patients have non-invasive VPD, which does not affect survival and should 
be considered a chronic disorder with a limited invasive potential. In case 
of invasive disease survival decreases significantly.
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Introduction
Vulvar Paget’s disease (VPD) is an extremely rare skin disorder. Most 
women are postmenopausal and experience vulvar or perineal irritation, 
burning sensations, itching and pain. Clinical examination may reveal an 
eczematous, papillomatous, scaling or ulcerating erythematous plaque.1 
At the first clinical presentation, VPD is often not recognised and misdiag-
nosed as eczema or mycosis. Early histological assessment with a biopsy 
is crucial to make the correct diagnosis.
In literature, about 25% of the VPD cases are associated with invasion or 
an underlying vulvar adenocarcinoma.2-4 Non-invasive VPD is considered 
an adenocarcinoma in situ, and a debate on the malignant potential of 
non-invasive VPD is ongoing. Treatment of women with invasive VPD is 
comparable with vulvar squamous cell carcinoma with surgery as the cor-
nerstone of treatment.
Historically, surgical excision was considered the treatment of choice for 
both invasive and non-invasive VPD. Recurrence rates range from 15 to 
70%: the influence of positive surgical margins on the recurrence rate 
is still debated. Wide local excision often leads to permanent mutilation 
and functional impairment.3, 5-8 Recently, there is more attention for other 
treatment options such as topical treatment with 5% imiquimod cream, 
but large studies on this topic are lacking.
The influence of VPD on survival is unclear. Retrospective analysis of lim-
ited literature (with the largest study in 76 women) shows that death of 
disease in cases of non-invasive and micro-invasive VPD is rare, and more 
common in invasive disease.1,8
Since two decades, treatment of vulvar malignancies is centralised in 
eight gynaecologic oncology centres in the Netherlands.9, 10 Gynaecologic 
oncologists are involved in multidisciplinary teams of vulvar clinics, due 
to their experience and surgical skills. 
To understand the course of this rare disease, and to optimise the current 
protocols it is important to gain more insight on VPD. Clinical data of a 
high number of women may help in recognizing possible areas for improve-
ment in clinical care, the effect of different treatment options and disease 
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specific outcomes. The objective of this national study is to assess the clin-
ical course of VPD, to analyse current treatment schedules, and to study 
the effect of invasion and treatment on recurrence and survival rates. 
Material and methods
This retrospective cohort study took place in all eight gynaecologic on-
cology units in the Netherlands: Amsterdam Medical Centre, Antoni van 
Leeuwenhoek Hospital Amsterdam, ErasmusMC in Rotterdam, Leiden 
University Medical Centre, Maastricht University Medical Centre, Rad-
boud university medical centre in Nijmegen, University Medical Centre 
Groningen, and the University Medical Centre Utrecht. 
Local pathology databases were searched for all women reported with a 
first diagnosis of VPD or a recurrence between January 1st,1991 and Jan-
uary 1st, 2016. The lesion had to be located on the vulva, perineum and/
or peri-anal skin. We retrieved medical files of all women. Data on woman 
characteristics, diagnostic methods and treatment schedule for the first 
episode as well as recurrences, including follow-up data were collected. All 
data were entered in a blinded digital database (CastorEDC, the Nether-
lands) according to Good Clinical Practice guidelines.11
Data on the woman characteristics, diagnostic processes and treatment 
schedules were analysed in a descriptive manner. We estimated the dis-
ease-free survival (DFS), defined as the time between the date of diagnosis 
to the date of the first recurrence, or in case of no recurrence until the 
last date of follow-up (or death), using a Kaplan-Meier curve. Five-year dis-
ease-specific survival (DSS), defined as the time between the date of diagno-
sis to the date of death of vulvar carcinoma, or in case of no death or death 
of other cause the date of last follow-up/date of death, was estimated using 
a Kaplan-Meier curve. Recurrences were defined as histologically confirmed 
diagnoses after a complete response, or in cases a complete response was 
not obtained and the residual lesion necessitated treatment. We performed 
subgroup analyses for three different initial diagnoses: non-invasive VPD 
versus microinvasive VPD and invasive VPD. We also analysed the main 
treatment methods: surgery, topical treatment and no treatment (watchful 
waiting), and surgical margin status in women that underwent surgery. 
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Differences in DFS and DSS rates between groups were analysed with log-
rank tests. A p-value < 0.05 was considered statistically significant. All 
analyses were performed using SPSS for Windows, version 20.
As assessed by the institutional review board of the Radboudumc, the 
study was not subject to the Dutch ‘Medical Research Involving Human 
Subjects Act’, i.e. it was exempt from approval.
Results
Study population
Searches of the local pathology databases in the eight participating cen-
tres identified 151 cases of VPD diagnosed before January 1st, 2016. After 
excluding cases because data was not available (n=27), or they were di-
agnosed with other diseases (n=11), data of a total number of 113 women 
were available for the study. 
Women characteristics
Overall, 87 women (77.0%) were initially diagnosed with non-invasive 
VPD, 10 (8.8%) with micro-invasive VPD, seven (6.2%) with invasive VPD, 
six (5.3%) with VPD with an underlying vulvar adenocarcinoma, and in 
three (2.7%) cases the VPD was metastasised. The median age of the 113 
included women was 73 years (range 41-97 years) at time of diagnosis, 
and there was no statistically significant difference between the different 
diagnoses (p >0.3). See table 1. 
Non-invasive VPD
At the first consultation with the medical specialist, the duration of symp-
toms was often reported as “symptoms for several months”, or “about a 
year”, or even “a few years”. Forty-nine women (56.3%) were diagnosed 
within four weeks after first consultation. Twenty-nine women (34.5%) 
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ni-VPD 
n = 87
mi-VPD 
n = 10
i-VPD 
n = 16
Age 72 (41-97) 73.5 (54-86) 74 (49-89)
Hospital of diagnosis:
Referring hospital 56 (64.4%) 6 (60%) 10 (62.5%)
University medical centre 30 (34.5%) 4 (40%) 6 (37.5%)
Unknown 1 (1.1%) 0 0
Initial treatment:
Surgery 51 (58.6%) 10 (100%) 13 (81.3%)
Topical, imiquimod 18 (20.7%) 0 0
Topical, other 3 (3.6%) 0 0
Chemotherapy 1 (1.1%) 0 0
Radiotherapy 1 (1.1%) 0 2 (12.5%)
None 12 (13.8%) 0 1 (6.2%)
Unknown 1 (1.1%) 0 0
Table 1 Clinical characteristics of patients with VPD.
Ni-VPD: non-invasive vulvar Paget disease, mi-VPD: micro-invasive vulvar Paget disease, 
i-VPD: invasive vulvar Paget disease.
had a history of VPD, or were already diagnosed elsewhere when they 
first presented at the hospitals included in our study. Reports of mammo-
graphy performed as screening after VPD diagnosis were available for 33 
women after diagnosis with VPD and in one case (1.1%) a malignancy was 
found. Additional diagnostics and screening did not reveal any abnormal-
ities. Vulvar mapping, where several biopsy samples are taken from all 
suspected areas, was performed in 37 women (42.5%): one woman was 
suspected to have invasive disease and was treated with a skinning vul-
vectomy, but invasion was not found in the surgical specimen. 
Of the 51 surgically treated women, 33 women (64.7%) underwent a wide 
local excision, five (9.8%) a hemivulvectomy, and 12 (23.5%) a (skinning) 
vulvectomy. Data on the type of surgery was missing for one woman. 
Margin status was available for 47 women (92%) of the surgically treated 
women: surgical margins were clear in only five women.
Eighteen women were treated with topical 5% imiquimod cream, treat-
ment schedules differed from one to five times per week, and women were 
treated for three weeks to an entire year. Of all women initially treated 
with topical 5% imiquimod cream, four (22.2%) had a complete response, 
seven (38.8%) a partial response and four (22.2%) no response or stable 
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disease. Data on the treatment response was unavailable for three wom-
en. Of the 13 women without a complete response, four (30.7%) under-
went additional surgery. 
Micro-invasive VPD
Five out of ten women (50%) with micro-invasive VPD were diagnosed at 
their first hospital visit. Three women (30%) were already diagnosed at 
time of referral. Screening for additional malignancies did not reveal other 
tumours. Vulvar mapping was performed in six cases (60%).
All women with micro-invasive VPD were treated with surgery. None of 
the women with micro-invasive disease underwent groin surgery. Margin 
status was available for nine cases: all were positive for Paget cells, but 
clear of micro-invasion.
Invasive VPD
All women with invasive VPD were diagnosed within four weeks of the first 
hospital visit. Five women (31.3%) had a history of VPD or were already 
diagnosed at time of referral. Screening for additional malignancies via 
mammography, colonoscopy, or cystoscopy was performed in five women 
and did not reveal other tumours. Vulvar mapping was performed and 
was positive for invasion in nine cases (56.3%). In five women an ultra-
sound of the groins was performed, in four women a suspected groin le-
sion was detected. 
Most women with invasive VPD were initially treated with surgery: 13 
women (81.3%). Six (37.5%) underwent a (skinning) vulvectomy, two 
(12.5%) a hemivulvectomy, and five (31.3%) a wide local excision. The 
type of surgery was unknown for one woman. Groin surgery, uni- or bilat-
eral sentinel lymph node procedure or inguinofemoral lymphadenectomy, 
was performed in seven women (29.2%). Six women had lymph node me-
tastase, see table 2 for details on lymph node status for all patients with 
invasive disease.
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Groin treatment Groin metastases Status at last FU FU (months)
1 None DVC 6
2 None DVC 2
3 None AWD 42
4 None NED 118
5 None AWD 5
6 None NED 138
7 None DVC 1
8 None AWD 21
9 SLN bilateral Negative for metastasis DOC 7
10 IFL unilateral Negative for metastasis DVC 131
11 SLN unilateral Positive for metastasis DVC 18
12 IFL unilateral Positive for metastasis DVC 6
13 IFL unilateral Positive for metastasis DOC 17
14 IFL bilateral Positive for metastasis DVC 19
15 Radiotherapy Positive for metastasis DVC 2
16 Radiotherapy Positive for metastasis AWD 6
Table 2 Groin metastases in patients with invasive vulvar Paget disease
Overview of treatment of the groins in all patients with initial diagnosis of invasive VPD, 
conclusion of the pathology report, and the status of the patient. SLN: sentinel lymph 
node. FU: follow-up. AWD: Alive with disease. DOC: death of other cause. DVC: death of 
vulvar carcinoma. NED: no evidence of disease.
Margin status was available for 11 women, margins were clear of Paget 
cells in only one patient. 
Two women with invasive VPD were initially treated with radiotherapy, of 
whom one received chemotherapy in advance. Limited data on the details 
of treatment were available. 
Recurrence rates 
Overall, 46 women (37.4%) had 87 recurrences: ranging from one to nine 
recurrences per woman. 
Of the 87 women with non-invasive VPD, 32 women (36.8%) had one or 
more recurrences. Nineteen (59.4%) had only one recurrence: in one case 
the recurrence was invasive, and in one case the disease metastasised, 
in all other women the recurrences were non-invasive. See figure 1 for an 
overview of all recurrences in women with non-invasive VPD. One woman 
had a clinical recurrence and was also diagnosed with a metastasised cer-
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Figure 1 Recurrences in VPD.
VPD: vulvar Paget disease.
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vical adenocarcinoma, which was the cause of death: invasion of the VPD 
was not reported. 
In all 87 women with an initial diagnosis of non-invasive VPD, seven (8.0%) 
eventually progressed, see figure 1. Progression into invasion occurred after a 
median of 62 months after initial diagnosis, ranging from 31 to 165 months. 
Of the 10 women with micro-invasive VPD, six women (60%) had one 
or more recurrences. Two had micro-invasive recurrences, and four had 
non-invasive recurrences. See figure 1.
Five women (31.3%) with invasive disease had one or more recurrences. In 
two cases the VPD was metastasised. Three women (18.7%) had non-inva-
sive recurrences, see figure 1 for an overview of all recurrences in women 
with invasive VPD. 
Survival 
The estimated median DFS was 69.3 months for non-invasive, 39.3 
months for microinvasive disease, and 26.5 months for invasive disease (p 
0,301). There was no difference in the DFS between women with margins 
clear or positive for Paget cells after initial surgical treatment (p 0,491).
The median follow-up after the VPD diagnosis of all women was 38 months 
(range 0-451). Table 3 presents an overview of disease status at time of last 
follow-up. Five-year DSS was significantly better in women with initially 
Non-invasive VPD 
(n=87)
Microinvasive VPD 
(n=10)
Invasive VPD  
(n=16)
Alive:
With disease 35 (40.2%) 3 (30.0%) 4 (25.0%)
No evidence of disease 33 (37.9%) 5 (50.0%) 2 (12.5%)
Disease status unknown 3 (3.4%) 1 (10.0%) -
Dead:
Of vulvar carcinoma 1 (1.1%) - 8 (50.0%)
Other cause 7 (8.0%) 1 (10.0%) 2 (12.5%)
Cause unknown 8 (9.2%) - -
Table 3 Disease status at last follow-up.
VPD: Vulvar Paget disease
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non-invasive and microinvasive VPD compared to invasive VPD: 98.8%, 
100.0% versus 50.0% (p<0.0005, figure 2). One patient with non-invasive 
VPD died from metastasised VPD at time of first recurrence 30.6 month 
after initial diagnosis. The five-year overall survival of non-invasive VPD 
women did not differ between women that were surgically treated, under-
went topical treatment or without treatment (p=0.713). 
Discussion
This is the largest cohort study of women with vulvar Paget disease so far. 
We analysed clinical data of 113 VPD women who have been treated in all 
gynaecologic oncology university centres in the Netherlands.
We found that women had symptoms for several months to years before 
the diagnosis was finalised. Due to its rarity VPD is not often recognised at 
first evaluation by clinicians. Most medical specialist performed a vulvar 
Figure 2 Disease specific survival in non-invasive versus micro-invasive and invasive 
VPD
Ni-VPD: non-invasive VPD, mi-VPD: microinvasive VPD, i-VPD: invasive VPD. 
Women at risk: ni-VPD 87, mi-VPD 10, i-VPD 16. 
Vulvar paget disease in the Netherlands
83 
biopsy at the woman’s first visit, confirming the diagnosis. The importance 
of early histological assessment is stressed, especially in cases of vulvar 
lesions not responding to therapy. In the majority of cases the pathologist 
had no difficulties with recognising the Paget cells in VPD.
VPD may be associated with invasion; we found 23% of cases at initial di-
agnosis were invasive, and in 2.7% disease was already metastasised. Pro-
gression of non-invasive VPD into invasive disease occurred in seven cases 
(8%) after a median time of five years. This long interval might suggest a de 
novo invasive lesion, instead of progression of the non-invasive VPD.
The main issue in surgical excision of VPD is obtaining free surgical mar-
gins, as the histological presence of disease does not overlap with the 
visibly affected skin due to intradermal localisation.12 In our series, sur-
gical margins were clear in only 9.4% of the women. A different surgical 
technique, such as Moh’s Microsurgery seems to improve these figures.13 
With Moh’s Microsurgery the lesion is excised through the epidermis and 
dermis, and 100% of the peripheral margins are examined immediate-
ly. Excision is repeated, enlarging the circumference each time, until the 
margins are clear. The DFS seems longer, and recurrence rate lower in 
women treated with Moh’s Microsurgery.13-15 Our study did not find that 
the margin status influences the DFS. Moreover, enlarging the excision 
will raise morbidity of treatment. 
Topical 5% imiquimod cream is suggested as a new treatment option. It 
has shown to be effective for high grade vulvar squamous cell intraepithe-
lial lesions.16 Several case series and two small prospective studies have 
reported on imiquimod for VPD.17, 18 We found that 20% of the women 
initially treated with imiquimod had a complete response, and 40% a par-
tial response, although data of histological response were not available in 
most cases. Treatment schedules vary a lot with respect to frequency and 
overall duration. There is currently one study ongoing investigating the 
efficacy of topical 5% imiquimod cream in VPD in a standardised treat-
ment schedule (Clinicaltrials.gov NCT02385188). Results can be expected 
at the end of 2018.
Care for women with VPD should take place in specialised centres. Wom-
en should frequently consult their physician whenever new lesions and/or 
symptoms arise. In case of non-invasive VPD, a watchful waiting or symp-
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tomatic treatment with regular check-ups may be advised as recurrence 
rates are high and the presence of residual non-invasive disease does 
not influence the survival. Women with invasive VPD should be treated 
according the guidelines for vulvar squamous cell carcinoma. However, 
sentinel lymph node procedures are not recommended in these women. 
Recurrences after invasive VPD are not always invasive as well, a phe-
nomenon which is also seen in squamous vulvar (pre)malignancies. Our 
study identified one case of non-invasive VPD with an invasive recurrence 
which led to the death of the patient. This patient was initially treated with 
topical imiquimod cream in a referring hospital: 31 months after initial di-
agnosis she was diagnosed with a vulvar adenocarcinoma and referred to 
a tertiary centre. Groin and bone metastases of  a vulvar adenocarcinoma 
were found and the patient received chemotherapy. Disease progressed 
and she died 42 months after initial diagnosis. The pathology reports of 
the first biopsy samples taken in the referring hospital were not available 
for reviw. The available reports have suggested a possible relation with the 
breast carcinoma the patient was diagnosed with 9 years prior.
The main limitation of this study is that we only analysed clinical files 
and it was not possible to review pathology. The diagnosis of invasive VPD 
lacks a clear description: it can be hypothesised that the natural phenom-
enon of Paget cells in the skin adnexa are mistaken for invasive disease. 
Whereas an inevitable vulvar adenocarcinoma may be a second diagnosis 
in cases where the overlying, i.e. intact, epithelium contains Paget cells. 
This may be regarded as non-invasive VPD with an underlying vulvar ad-
enocarcinoma. The prognosis of the patient may then depend on the ad-
enocarcinoma, rather than the VPD. We therefore advise, combined with 
the rarity of the disease, that all cases should be reviewed by a specialist 
gynaecological and/or dermatological pathologist.
In conclusion, this study presents an overview of 113 VPD patients from 
the Netherlands. In case of a lesion suspicious for VPD, histology should 
confirm the diagnosis. Invasion occurs in about 14%, generally diagnosed 
with the first biopsy, which has a worse prognosis compared to non-inva-
sive or micro-invasive disease. A symptomatic or watchful waiting policy 
is acceptable in women with non-invasive VPD. The risk of recurrence 
is high, but the risk of progression is limited and generally occurs after 
several years. Care for women with VPD should take place in centres with 
specialised clinicians and pathologists, experienced with this rare disease. 
Vulvar paget disease in the Netherlands
85 
References
1. van der Linden M, Meeuwis KA, Bulten J, et al. Paget disease of the vulva. Crit 
Rev Oncol Hematol 2016; 101: 60-74.
2. Cai Y, Sheng W, Xiang L, et al. Primary extramammary Paget's disease of the 
vulva: the clinicopathological features and treatment outcomes in a series of 
43 women.  Gynecol Oncol 2013; 129(2): 412-6.
3. Fanning J, Lambert HC, Hale TM, et al. Paget's disease of the vulva: preva-
lence of associated vulvar adenocarcinoma, invasive Paget's disease, and re-
currence after surgical excision. Am J Obstet Gynecol 1999; 180(1 Pt 1): 24-7.
4. Jones IS, Crandon A, Sanday K. Paget's disease of the vulva: Diagnosis 
and follow-up key to management; a retrospective study of 50 cases from 
Queensland. Gynecol Oncol 2011; 122(1): 42-4.
5. Funaro D, Krasny M, Lam C, et al. Extramammary Paget disease: epidemiolo-
gy and association to cancer in a Quebec-based population. J Low Genit Tract 
Dis 2013; 17(2): 167-74.
6. Chan J, Li G, Chung J, et al. Extramammary Paget's Disease: 20 Years of Ex-
perience in Chinese Population. Int J Surg Oncol 2012; 2012:416418 [EPub].
7. Black D, Tornos C, Soslow RA, et al. The outcomes of women with positive 
margins after excision for intraepithelial Paget's disease of the vulva. Gynecol 
Oncol 2007; 104(3): 547-50.
8. Shaco-Levy R, Bean S, Vollmer R, et al. Paget Disease of the Vulva: A Histo-
logic Study of 56 Cases Correlating Pathologic Features and Disease Course. 
Int J Gynecol Pathol 2009; 29: 69-78.
9. de Hullu JA, van der Zee AG. Surgery and radiotherapy in vulvar cancer. Crit 
Rev Oncol Hematol 2006; 60(1): 38-58.
10. van den Einden LC, Aben KK, Massuger LF, et al. Successful centralisation of 
women with vulvar carcinoma: a population-based study in The Netherlands. 
Eur J Cancer 2012; 48(13): 1997-2003.
11. International Conference on Harmonisation. Good Clinical Practice [Internet].
Available from: http://ichgcp.net/.
12. Gunn RA, Gallager HS. Vulvar Paget's disease: a topographic study. Cancer 
1980;46(3):590-4.
13. Long B, Schmitt AR, Weaver AL, et al. A matter of margins: Surgical and 
pathologic risk factors for recurrence in extramammary Paget's disease. Gy-
necol Oncol 2017; 147(2): 358-63.
14. Kim SJ, Thompson AK, Zubair AS, et al. Surgical Treatment and Outcomes of 
Women With Extramammary Paget Disease: A Cohort Study. Dermatol Surg 
2017; 43(5): 708-14.
Chapter 4
86
15. Bae JM, Choi YY, Kim H, et al. Mohs micrographic surgery for extramammary 
Paget disease: a pooled analysis of individual woman data. J Am Acad Derma-
tol 2013; 68(4): 632-7.
16. van Seters M, van Beurden M, ten Kate F, et al. Treatment of Vulvar Intraepi-
thelial Neoplasia with Topical Imiquimod. N Engl J Med 2008; 358(14): 1465-
73.
17. Marchitelli C, Peremateu MS, Sluga MC, et al. Treatment of primary vulvar 
Paget disease with 5% imiquimod cream. J Low Genit Tract Dis 2014; 18(4): 
347-50.
18. Cowan RA, Black DR, Hoang LN, et al. A pilot study of topical imiquimod ther-
apy for the treatment of recurrent extramammary Paget's disease. Gynecol 
Oncol 2016;  142(1): 139-43. 
Vulvar paget disease in the Netherlands
87 

Stop routine screening  
for associated malignancies 
in non-invasive cutaneous  
vulvar paget disease?
M. van der Linden
M.S. Schuurman
J. Bulten
L.F.A.G. Massuger 
J. IntHout
M.A. van der Aa
J.A. de Hullu
Chapter 5
British Journal of Dermatology
2018; 179(6): 1315-21 
Abstract
Background: Vulvar Paget disease (VPD) is extremely rare and thought to 
be associated with other malignancies. 
Objective: The aim of this study was to evaluate the risk of developing 
breast, intestinal, and urological malignancies in patients with VPD com-
pared with the general population, and in particular focus on the risk of 
malignancy in patients with cutaneous non-invasive VPD.
Methods: Data on the oncologic history of patients with any type of VPD 
between 2000 and 2015 were obtained from PALGA, a nationwide archive 
containing all pathology reports in the Netherlands. Follow-up data and a 
control group from the general population were obtained from the Neth-
erlands Cancer Registry. After correction for age and calendar year at 
time of diagnosis, standardised incidence ratios (SIR) for the first three 
years after VPD diagnosis were estimated with 95% confidence intervals 
(95%CI). 
Results: We identified 199 patients with a first diagnosis of VPD (164 
non-invasive, 35 (micro-) invasive) between 2000 and 2015. The SIR of 
developing an associated malignancy in the first 3 years after diagnosis 
was 4.67 (95%CI 2.66-7.64). This was mainly due to the high incidence 
of intestinal malignancies among patients with secondary VPD. Subgroup 
analysis for cutaneous non-invasive VPD did not reveal a significantly in-
creased risk for associated malignancies, i.e. SIR 2.08 (95%CI 0.76-4.62). 
Conclusions: Of patients with VPD, 76.9% is diagnosed with cutaneous 
non-invasive VPD, and this group has no increased risk for developing 
malignancies of the breast, intestinal or urological tract. Our study sug-
gests that routine screening for these malignancies in patients diagnosed 
with cutaneous non-invasive VPD may not be necessary. 
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Introduction
Vulvar Paget disease (VPD) is a rare skin disorder, most commonly seen 
in postmenopausal Caucasian women.1 VPD causes itching or burning 
erythematosquamous plaques and is diagnosed when typical Paget cells 
are seen in the epidermis. VPD can be classified according to origin and 
invasion: VPD can be primary of cutaneous origin (type 1) or secondary 
to an intestinal (type 2) or urological (type 3) malignancy.2 Most cases of 
primary disease, i.e. cutaneous, are non-invasive (type 1a). Cutaneous 
VPD can invade through the basal membrane (type 1b), or be seen in con-
junction with a vulvar adenocarcinoma (type 1c). The difference between 
primary or secondary VPD cannot be made on histopathological assess-
ment alone.3 The aetiology and origin of Paget cells remains unknown.1
VPD has been considered to be associated with malignancies of the breast, 
intestinal and urological tract.4,5 Some consider VPD secondary to intes-
tinal or urological malignancies a Pagetoid spread rather than a separate 
entity. Therefore, by some primary non-invasive VPD may be considered 
the only ‘true’ VPD, and secondary VPD a ‘Pagetoid phenomenon’.6-9
In the late 19th century, skin lesions like the nipple ulceration associat-
ed with breast cancer, became known as extramammary Paget disease 
(EMPD).10-12 The histological characteristics of EMPD resembles mammary 
Paget disease, raising the suspicion of a comparable pathogenesis.13 The 
term VPD is used for EMPD specifically localised at the female genital 
skin. In 1975, Friedrich et al. analysed 11 published articles, including 78 
patients with VPD of whom 14 (18%) were diagnosed with breast cancer 
around VPD diagnosis.4 The authors concluded that screening for breast 
cancer should be standard care in VPD patients. 
In 1985, Chanda summarised 197 cases of EMPD in a literature review.5 
Of these patients, 128 had VPD. Simultaneous occurrence of a malignan-
cy and VPD was reported in 12% of cases, and overall 29% of the patients 
were reported to have had a malignancy of either the breast, gynaecological, 
intestinal, or urological tract. The true association between these so-called 
“associated” malignancies and EMPD was questioned, as most malignancies 
were not diagnosed at the same time as EMPD, nor showed the two diseases 
a parallel course. However, Chanda concluded that clinicians should con-
sider a search for malignancies of the gastrointestinal tract in cases of peri-
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anal EMPD, or for genitourinary malignancies in genital EMPD. Ever since, 
the assumed association between VPD and malignancies has been generally 
accepted. Nowadays, international guidelines advise that women with VPD 
should be screened for associated malignancies.14,15 However, the extent and 
timing of screening, and the preferred diagnostics, are not exemplified.
Our recent analysis of publications describing 10 or more patients with 
VPD, suggests that breast, intestinal and urological malignancies in VPD 
patients are rare: 3.2% had a history of breast cancer, 2.2% of intestinal 
cancer, and 3.9% of urological cancer.1
The aim of this study is to estimate the risk of developing breast, intesti-
nal or urological malignancies in all patients with (non-)invasive VPD in 
comparison with the general population: moreover to evaluate whether all 
VPD patients should be routinely screened for malignancies.
Patients and methods
Patient selection
The PALGA database, a nationwide network and registry of histo- and cy-
topathology in the Netherlands with national coverage since 1991, was 
searched for all cases of vulvar Paget disease and vulvar adenocarcinomas. 
All cases with a first diagnosis of VPD, non-invasive and invasive, between 
January 1st 2000 and December 31st 2014 were included. We excluded cas-
es of adnexal gland tumours, mammary-like gland tumours or vulvar ade-
nocarcinomas without evidence of VPD. Patients with vulvar localisation of 
an intestinal or urological malignancy were also excluded. We reported the 
type of VPD as reported in the pathology report: primary VPD (of cutaneous 
origin) which can be distinguished with the following immunohistochemical 
(IHC) profile: CK7+, CK20-. Secondary VPD of intestinal origin can be dis-
tinguished with the IHC profile CK7-, CK20+, CDx2+, and secondary VPD 
of urological origin with the IHC profile CK7+/-, CK20+, and Uroplakin-III+. 
Pathology reports that concluded with “vulvar Paget disease” but in which 
IHC were not available, were reported as VPD not otherwise specified (NOS), 
and assumed to be primary VPD, since this is the most common type.1 
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Follow up data were retrieved via the Netherlands Cancer Registry (NCR), 
which has national coverage since 1989 and registers all malignancies in 
the Netherlands. If follow-up data were not available from the NCR, we used 
the date of the last pathology report as the last date of follow-up.
Associated malignancies
VPD patients diagnosed with associated malignancies were identified from 
the pathology reports, as were the age at diagnosis of the associated ma-
lignancy and the date of diagnosis. 
All invasive breast, intestinal or urological tumours were defined as po-
tentially VPD associated. Besides invasive tumours, ductal carcinoma in 
situ (DCIS) of the breast was also included, because DCIS is considered to 
be a malignancy. Intestinal malignancies included tumours of the colon, 
rectum, rectosigmoid junction and anus. Urological malignancies includ-
ed tumours of the kidney, ureter, bladder and urethra.
All women with histological confirmation of one or more aforementioned 
tumours between 2000 and 2015 were selected from the NCR. The total 
number of women living in the Netherlands by age category and calendar 
year was obtained from Statistics Netherlands.
Statistical analysis
The incidence of associated malignancies in women with VPD was com-
pared with the incidence of these malignancies in women from the general 
population. The expected incidence was extracted from data from the NCR 
and population data from Statistics Netherlands. Risks were stratified by 
age and calendar year diagnosis of malignancy. The standardised inci-
dence ratio (SIR) was estimated as the ratio between the observed inci-
dence of an associated malignancy in women with VPD divided by the 
expected incidence in women from the general population. SIRs were esti-
mated until 36 months after VPD diagnosis, we assumed that malignan-
cies diagnosed within 36 months after VPD diagnosis might have already 
been present, possibly as a premalignancy, at the time of VPD diagnosis. 
Furthermore, this time frame ensured a reasonable sample size of the 
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study cohort. We performed subgroup analyses for cases reported as pri-
mary non-invasive VPD only. Statistical models were based on a Poisson 
distribution using person time at risk as an offset. 
Person time at risk was calculated as time from the date of first VPD diag-
nosis to the date of first histological confirmation of the associated malig-
nancy of interest, date of death or date of last follow-up, whichever came 
first. Follow-up data were available up to January 1, 2015. Analyses were 
performed using STATA/SE 13.0 (StataCorp, College Station, TX). SIRs 
and their 95% confidence intervals (95%CI) were based on the Mid-P ex-
act test,16 and calculated using the OpenEpi Standardised Mortality Ratio 
Calculator (OpenEpi version 3.01)17. Figures were designed using Micro-
soft Office Excel 2007 and Visio 2007.
Results
Population
In total, 199 women with a first diagnosis of VPD in the Netherlands (~17 
million inhabitants) between 2000 and 2015 were identified from the pa-
thology reports. Non-invasive VPD was diagnosed in 164 (82.4%) patients, 
micro-invasive VPD in 12 (6.0%), and invasive VPD in 23 (11.6%). An over-
view of the types of VPD per diagnosis is presented in table 1. We consid-
ered NOS as primary cutaneous VPD in further analyses. The median age 
at diagnosis was 74 years (range 40-97), and did not differ between patients 
with non-invasive and (micro-) invasive disease (p=0.838). The median fol-
low-up of all patients was 36 months (range 0-182) after VPD diagnosis.
Non-invasive VPD (Micro-)invasive VPD Total
NOS 133 (66.8%) 25 (12.5%) 158 (79.4%)
Type 1, cutaneous 20 (10.1%) 8 (4.0%) 28 (14.1%)
Type 2, intestinal 8 (4.0%) 2 (1.0%) 10 (5.0%)
Type 3, urological 3 (1.5%) 0 3 (1.5%)
Total 164 (82.4%) 35 (17.6%) 199 (100%)
Table 1  Overview of type of VPD per diagnosis.
Overview of the different types of VPD per diagnosis. NOS: not otherwise specified. VPD: 
vulvar Paget disease.
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Associated malignancies
Of all patients, 27 (13.6%) were diagnosed with breast cancer, 17 (8.5%) 
with an intestinal and 9 (4.5%) with a urological malignancy before, si-
multaneously with, or after the diagnosis with VPD. See supplemental 
table 1 for an overview. Three patients (1.5%) had a history of two associ-
ated malignancies. 
Eighteen of the 27 patients (66.7%) with breast cancer were diagnosed before 
they were diagnosed with VPD: the median time difference was 102 months 
(range 3-213). Three of these 18 patients were diagnosed with breast cancer 
within 3 to 6 months prior to the VPD diagnosis, which was primary non-in-
vasive in all three. Eight of the 27 patients (29.6%) were diagnosed with 
breast cancer after their VPD diagnosis, the median time difference between 
both diagnoses was 46 (range 1-116) months. Two of these eight patients 
were diagnosed with breast cancer within 2 months after the VPD diagno-
sis, which was primary non-invasive in both. It is uncertain whether these 
malignancies were detected with the VPD screening protocol. Time of breast 
cancer diagnosis in relation to VPD diagnosis was unknown for one patient.
In six (35.3%) of the 17 patients with intestinal malignancies and VPD, 
the intestinal malignancy was diagnosed before they were diagnosed with 
VPD, with a median time difference of 201 months (range 96-272). Two 
of the 17 patients (11.8%) were diagnosed with the intestinal malignancy 
and VPD simultaneously: both being type 2 VPD. Nine (52.9%) patients 
were diagnosed with an intestinal malignancy at a median time difference 
of 16 months (range 1-90) after VPD diagnosis. 
Four of the 9 patients (44.4%) had a urological malignancy before the VPD 
diagnosis, with a median time difference of 152 months (range 103-249). 
Urological malignancies were diagnosed after VPD in the other five pa-
tients (55.6%), after a median time difference of 50 months (range 11-147).
Figure 1A shows the time difference between diagnoses of VPD and the 
associated malignancies for all patients, whereas figure 1B shows the time 
difference between VPD diagnosis and the associated malignancies for the 
subgroup of primary non-invasive VPD. The time difference between VPD 
diagnosis and for example urological malignancies was up to 250 months 
prior, and 150 months after VPD diagnosis.
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Risk of developing an associated malignancy after any type of VPD diagnosis
The cumulative risk of developing any of the associated malignancies 
within 36 months after diagnosis with any type of VPD was increased with 
a SIR of 4.77 (95%CI 2.66-7.64). This increased risk was mainly based on 
the significantly statistically increased risks of developing an intestinal 
malignancy, SIR 8.18 (95%CI 3.99-15.01), and for a urological malignan-
cy: SIR 6.67 (95%CI 1.19-22.03). The SIR for developing a breast malig-
nancy was not statistically significant 2.00 (95%CI 0.51-5.44), see table 2.
Year after VPD Obs Exp SIR 95% CI
1 9 1.2
2 4 1.0
3 1 0.8
Cumulative risk 14 3.0 4.67* 2.66-7.64
1 2 0.6
2 1 0.5
3 0 0.4
Breast cancer 3 1.5 2.00 0.51-5.44
1 6 0.4
2 2 0.4
3 1 0.3
Intestinal malignancy 9 1.1 8.18* 3.99-15.01
1 1 0.1
2 1 0.1
3 0 0.1
Urological malignancy 2 0.3 6.67* 1.12-22.03
Table 2 Risk of developing an associated malignancy, all types of VPD.
Risk of developing an associated malignancy within 3 years after diagnosis with VPD, ir-
respective of type of VPD. VPD: vulvar Paget disease. Obs: observed cases per year and in 
total. Exp: expected cases per year and in total. SIR: standardised incidence ratio. 95%CI: 
95% confidence interval. Statistically significant SIRs are marked with an asterisk (*). 
Risk of developing an associated malignancy after primary non-invasive VPD diagnosis
See table 3 for the analysis restricted to patients with primary non-inva-
sive VPD. The SIR for developing any of the associated malignancies was 
2.08 (95%CI 0.76-4.62). The SIR for breast cancer was 2.50 (95%CI 0.64-
6.80), the SIR for intestinal malignancies was 1.11 (95%CI 0.06-5.48), and 
the SIR for urological malignancies was 3.33 (95%CI 0.17-16.44). None of 
these results were statistically significant.
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Year after VPD Obs Exp SIR 95% CI
1 3 1.0
2 2 0.8
3 0 0.6
Cumulative risk 5 2.4 2.08 0.76-4.62
1 2 0.5
2 1 0.4
3 0 0.3
Breast cancer 3 1.2 2.50 0.64-6.80
1 0 0.4
2 1 0.3
3 0 0.2
Intestinal malignancy 1 0.9 1.11 0.06-5.48
1 1 0.1
2 0 0.1
3 0 0.1
Urological malignancy 1 0.3 3.33 0.17-16.44
Table 3 Risk of developing an associated malignancy, non-invasive primary VPD.
Risk of developing an associated malignancy within 3 years after diagnosis with non-in-
vasive primary VPD. VPD: vulvar Paget disease. Obs: observed cases per year and in 
total. Exp: expected cases per year and in total. SIR: standardised incidence ratio. 95%CI: 
95% confidence interval. Statistically significant SIRs are marked with an asterisk (*). 
Discussion
This is the first population-based study investigating the incidence of pos-
sibly associated malignancies in patients with VPD. The risk of develop-
ing an associated malignancy within 3 years after VPD diagnosis of any 
subtype is significantly increased compared to the general Dutch female 
population. However, subgroup analysis of primary non-invasive VPD pa-
tients showed no significant increased risk to develop one of the associ-
ated malignancies. Therefore, there is no evidence for a routine screening 
program for these malignancies when diagnosed with non-invasive prima-
ry VPD.
All patients that were diagnosed with an intestinal or urological malignan-
cy around the time of VPD diagnosis were diagnosed with secondary VPD 
(type 2 or 3). In patients with primary, i.e. cutaneous, non-invasive VPD 
the time interval between VPD diagnosis and the diagnosis of the asso-
ciated malignancy varied greatly. We were therefore unable to identify a 
clear parallel course between primary non-invasive VPD and the so-called 
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associated malignancies. This raises the question of a consistent or com-
parable aetiology.
The main limitation of our study is the large group of cases labelled NOS. 
Our data is collected from two nation-wide databases. This means it was 
not viable to review the histopathological samples and perform additional 
IHC to define the origin. We relied on the assessment of multiple pathol-
ogists throughout the country, which reflects daily practice. We assumed 
patients with NOS VPD to have non-invasive cutaneous VPD. The distri-
bution of the different types of VPD in our study cohort, resembles the 
distribution reported in literature.1 It is possible this assumption caused 
us to overestimate the incidence of associated malignancies in this sub-
group, since we might have included patients with VPD secondary to an-
other malignancy. 
Several studies report that perianal localisation of EMPD is a risk factor 
for intestinal or anal malignancies, and recent literature indicates that 
the location of the skin lesion influences the disease-specific survival.18,19 
Nonetheless, it is uncertain how the skin lesion and the intestinal ma-
lignancy are related to each other in case of secondary VPD. A recent 
epidemiological study by Karam et al. reported a higher risk of intesti-
nal malignancies in EMPD.20 They reported a SIR for any malignancy of 
1.47 (95%CI 1.17-1.84), but did not find a statistically significantly in-
creased risk for breast cancer (SIR 1.41, 95%CI 0.85-2.20), anorectal and 
colorectal malignancies (SIR 1.64, 95%CI 0.90-2.76), and bladder (SIR 
2.39, 95%CI 0.65-6.13) or kidney/pelvic malignancies (SIR 0.93, 95%CI 
0.02-5.21). However, this study included male and female patients with 
invasive disease. If the intestinal malignancy grows continuously to the 
epidermis, the question may be raised whether the EMPD lesion should 
be considered an expansion of the tumour rather than a separate entity. 
This holds especially in cases with invasive disease, as it is impossible to 
determine which lesion came first. 
As suggested above, differentiation between the subtypes of VPD (prima-
ry cutaneous, secondary to an intestinal, or secondary to a urological 
malignancy) may be of great importance for the risk of developing other 
malignancies. However, currently there are no clear guidelines for this dif-
ferentiation. It is generally accepted that the immunohistochemical profile 
of Paget cells can help to characterise different subtypes. As stated above, 
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the cutaneous phenotype is determined by a CK7+ and CK20- profile, the 
intestinal phenotype is determined by CK7-, CK20+, CDx2+, and the uro-
logical phenotype is determined by CK7+/-, CK20+, and Uroplakin-III+. 
These are the main markers used to distinguish primary from secondary 
VPD for almost two decades.3,21-23 There are no studies assessing the sen-
sitivity and sensibility of IHC in differentiating the different subtypes of in 
VPD, and the reliability of several other IHC stains can be discussed. For 
example GATA3, which is both reported to be sensitive as well as a po-
tential pitfall in recognising VPD secondary to urothelial malignancies.24,25 
Acknowledging this limitation, we assessed the risk of not screening for 
malignancy in those with a cutaneous IHC profile. Based on our data, 
refraining from additional screening for malignancies in case immuno-
histochemistry shows a cutaneous profile would have missed 5 patients 
over 15 years in the Netherlands, a country of ~17 million inhabitants. 
However, there are national screening programs for both breast and in-
testinal malignancies in which most patients would be screened anyhow. 
In case immunohistochemistry shows an intestinal or urological origin 
for the VPD lesion, a directed surveillance for the specific malignancies 
can be performed. To assist clinicians in the work-up of newly diagnosed 
VPD patients, we suggest a work-up according to the flowchart in figure 2. 
Even though our results indicate there may be no association with cuta-
neous VPD and underlying malignancy, screening may still be warranted 
depending on the clinical context.
Our study population contains 15 years of national data, and is the first to 
focus on primary non-invasive VPD. We were not able to match all cases 
reported in the PALGA database to patients registered in the NCR to obtain 
follow-up data. We therefore used the date of the last pathology report as 
the last date of follow-up. This may shorten follow-up times and therefore 
reduce the sample size: at 36 months after VPD diagnosis the cohort con-
sists of 101 patients. With a small cohort the number of expected events, 
i.e. the development of one of the associated malignancies, based on the 
incidence in the general age and calendar year corrected population would 
be smaller than 1 patient per year. This causes the SIR to be disproportion-
ately high for those years an associated malignancy was diagnosed. 
For inclusion in the study we required that associated malignancies had 
to be histologically confirmed. It is possible we missed cases of associat-
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Patient suspected for VPD
Consultation
Physical Examination:
Including vulvar biopsy.
Consider cervical smear and transvaginal
ultrasound
Histopathological examination:
Additional IHC, at least:
CK7, CK20, Uroplakin-III
Non-cutaneous VPD
CK7-/CK20+ or
Uroplakin-III +
Cutaneous VPD
CK7+/CK20-
Non-invasiveInvasive
Perform vulva
mapping
Treat as VSCC:
Surgery
Symptomatic approach:
Follow-up, medical or
surgical treatment
Cystoscopy and/or
colonoscopy
Individualized therapy, taking into account:
Location and extent of malignancy, location
and extent of vulvar lesion, patient factors
Screening positive
for malignancy
Screening
negative for
malignancy
Figure 2 Flowchart for the workup of newly diagnosed VPD patients.
VPD: vulvar Paget disease. IHC: Immunohistochemistry. Vulvar mapping: ideally consist-
ing of several punch biopsies taken from all suspicious lesions, histological slides are 
reviewed under the microscope and additional IHC is performed on all of the slides. VSCC: 
Vulvar squamous cell carcinoma.
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ed malignancies that were diagnosed via clinical examination or imaging, 
without histology. However, this is corrected by including only histologi-
cally confirmed malignancies in our background file of the general popu-
lation. 
The main goal of this study was to estimate the risk of developing associat-
ed malignancies in patients with VPD and to evaluate the need for screen-
ing for these malignancies. Looking at all patients with any type of VPD, 
we find that the risk of developing an associated malignancy is increased. 
VPD can be a sign of an internal malignancy, and may be a valuable cu-
taneous sign prompting earlier diagnosis. A diagnoses of secondary VPD, 
with an IHC phenotype favouring non-cutaneous origin, should prompt a 
search for internal malignancy above and beyond physical exam. 
The data in this study suggests promisingly that there is no statistical-
ly significant increase in cancer diagnosed in the first three years after 
primary non-invasive VPD compared with the general population. This 
may assist clinicians in reassuring and allaying concerns of patients with 
non-invasive VPD. Reassuringly, most of these patients are often at an age 
where they are offered screening for bowel, breast and cervical cancer. So, 
our main conclusion is that there is no evidence for routine screening in 
patients diagnosed with primary non-invasive VPD.
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Supplement table 1  Overview of patients with associated malignancy
Diagnosis Type Malignancy Before/After 
VPD diagnosis
Time between  
diagnoses (months)
1 ni-VPD NOS Breast
Urological
Before
Before
157
166 
2 ni-VPD Type 2 Breast
Intestinal
Before
After
158
2
3 ni-VPD Type 2 Intestinal
Urological
After
After
82
23
4 i-VPD NOS Breast Unknown Unknown
5 ni-VPD NOS Breast Before 213
6 ni-VPD NOS Breast Before 196
7 ni-VPD NOS Breast Before 160
8 ni-VPD NOS Breast Before 151
9 ni-VPD Type 3 Breast Before 138
10 ni-VPD NOS Breast Before 132
11 ni-VPD Type 1 Breast Before 118
12 ni-VPD NOS Breast Before 110
13 ni-VPD NOS Breast Before 95
14 ni-VPD Type 1 Breast Before 82
15 ni-VPD Type 1 Breast Before 47
16 ni-VPD NOS Breast Before 29
17 mi- VPD NOS Breast Before 24
18 ni-VPD Type 1 Breast Before 8
19 ni-VPD NOS Breast Before 6
20 ni-VPD NOS Breast Before 3
21 ni-VPD Type 1 Breast Before 3
22 ni-VPD NOS Breast After 1
23 ni-VPD NOS Breast After 2
24 ni-VPD NOS Breast After 17
25 ni-VPD Type 1 Breast After 75
26 mi- VPD NOS Breast After 83
27 ni-VPD NOS Breast After 108
28 ni-VPD Type 1 Breast After 116
29 i-VPD Type 1 Intestinal Before 272
30 ni-VPD NOS Intestinal Before 251
31 ni-VPD Type 2 Intestinal Before 247
32 ni-VPD NOS Intestinal Before 155
33 i-VPD Type 2 Intestinal Before 150
34 ni-VPD NOS Intestinal Before 96
35 i-VPD Type 2 Intestinal Same time -
36 ni-VPD Type 2 Intestinal Same time -
37 ni-VPD Type 2 Intestinal After 2
38 ni-VPD Type 2 Intestinal After 3
39 ni-VPD Type 2 Intestinal After 9
40 ni-VPD Type 2 Intestinal After 16
41 ni-VPD NOS Intestinal After 19
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Diagnosis Type Malignancy Before/After 
VPD diagnosis
Time between  
diagnoses (months)
42 i-VPD NOS Intestinal After 26
43 ni-VPD NOS Intestinal After 90
44 ni-VPD NOS Urological Before 249
45 ni-VPD NOS Urological Before 138
46 ni-VPD Type 3 Urological Before 103
47 ni-VPD NOS Urological After 11
48 ni-VPD NOS Urological After 39
49 ni-VPD Type 3 Urological After 50
50 i-VPD NOS Urological After 147
ni-VPD: non-invasive vulvar Paget disease, mi-VPD: micro-invasive vulvar Paget disease, 
i-VPD: invasive vulvar Paget disease, NOS: not otherwise specified.
Supplement table 1  Continued
Chapter 5
106
Stop routine screening for associated malignancies in non-invasive cutaneous vulvar paget disease?
107 

Cervical metastases  
originating from a primary 
rectal adenocarcinoma  
due to a pagetoid spread
M. van der Linden
P. Bult
I.D. Nagtegaal
L.F.A.G. Massuger
J.A. de Hullu
J. Bulten
Chapter 6
Human Pathology 
2017; 68: 184-8
Abstract
Vulvar Paget disease is a rare skin disorder, considered an in situ ade-
nocarcinoma. It is characterised by intraepithelial Paget cells, of which 
the origin is unclear. About 75% of cases have a cutaneous origin; the 
 other 25% originate from an intestinal or urological malignancy. We report 
the first case of retrograde pagetoid spread from a rectal adenocarcinoma 
to the vulva and cervix. A 66-year-old woman presented with postmeno-
pausal bleeding and a history of Crohn’s disease. Gynaecological workup 
revealed vulvar and endocervical lesions consisting of Paget cells and ad-
enocarcinoma, respectively. A rectal adenocarcinoma with in situ ade-
nocarcinoma was diagnosed. The surgical specimen demonstrated Paget 
cells in the squamous epithelium of the anus and vulva. Immunohisto-
chemistry demonstrated an intestinal phenotype of these cells. Genetic 
testing revealed the same TP53 mutation in tumour cells of the rectal 
adenocarcinoma and vulvar and endocervical lesions, demonstrating that 
the Paget cells originated from the same intestinal tumour.
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Introduction
Vulvar Paget disease (VPD) is a rare skin disorder that causes erythema-
tous scaling plaques.1 It is characterised by the presence of Paget cells in 
the epidermis. The origin of these Paget cells remains largely unknown. It 
is hypothesised that these Paget cells originate from the skin appendag-
es, from the mammary-like glands of the vulva, or from precursor Toker 
cells.1 The classification of Wilkinson and Brown distinguishes 3 types of 
VPD: primary cutaneous disease, and secondary spread of an intestinal or 
an urological malignancy.2 A few case reports reported a spread of cutane-
ous VPD via the vagina to the cervix.3-7 We present the first case of spread 
of Paget cells via the vulva to the cervix secondary to a rectal tumour. 
Materials and methods
Patient
A 66-year-old woman was referred to the department of Obstetrics and Gy-
naecology in our university medical centre for analysis of postmenopausal 
vaginal bleeding. In 1982, she was diagnosed with Crohn’s disease and 
underwent multiple abdominal surgical procedures. She had a history of 
rheumatoid factor-negative polyarthritis and uses disease-modifying anti-
rheumatic drugs. Her medical history also included hypertension, chron-
ic obstructive pulmonary disease, a meningioma, and recurrent urinary 
tract infections. She was referred to the urologist for analysis of hematuria 
and the recurrent urinary tract infections. Analyses excluded the urethra 
or bladder as the origin of the hematuria. Therefore, she was referred to 
investigate whether the bleeding originated from the gynaecological tract.
For several months, the patient noticed irregular bleeding of unknown or-
igin. Result of the last cervical smear, 5 years ago, was normal. Transvagi-
nal ultrasonography showed a retroverted uterus with normal ovaries and 
little fluid in the pouch of Douglas. Palpation of the cervix was normal. 
Some suspicious tissue was visible in the external ostium of the cervix 
and biopsied for histological assessment. A probable adenocarcinoma of 
1.3 cm was seen, suspected for an endometrial adenocarcinoma. The cer-
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Invasive rectal tumour: IHC/TP53 + 
Vulvar lesion: IHC/TP53 +
Rectal dysplasia: IHC/TP53 +
Endocervix: IHC/TP53 +
Distal anus: IHC (p53) +
LEGEND
vical smear showed malignant cells suspicious for endometrial adenocar-
cinoma, and was negative for high-risk human papilloma virus. Shortly 
after that, a vague erythematous vulvar lesion was biopsied and showed 
Paget cells in the vulvar epithelium with an intestinal phenotype: cyto-
keratin 7 negative and cytokeratin 20 positive. The patient underwent a 
hysterectomy with salpingo-oophorectomy for the suggested endometrial 
adenocarcinoma. Histological analysis revealed that an adenocarcinoma 
of the endometrium was not present. Leydig cell hyperplasia was present 
in the hilus of the ovaries. The cervical epithelium showed several atypical 
tubular structures, mainly consisting of Paget cells. 
Figure 1 Overview of anatomical location of lesions
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Additional colonoscopy was performed, and 2 polypoid lesions were bi-
opsied at the pectinate line and revealed a rectal adenocarcinoma with 
a diameter of 1.5 cm, surrounded by in situ adenocarcinoma. Figure 1 
presents the anatomical location of the several lesions. A positron emis-
sion tomographic scan ruled out lymph node metastases in the pelvis and 
groins, and an abdominoperineal resection was performed a few weeks 
later. Except for spontaneous discharge of an internal hematoma, the pa-
tient recovered well.
Samples
The endocervical tissue, complete vulvar lesion and multiple sections of 
the intestinal tissue were embedded in paraffin. Subsequent sections were 
stained with haematoxylin and eosin (H&E) and Alcian Blue. Paget cells 
were seen in the endocervical epithelium, in the epidermis of the vulva 
and adjacent to the rectal tumour. Representative slides of the adenocar-
cinoma of the pectinate line, surrounding in situ adenocarcinoma, and 
vulvar and endocervical lesions were selected and examined by 2 expert 
pathologists (JB, PB). 
Immunohistochemistry 
Immunohistochemistry (IHC) was performed using the routine steps of 
deparaffinisation, dehydration and antigen retrieval which was achieved 
after boiling with sodium citrate. Primary and secondary antibodies were 
used in the LabVision Autostainer 360 (ThermoFisher, Waltham, MA, 
USA), slides were counterstained with haematoxylin. CK7 (Clone OV-TL 
12/30 EDTA 1:400; VWR ImmunoLogic, Duiven, the Netherlands), CK20 
(Clone E19-1 citrate 1:100; VWR ImmunoLogic, Duiven, the Netherlands), 
CK8.18 (Clone CAM5.2 EDTA 1:10; BD Biosciences, San Jose, CA), and 
CDx2 (Clone CDx2-88 EDTA 1:50; VWR Klinipath, Duiven, the Nether-
lands) were used as primary antibodies. A p53 nuclear stain was performed 
as well (Clone DO-7 EDTA 1:400; ThermoFisher Scientific, Waltham, MA). 
Positive and negative controls were run for all samples.
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Genetic analysis
Selected representative slides of the rectal tumour, surrounding in situ 
adenocarcinoma, and vulvar and cervical lesions were verified by both ex-
pert pathologists (JB, PB) for mutation analysis. The neoplastic cells were 
marked in each slide, and the percentage of atypical cells was assessed. 
The fallopian tube was selected as normal tissue, to rule out a germ line 
mutation. Single molecule Molecular Inversion Probe base sequence ana-
lysis of the TP53 and CDKN2A genes was performed in a NextSeq 500 (Illu-
mina, San Diego, CA, USA). The selected gene panel analyzes >95% of the 
coding regions of TP53 (NM_000546.4) and CDKN2A (P14:NM_058195.1 
and P16: NM_000077.3). 
Results
Immunohistochemistry
The endocervical and vulvar lesions, distal anus, rectal in situ adenocarci-
noma, and adenocarcinoma had the same IHC profile: CK7 negative, and 
CK20, CK8.18 and CDx2 positive. These aforementioned lesions were now 
interpreted to be metastases of the rectal adenocarcinoma with Paget cells 
with an intestinal phenotype. p53 nuclear stain was strongly positive in 
the tumour cells in all slides as well. See figure 2 for an overview of the 
performed stains. 
Genetic analysis
TP53 mutation analysis revealed the same mutation (c.524G>A [p.{Ar-
g175His } ]) in all tissue samples: adenocarcinoma of the pectinate line, 
surrounding in situ adenocarcinoma, vulvar lesion, and endocervical ep-
ithelium. This mutation was not found in the healthy tissue of the fallo-
pian tube, suggesting that all lesions originated from the same tumour.
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 Alc Blue
HE
CDX2
CK8.18
p53
CK20
CK7
Rectal adenoca (      100µm) Vulvar Paget cells (      50µm) Cervical meta (      200µm)
Discussion
We have presented the first case of spread of Paget cells to the vulva and 
cervix, originating from a rectal tumour. Extension of VPD to the cervix has 
been reported in a few cases. Lloyd et al.7 reported a patient with a vulvar 
Figure 2 Overview of performed stains.
Overview of the different stains in the TP53+ rectal adenocarcinoma, vulvar Paget cells and 
the cervical metastasis. HE: Haematoxylin-Eosin, Alc Blue: Alcian Blue, CK: cytokeratin.
Cervical metastases originating from a primary rectal adenocarcinoma due to a pagetoid spread
115 
adenocarcinoma, the adjacent and overlying epidermis contained epithe-
lial membrane antigen-positive cells, diagnosed as Paget cells. These cells 
were also present in the vaginal mucosa, but not in a continuous pattern. 
Four weeks after the vulvectomy, a hysterectomy was performed because 
of a symptomatic prolapse, and Paget cells were also seen in the cervical 
tissue. Another case report described a patient with VPD of a cutaneous 
origin confirmed by IHC.3 A routine cervical smear revealed atypical cells 
and a cone biopsy was performed. In the histological tissue sample Paget 
cells were seen. Further sampling of the vaginal tissue was performed, also 
revealing Paget cells. Three case reports described patients with a cervical 
lesion or dysplasia.4, 6, 8 Two of the patients had a history of non-invasive 
primary VPD. Histological samples of the cervical lesions in all 3 patients 
contained Paget cells. During postoperative follow-up, the vaginal tissues 
of 2 patients were sampled, which revealed Paget cells as well.
One study retrospectively investigated the incidence of abnormal cervical 
smears in VPD patients.5 Three of the 19 VPD patients had an abnormal 
cervical smear result. In one case the cervical smear result was abnormal 
24 months after diagnosis with VPD and vaginal spread of the Paget cells 
was confirmed with a biopsy. Four years later, the patient was diagnosed 
and treated for a mucinous anal adenocarcinoma and an urothelial car-
cinoma of the bladder. The second case had an abnormal cervical smear 
result 84 months after the diagnosis of VPD, the assessment of the endo-
cervix revealed an invasive cervical adenocarcinoma with Paget cells, and 
follow-up smears remained positive for Paget disease. Histological sam-
ples revealed Paget cells in the vaginal tissue and invasive Paget disease in 
the urethra with metastases to the inguinal lymph nodes. A third patient 
had an atypical PAP smear result and the subsequent biopsies of the cer-
vix and vagina contained Paget cells. The patients were lost to follow-up 
after diagnosis. These cases may resemble our presented case. However, 
because of the limited description of the cases and the lack of IHC, we are 
not able to make a comparison between the cases. However, it is empha-
sised that Paget cells have the ability to migrate to other locations than 
their primary origin.
Most of the above mentioned reports of spread of Paget cells also reported 
IHC profiles consistent with a primary, or cutaneous, origin. The retro-
spective study of Gu et al. reported 1 patient with intestinal and urological 
malignancies, associated with VPD, and one patient with invasion.5 Re-
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sults of IHC in these specific patients would have been valuable to identify 
the origin of the Paget cells and the possible relation to the other malig-
nancies. 
A recent Japanese study included 6 patients with perianal or vulvar Paget 
disease and suspected spread of Paget cells to the anal canal, to investi-
gate the optimal surgical margin.9 Five patients underwent anal mapping: 
2 patients with perianal Paget disease (1 male and 1 female) had evidence 
of Paget cells at or close to the dentate line. The 3 other patients had VPD; 
the biopsies showed Paget cells of the anal verge, but not in the anal canal 
itself. Additional IHC to identify the origin of the Paget cells had not been 
performed in any of these cases.
Abnormal nuclear p53 is generally accepted as a marker for a mutation 
in the corresponding tumour suppressor gene at 17p13. Several studies 
have evaluated p53 IHC in vulvar Paget disease, with variable results.10-15 
In some studies p53 positivity was correlated to invasion; because of small 
sample sizes in the individual cases and variable definitions of invasion, 
it is uncertain whether this conclusion can be made. To our knowledge, 
TP53 mutation analysis in VPD has not yet been reported.
In our case, the cervical, vulvar, and intestinal lesions all originate from 
the same intestinal tumour or in situ adenocarcinoma based on the TP53 
mutation analysis. Further research into the genetics of Paget cells may 
help identifying the origin of these particular cells. Our case strongly sug-
gests that VPD with a cutaneous IHC profile has a different origin than 
secondary VPD. Additional research and evidence of this hypothesis may 
lead to further understanding of this rare disease and highlight possible 
clinical differences between primary and secondary disease. 
In conclusion, this is the first report of spread of secondary, intestinal ex-
tramammary Paget disease to the vulva and cervix. All affected locations 
were genetically proven to originate from the same rectal tumour. This 
raises the question of whether secondary Paget’s disease should be con-
sidered as a Pagetoid phenomenon, rather than a type of Paget’s disease.
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Abstract
Background: Non-invasive vulvar Paget disease (VPD) is a rare skin dis-
order mainly affecting elderly women. Recently, the immune modulator 
imiquimod was reported as an effective treatment option. Knowledge 
about the immune microenvironment of VPD is lacking. 
Methods: This study investigates the basic characteristics of the immune 
infiltrate in VPD (n=10); moreover the influence of imiquimod was stud-
ied (n=6). Immunohistochemistry for CD4, CD8, CD14, CD20, CD56 and 
FoxP3 was performed. The infiltrates of VPD were compared to vulvar 
high-grade squamous cell intraepithelial lesions (HSIL) (n=43), a HPV in-
duced vulvar premalignancy with known response to imiquimod cream, 
and healthy controls (n=30). Immune cell counts in samples taken before 
and after treatment were compared. 
Results: The microenvironment in VPD differs from the healthy vulvar 
skin and vulvar HSIL. VPD is characterised by a decrease in immune cells 
in the epithelium and an abundant number of immune cells in the stro-
ma, consisting predominantly of T cells. The intraepithelial CD8+/Foxp3+ 
ratio and number of CD56+ increased after imiquimod therapy, whereas 
the numbers of CD14+ cells decreased which may point to a treatment-in-
duced type 1 immune response.
Conclusions: The epithelium in VPD contains less immune cells, but a 
dense stromal immune infiltrate. Changes in immune cell counts after 
immune modulation in relation to clinical responses should be further 
investigated.
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Background
Vulvar Paget disease (VPD) is an uncommon non-invasive skin disorder 
mainly seen in elderly women. VPD causes symptoms like pain, pruritus 
and a skin lesion, which may be scaling or ulcerated.1 Patient’s as well as 
doctor’s delay play a significant role in recognising VPD because it pre-
sents like a dermal mycosis or eczema. The diagnosis is confirmed when 
so-called Paget cells are seen in histological skin samples. Paget cells are 
large, pleomorphic, pale cells with vacuolated cytoplasm in the epider-
mis. Secondary changes of the epidermis, such as acanthosis, papilloma-
tosis, elongated dermal rete ridges and parakeratotic hyperkeratosis are 
frequently seen. An inflammatory infiltrate in the papillary dermis and 
stroma of VPD has been noted.2 The mechanisms underlying of VPD and 
its treatment are a subject of discussion.
The aetiology of non-invasive VPD remains unclear; a commonly used 
hypothesis is that it is a premalignant abnormality of the skin adnexa, 
eccrine and/or apocrine glands.2 The risk of malignant progression in 
patients with non-invasive VPD is about 8% (unpublished submitted data 
van der Linden et al.). Paget cells generally stain positive for carcinoem-
bryonic antigen (CEA), cytokine 7 (CK7), epithelial membrane antigen 
(EMA) or mucin 1 (MUC1), MUC5AC and androgen receptors (AR). These 
Paget cells show variable expression for CK20, gross cystic duct fluid 
protein 15 (GCDFP-15) and the proliferation marker Ki-67.3, 4 The mech-
anisms underlying malignant transformation in non-invasive VPD are 
unclear.
Currently, the treatment of choice is surgical excision of the skin lesion, 
which often causes severe morbidity and psychosexual problems.1 Irre-
spective of the margin status, the recurrence rate is high (~35%), often 
resulting multiple surgical procedures.1 Moreover, comorbidity and age 
may hamper optimal surgery. Clearly, there is need for less invasive treat-
ment options. Topical 5% imiquimod cream is an immune modulator and 
has been reported to be effective in patients with anogenital warts, vulvar 
high-grade squamous cell lesions (HSIL) or actinic keratosis.5, 6 
Recent literature also reports clinical efficacy of imiquimod for non-inva-
sive VPD.7-9 A literature review reported complete clinical and histological 
remission in 73% of the case reports and case series.8 Two prospective 
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observational studies reported complete clinical and histological remis-
sion in 75% and 90% of the patients.7,9 The mechanism of response of 
topical 5% imiquimod cream in VPD is unclear and also the basic com-
position of the immune infiltrate in VPD.10 At present only two immune 
parameters in VPD are described; a higher number of FoxP3+ Tregs at 
the dermal-epidermal junction was associated with recurrent disease,11 
and CD163+ macrophages were detected more frequently in invasive 
VPD.12
The aim of this study was to investigate the microenvironment of VPD by 
examining the baseline composition of the immune infiltrate of the epithe-
lium and stroma in VPD, and to compare these findings to the immune in-
filtrate seen in healthy vulvar tissue samples and vulvar HSIL. In addition, 
we compared the immune cell counts before and after treatment with 5% 
imiquimod. The results of this study may help to understand the rationale 
of effectiveness of topical 5% imiquimod cream treatment for VPD. 
Methods
Patient material
We selected consecutive patients between 2000 and 2015 who underwent 
treatment with topical 5% imiquimod cream for non-invasive VPD at the 
Leiden University Medical Center (LUMC) and the Radboud university 
medical centre (Radboudumc), Nijmegen, the Netherlands. 
We included diagnostic tissue samples prior to treatment, and, if avail-
able, samples taken after treatment with imiquimod. As assessed by the 
institutional review board of the Radboudumc and the LUMC, the study 
was not subject to the Dutch ‘Medical Research Involving Human Sub-
jects Act’, i.e. it was exempt from approval. Clinical data were retrieved. 
Response to treatment is reported as the clinician reported the response 
in the medical files: complete response (CR) when there was no visible re-
sidual lesion, partial response (PR) when the lesion decreased in size, no 
response (NR) for cases in which the lesion size was stable or increased. 
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Pathology review
We obtained archival formalin fixed paraffin embedded (FFPE) blocks: 17 
diagnostic biopsy samples taken before treatment of a total number of 10 
patients. From 6 patients we obtained different samples taken after treat-
ment: 4 biopsy samples and 3 surgical excision specimens. All haematox-
ylin and eosin (HE) slides were reviewed by a gynaecological pathologist 
(TB) blinded for treatment. Vulvar (in situ) melanoma was excluded by ad-
ditional immunohistochemical staining (S100, MART, or HMB-45). CK7, 
p63, or CK8.18 staining was performed to confirm a cutaneous origin. In 
one case (patient 1), there was no evidence of disease in the sample after 
treatment. 
Immunohistochemistry
FFPE tissue blocks were retrieved from the pathology archives of the 
LUMC, and the Radboudumc, Nijmegen, the Netherlands. Ten blank 4µm 
slides were cut and blank slides were deparaffinised in xylene and rehy-
drated with ethanols. We selected CD4 as a marker for T-helper cells, CD8 
for cytotoxic T-cells, CD14 for monocytes as an indicator for macrophages, 
CD20 for B-cells, CD56 for NK-cells, and FoxP3 for regulatory T-cells. We 
performed single stain IHC for CD4 (anti-CD4, mouse monoclonal, clone 
4B12; DAKO 1:100), CD8 (anti-CD8+, mouse-IgG2b, clone 4B11; Leica 
1:400), CD14 (anti-human CD14, mouse, clone M5E2; BD Bio sciences 
1:100), CD20 (CD20cy, mouse, clone M0755; DAKO 1:1600), CD56 (an-
ti-CD56, mouse, clone M7304; DAKO 1:15) and FoxP3 (Anti-FOXP3, 
mouse, clone 236A/E7; ABCAM 1:400). 
For all stains endogen peroxidise activity was blocked with 0.3% H2O2/
MeOH solution for 20 minutes. Antigen retrieval was achieved in boil-
ing 10/1 mM Tris/EDTA buffer for 10 minutes and washed with phos-
phate-buffered saline (PBS) twice for 5 minutes for CD4, CD8, CD14 and 
CD56. For CD20 and FoxP3 antigen retrieval was achieved in boiling 
citrate (pH 6.0) for 12 minutes, cooling for 2 hours and washed with 
demiwater twice for 5 minutes. Tissue sections were incubated with 
the primary antibody diluted in PBS containing 1% bovine serum albu-
min (BSA) overnight. The tissue sections were incubated with BrightVi-
sion-Poly/HRP for 30 minutes. The slides were washed 3 times with PBS 
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for 5 minutes between each step. The antigen-antibody reaction was 
visualised with 0.05M Tris-HCL buffer (pH 7.6) with 0.05% of 3,3’-di-
aminobenzidine (DAB) and H2O2 30% for 10 minutes in CD8, and with 
DAB+ for the other stains. All slides were counterstained with haema-
toxylin. Cells positive for the antigens stained brown. A tonsil was used 
as a positive control, and a section without primary antibody served as 
a negative control.
Cell counts
Images were captured using the Pannoramic 250 digital slide scanner 
(3DHISTECH Ltd.). We selected five areas representing the density of the 
immune infiltrate in each sample. Images of these five areas were captured 
in each stained slide using Pannoramic viewer at 40x. Half of the images 
contained the epithelial layer and half of the image contained the sub-
dermal stroma. Stromal and epithelial cells were manually counted using 
the cell counter plug-in in ImageJ 1.48v software (National Institutes of 
Health, USA) by two individual researchers (MvdL and SvdS). The mean 
cell count for epidermal and stromal cells per image was calculated. Cell 
counts are converted and presented as number of cells per mm2. Each 
case was assigned a random subject number to ensure both researchers 
were unaware of the clinical characteristics of each case when analysing 
the immune infiltrate. 
The T-cell and monocyte infiltrate in VPD patients were compared to the 
infiltrate seen in samples of vulvar HSIL patients and healthy controls as 
published previously.13, 14 We used the median cell counts for CD4, CD8, 
CD14, and FoxP3 for healthy controls (n=30) and patients with vulvar 
HSIL (n=43).
Statistical analysis
All data were analysed using Statistical Package for the Social Sciences 
software package 20 (IBM SPSS 20). Data are presented in a descriptive 
manner. GraphPad Prism 5.03 (Graphpad Software Inc.) was used to il-
lustrate the data. 
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The average measures Intraclass Correlation Coefficient (ICC) was calcu-
lated using the Cronbach’s alpha method for inter-rater reliability. In case 
of poor consistency, defined as Cronbach’s alpha <0.7, cases in which the 
cell counts differed more than 25% were identified. In cases with less than 
10 counted cells, the difference was accepted. In cases the counted cells 
were more than 10, the cases were reassessed to ensure the entire views 
were counted, and difficulties in differentiating stained cells and blur was 
discussed to resolve disagreement between the two researchers to decide 
on a representative cell count. A log-transformation was performed as 
the inter-observer residues were not normally distributed. The ICC was 
excellent for all stains except for the epithelial counts in the CD14 stain. 
This was due to one outlier in a case of an extremely dense infiltrate which 
covered the basal membrane. After sensitivity analysis in which the outli-
er was excluded, the ICC was acceptable. The ICC and sensitivity analysis 
are reported in supplement table 1. 
The Shapiro Wilk test was used to determine a normal distribution. All 
variables were non-parametric. The Mann Whitney U test was used to 
compare independent groups: healthy controls versus vulvar HSIL pa-
tients versus vulvar Paget disease patients. The Wilcoxon Signed Rank 
test was used to compare the continuous variables between groups: first 
sample taken before versus first sample taken after treatment. Two sided 
p values <0.05 were considered statistically significant.
Results
Patient characteristics
We selected 10 patients with non-invasive VPD who were treated with top-
ical 5% imiquimod cream: 6 from the Radboudumc and 4 from the LUMC. 
The median age of the patients at time of diagnosis was 72 (63-90) and the 
median follow-up time was 39 months (range 4-166 months). Of the 10 
patients, four (40%) had a complete response, 4 (40%) a partial response 
and 2 (20%) no response to treatment. See table 1 for an overview of the 
patient characteristics. An overview of the used patient materials is given 
in supplement table 2.
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Characteristic N=10
Age at diagnosis (years)
Median 72 (63-90)
Imiquimod treatment (weeks)
Median 13 (10-24)
Response to imiquimod treatment, n (%)
CR 4 (40%)
PR 4 (40%)
NR 2 (20%)
Follow-up time (months)
Median 39 (4-166)
Follow-up status
Alive 9 (90%)
Dead, cause unknown 1 (10%)
Table 1 Patient characteristics.
CR: complete response, defined as no visible residual lesion. PR: partial response, defined 
as a decrease in lesion size. NR: no response, defined as stable disease or increase in 
lesion size.
Characteristic Samples taken 
before treatment 
n (%)
(N=17)
Samples taken 
after treatment 
n (%)
(N=7)
Infiltrate Strong 5 (29.4%) 4 (57.1%)
Moderate 6 (35.3%) 1 (14.3%)
Minimal 5 (29.4%) 2 (28.6%)
None 1 (5.9%) 0
Cell type Mixed 1 (5.9%) 2 (28.6%)
Mixed, favouring granulocytes 1 (5.9%)
Mixed, favouring eosinophiles 0 1 (14.3%)
Granulocytes 1 (5.9%) 0
Lymphocytes 8 (47.0%) 1 (14.3%)
Lymphocytes and granulocytes 1 (5.9%) 0
Lymphocytes and eosinophiles 0 1 (14.3%)
Neutrophiles 1 (5.9%) 0
Unclear 4 (23.5%) 2 (28.6%)
Table 2 Semi-qualitative analysis of immune infiltrate VPD.
Characteristics of the immune infiltrate and cell types after semi-qualitative analysis of 
vulvar Paget disease samples taken before and after treatment with imiquimod cream.
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Semi-qualitative analysis of the immune infiltrate
To establish that immune cells are present in VPD, we characterised the 
immune infiltrate in the epithelium and stroma on H&E slides (supple-
mental figure 1 and table 2). The composition of the immune infiltrate of 
the diagnostic VPD biopsies showed a mixed morphology, consisting most-
ly of mononuclear cells (52.9%), admixed with granulocytes in a subset of 
cases (17.7%). The majority of the pretreatment samples showed a moder-
ate to prominent immune infiltrate (11 of 17 samples, data not shown). On 
H&E no obvious difference in immune infiltrate composition was noted in 
the 7 specimens taken after treatment. In a subset of the specimens taken 
after treatment, eosinophilic granulocytes were present (28.6%). 
Immune microenvironment in VPD
To characterise the type of immune cells present in VPD, we performed 
immunohistochemical stainings. We found a great variety between the 
five images of each slide, and between the multiple samples taken per 
Figure 1 Distribution of immune cell types in non invasive VPD.
Number of median cell counts per sample for CD4 (T helper cells), CD8 (cytotoxic T-cells), 
CD14 (monocytes), CD20 (B cells), CD56 (NK cells), FoxP3 (regulatory T-cells) per mm2, 
and CD8+/FoxP3+ ratios in non-invasive vulvar Paget. 
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Figure 2 Distribution of immune cell counts in healthy controls, vulvar HSIL patients, 
and VPD patients.
Number of CD4 (T helper cells), CD8 (cytotoxic T-cells), CD14 (monocytes) or FoxP3 (regula-
tory T-cells) per mm2 and CD8+/FoxP3+ ratios. * is a significant (<0.05), or non significant 
(ns) p-value, analysed with the non-parametric Mann-Whitney U test used to determine 
differences between healthy controls versus vulvar Paget disease patients, and vulvar 
HSIL patients versus vulvar Paget disease patients. A: epithelial, B: stromal cell counts.
Chapter 7
130
patient. The vast majority of immune infiltrate consisted of T cells (94% of 
the epithelial compartment, and 67% of the stromal compartment, data 
not shown). The microenvironment of VPD is mainly infiltrated with CD4+ 
and CD8+ T-cells, followed by CD14+ cells, FoxP3+, CD56+ and CD20+ 
cells. See figure 1 for the distribution of the different cell types, and sup-
plemental figure 2 for all stains in a representative case with a moderate 
immune infiltrate. 
Comparison of VPD to healthy controls and vulvar HSIL
The immune infiltrate of VPD was compared to healthy vulvar tissue and 
vulvar HSIL, a premalignant vulvar disease with a known response to 
treatment with 5% imiquimod cream. The median epithelial and stromal 
cell counts for 30 healthy controls, 43 vulvar HSIL and for 10 diagnostic 
VPD samples (prior to treatment) are presented in figure 2. 
In the epithelial compartment of pretreatment VPD samples, the numbers 
of CD4+ and CD8+ T-cells are significantly decreased compared to healthy 
controls, and also was the CD8+/Foxp3 ratio. The numbers of intraepi-
thelial CD14+ and FoxP3+ cells did not differ from healthy controls. In 
contrast, stromal numbers of CD4+, CD8+, Foxp3+ and CD14+ cells and 
the CD8+/Foxp3 ratio were significantly higher than healthy controls. 
Both intraepithelial and stromal Foxp3+ cells were much more pronounced 
in vulvar HSIL compared to VPD, whereas the number of intraepithelial 
CD4+, CD8+, and Foxp3+ T-cells were decreased in VPD (figure 2). The 
CD8+/FoxP3 ratio was significantly lower in the epithelium of VPD com-
pared to HSIL, and significantly higher in the stroma of VPD compared to 
HSIL.
In summary, we found that VPD lesions are highly infiltrated by immune 
cells. In the epidermis of VPD patients, numbers of CD4+ and CD8+ 
T-cells and the CD8+/Foxp3 ratio were lower compared to healthy con-
trols. In contrast, VPD is immunologically characterised by high numbers 
of CD4+, CD8+, Foxp3+ and CD14+ cells in the stroma.
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Immune cell counts in VPD before and after topical 5% imiquimod therapy
Immune cell counts before and after imiquimod therapy for the patient 
group and in individual patients are reported in table 3 and figure 3. Over-
all, there were no significant differences between samples taken before 
and after treatment. However, the numbers of CD8+ and FoxP3+ T cells in 
the epithelial compartment were increased after imiquimod treatment as 
was the ratio of CD8/FoxP3, reflecting a relative increase in CD8+ T cells. 
A decrease of CD14+ and an increase of CD56+ cells in the epithelium 
was seen in the post treatment samples. Due to the small sample size and 
differences in time point of post treatment samples it was not possible 
to draw any definite conclusions about changes in immune cell counts 
and relation to clinical responses in VPD patients who were treated with 
imiquimod.
Cell type Before treatment (n=10)
Median (range)
After treatment (n=6)
Median (range)
p-value*
CD4+ (E) 16.3 (0.0-127.0) 13.0 (3.3-78.2) 0.600
CD4+ (S) 869.7 (397.4-2384.2) 804.5 (74.9-1742.6) 0.600
CD8+ (E) 19.5 (3.3-13.2) 76.5 (0.0-211.6) 0.173
CD8+ (S) 437.8 (45.6-2128.7) 945.5 (19.5-1708.8) 0.600
CD14+ (E) 3.3 (0.0-6.5) 0.0 (0.0-182.3) 0.496
CD14+ (S) 485.0 (55.3-1087.1) 136.7 (13.0-1204.3) 0.686
CD20+ (E) 0.0 (0.0-6.5) 1.6 (0.0-19.5) 0.414
CD20+ (S) 195.3 (6.5-953.7) 200.2 (0.0-2226.4) 0.753
CD56+ (E) 0.0 (0.0-3.3) 9.8 (0.0-19.5) 0.066
CD56+ (S) 97.6 (13.0-247.4) 84.6 (26.0-188.8) 0.917
FoxP3+ (E) 4.9 (0.0-32.6) 14.6 (0.0-61.8) 0.500
FoxP3+ (S) 118.8 (22.8-322.2) 200.2 (26.0-813.7) 0.463
CD8/FoxP3 ratio (E) 1.0 (0.0-2.5) 3.7 (2.0-6.6) 0.138
CD8/FoxP3 ratio (S) 4.2 (0.0-9.3) 3.4 (0.8-5.5) 0.674
Table 3 Comparison of immune cells before and after treatment.
Median cell counts per mm2 in the first samples taken before or after treatment per patient. 
* Significant p-values <0.05 by analysis with the non-parametric Wilcoxon Signed Rank 
test used to determine differences between samples taken before versus after treatment 
with imiquimod cream. (E) = epithelium, (S) = stroma.
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Figure 3 Immune cell types in non invasive VPD before and after imiquimod treatment 
in individual patients.
Number of median cell counts per sample for CD4 (T helper cells), CD8 (cytotoxic T-cells), 
CD14 (monocytes), CD20 (B cells), CD56 (NK cells), FoxP3 (regulatory T-cells) per mm2, 
and CD8+/FoxP3+ ratios in non-invasive vulvar Paget disease before and after treatment 
with 5% imiquimod cream. A: epithelial compartment, B: stromal compartment.
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Discussion
This study is the first to describe the immune microenvironment in non-in-
vasive vulvar Paget disease compared to the immune infiltrate to healthy 
controls and vulvar HSIL. We found that the epithelium of VPD has few 
immune cells, whereas the stromal compartment is highly infiltrated by 
CD4+, CD8+, Foxp3+ T cells, and CD14+ cells. 
In the normal healthy vulvar skin, the immune infiltrate consists mainly 
of T-cells.13 Pathological review of non-invasive VPD samples revealed that 
VPD is histologically characterised by a prominent stromal infiltrate con-
sisting of a mixed population of immune cells with a prominence of T-cells. 
Monocytes, NK-cells and B-cells are present, but are much less abundant. 
The epithelial compartment of VPD seems immunocompromised as the 
numbers of CD4+ and CD8+ cells as well as the CD8+/Foxp3 ratio were 
significantly decreased compared to healthy controls, whereas the stromal 
compartment contains significantly more T-cells and monocytes. We hy-
pothesise that the immune cells are unable to penetrate the intraepithelial 
compartment to clear the Paget cells. There are three possible explana-
tions for this phenomenon. First, an acute immune response may occur at 
the onset of VPD. It is known that there is severe delay in diagnosing VPD, 
it is possible the acute immune response faded into a chronic infiltrate by 
the time the first histological biopsy is taken. Second, the Paget cells may 
excrete cytokines that suppress a local immune response and impede the 
immune cells to penetrate the basal membrane. This phenomenon where 
local immunity is suppressed was recently described in serous tubal in-
traepithelial carcinoma as a precursor for serous ovarian cancer.15 Third, 
it is possible that Paget cells are not recognised by the immune system 
as malignant or aberrant cells. This may be due to limited or no neo-an-
tigen production by Paget cells, which to our knowledge has never been 
investigated. Whether the immunocompromised epithelium or the strong 
stromal immune infiltration may point to the underlying pathogenesis of 
VPD, should be examined in future studies. 
We observed a high variability in the immune microenvironment between 
patients, as well as between samples from one patient. A possible expla-
nation is that the composition of the immune infiltrate is influenced by 
the experienced symptoms, or by topical treatments like dermatosteroids. 
Patients who experience severe symptoms like itching may scratch more 
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often, causing a non-specific chronic inflammation as often seen in lichen 
simplex chronicus.16 On the other hand, the main symptom in psoria-
sis is pruritus, whereas psoriasis is associated with a minimal infiltrate. 
Therefore it is unlikely the observed heterogeneity is solely based on an 
itch-scratch-cycle. 
In solid tumours, the tumour microenvironment has a key role in onco-
genesis and tumour progression.17 A strong Th1 cytotoxic microenviron-
ment, consisting of CD8+ cytotoxic T cells, CD4+ T helper cells, M1 mac-
rophages, NK-cells and dendritic cells, is associated with a more favorable 
prognosis and therapy responsiveness. In vulvar HSIL, high stromal 
CD8+/Treg ratio’s and low amounts of epithelial macrophages are associ-
ated with better clinical outcomes.14 A high CD8+/Treg ratio in the stroma 
or increased numbers of stromal CD4+ or CD8+ T-cells expressing the 
co-inhibitory markers TIM3 or NKG2A are associated with a prolonged re-
currence free survival time, or an absence of recurrences.13 In this study, 
we found a high CD8+/Foxp3 ratio in the stroma of VPD as well as high 
numbers of CD4+ and CD8+ cells, but the clinical significance should be 
examined in larger studies.
Compared to healthy controls and vulvar HSIL, high numbers of stromal 
CD14+ monocytes are present in VPD. The significance of these CD14+ 
cells in VPD is not clear. In general, CD14+ monocytes are marked as 
macrophages but can be precursors of (immature) inflammatory DCs as 
well; where CD14+ DCs are described to reside in the tissues and lymph 
nodes as interstitial DCs.18-20 Subtyping can be done by CD163 for M1 or 
M2 macrophages and by CD11c or CD68 cells for DCs or DC-like-mac-
rophages.21 In melanoma and cervical carcinoma, an adequate immune 
response is reflected by if stromal M1 macrophages predominate the M2 
macrophages.21, 22 A recent study showed that M2 type CD163+ macro-
phages were associated with malignant progression in VPD.12 Dendritic 
cells, and Langerhans cells in the epithelium, are important in the tumour 
micro-environment and are for example involved in the regression of mela-
nomas.23 Recently it is reported in melanoma research that DC’s express-
ing galectin 9 (Gal9) reflect an IFNy related Th1 cell immune response, and 
are an independent predictor of favourable survival.21 In dysplastic naevi 
a higher density of CD1a+ Langerhans cells was described as compared 
to both invasive melanoma and melanoma in situ illustrating the impor-
tance of presence of antigen presenting cells. Interestingly, it is known 
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that CD14+ cells can differentiate into CD1a+ Langerhans cells under in-
flammatory circumstances.24 Indeed, in vulvar HSIL, HPV clearance after 
treatment with imiquimod was associated with a decreased number of in-
traepithelial CD14+ cells and an increased number of CD1a+ Langerhans 
cells.6 Another study in patients with vulvar HSIL it was shown that the 
risk of recurrence was highly associated with a dense CD14+ macrophage 
intraepithelial infiltrate.14 Further characterization of the CD14+ cells is 
needed to clarify the significance in VPD.
Imiquimod is an immune response modifier that triggers toll-like receptor 
7 (TLR-7) which leads to T-cell activation and an anti-tumour response.25, 
26 In a melanoma-bearing humanised mouse model imiquimod was found 
to directly mobilise plasmacytoid dendritic cells and to trigger cytotoxic 
functions: the expression of type 1 IFN response genes was up regulated.27 
Topical immunotherapy with imiquimod cream was proven to be effective 
for vulvar HSIL.5 Clinical responses after imiquimod treatment were asso-
ciated with increased numbers of intraepithelial CD1a and CD8+ cells and 
a decrease in Treg cells in the stroma.6,28 Although our sample size was 
too small to draw any definite conclusions from the biopsies taken before 
and after imiquimod therapy, we found that the numbers of CD8+ cells 
and the ratio of CD8/FoxP3 in the epithelial compartment were increased 
after imiquimod treatment whereas the numbers of CD14 decreased, sug-
gesting a shift towards a type 1 IFNy related immune response which is 
the hallmark of an effective immune response. Recently, we completed a 
prospective study on treatment of VPD with topical 5% imiquimod cream 
(NCT02385188).29 An analysis of pre- and post treatment immune infil-
trate in treated patients will reveal if changes in immune cell counts cor-
relate with clinical outcomes in VPD. Based on the results of this study 
we will further focus on the phenotyping of T-cells, DC’s and macrophages 
in VPD.
In conclusion, the microenvironment of VPD differs from the healthy skin 
and vulvar HSIL. An immunocompromised epidermis and a stromal de-
partment rich of immune cells characterise VPD. Future research will fo-
cus on further specifying the T-cell population and myeloid cells in VPD, 
and correlation of changes in the immune infiltrate after imiquimod treat-
ment to clinical outcomes. 
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Supplement table 1  Intraclass correlation coefficient.
Cell type Epithelial cell count Stromal cell count
CD4+ 0.905 (95%CI 0.780-0.959) 0.990 (95%CI 0.977-0.996)
CD8+ 0.968 (95%CI 0.926-0.986) 0.990 (95%CI 0.976-0.996)
CD14+ 0.655 (95%CI 0.186-0.854) 0.967 (95%CI 0.921-0.986)
CD14+ SA 0.748 (95%CI 0.405-0.893) 0.856 (95%CI 0.660-0.939)
CD20+ 0.973 (95%CI 0.938-0.988) 0.995 (95%CI 0.989-0.998)
CD56+ 0.970 (95%CI 0.931-0.987) 0.979 (95%CI 0.951-0.991)
FoxP3 0.804 (95%CI 0.547-0.915) 0.984 (95%CI 0.963-0.993)
Intraclass correlation coefficient for the epithelial and stromal cell counts per staining 
protocol. SA: sensitivity analysis of ICC after exclusion of outlier.
Supplement table 1  Summary of available samples per patient.
Patient Type of 
sample
Moment of 
sample
Treatment 
(weeks)
Weeks be-
tween sam-
ple and end 
of treatment
Clinical 
response
Histological 
response
1 Biopsy Before treatment
Biopsy After treatment 11 0 PR CR
2 Biopsy Before treatment
3 Biopsy Before treatment
Excision After treatment 13 1 NR NR
4 Biopsy Before treatment
5 Biopsy Before treatment
Excision After treatment 12 12 NR NR
6 Biopsy Before treatment
Biopsy Before treatment
Excision After treatment 13 125 PR NR
7 Biopsy Before treatment
Biopsy After treatment 13 30 CR NR
Biopsy After treatment 10 36 CR NR
8 Biopsy Before treatment
Biopsy Before treatment
Biopsy Before treatment
Biopsy Before treatment
Biopsy After treatment 11 6 CR NR
9 Biopsy Before treatment
Biopsy Before treatment
10 Biopsy Before treatment
Biopsy Before treatment
Biopsy Before treatment
Overview of the available samples per patient, type of sample and moment the sample was 
taken, the number of weeks the patients received treatment with imiquimod cream, num-
ber of weeks between the end of treatment and moment the sample after treatment was 
taken, and the response to treatment. For clinical response; CR: complete response: no vis-
ible residual lesion. PR: decrease in lesion size. NR: no response, stable disease or increase 
in lesion size. For histological response; CR: no Paget cells present. NR: Paget cells present.
The immune infiltrate in vulvar paget disease
139 
A B
DC
Examples of the immune infiltrate in samples of 4 different patients with non-invasive 
vulvar Paget disease before treatment, H&E 20x. A: no infiltrate, B: minimal infiltrate, C: 
moderate infiltrate, D: strong infiltrate
Supplemental figure 1  Immune infiltrate density in non-invasive vulvar Paget disease.
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Examples of the immunohistochemistry in the sample of 1 patient (subject 2) with a mod-
erately dense immune infiltrate in non-invasive vulvar Paget disease before treatment 
with imiquimod cream. A: CD4, 20x. B: CD8, 20x. C: CD14, 20x. D: CD20, 20x. E: CD56, 
20x. F: FoxP3, 20x. e: epithelium. s: stroma.
Supplemental figure 2  Immunohistochemistry in a moderately dense immune infiltrate. 
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Abstract
Background: Vulvar Paget disease is a rare skin disorder, which is most 
common in postmenopausal Caucasian women. They usually present with 
an erythematous plaque that may show fine or typical "cake icing" scaling 
or ulceration that may cause itching, pain, irritation, or a burning sen-
sation. Although most cases are non-invasive, vulvar Paget disease may 
be invasive or associated with an underlying vulvar or distant adenocar-
cinoma. The histological evidence of so-called "Paget cells" with abundant 
pale cytoplasm in the epithelium confirms the diagnosis. The origin of 
these Paget cells is still unclear. Treatment of choice is wide local excision 
with negative margins. Obtaining clear surgical margins is challenging 
and may lead to extensive and mutilating surgery. Even then, recurrence 
rates are high, ranging from 15% to 70%, which emphasises the need for 
new treatment options. A number of case reports, retrospective case se-
ries, and one observational study have shown promising results using the 
topical immune response modifier imiquimod. 
Objective: This study aims to investigate the efficacy, safety, and immu-
nological response in patients with non-invasive vulvar Paget disease us-
ing a standardised treatment schedule with 5% imiquimod cream.
Methods: Topical 5% imiquimod cream might be an effective and safe 
treatment alternative for vulvar Paget disease. The Paget Trial is a multi-
center observational cohort study including eight tertiary referral hospitals 
in the Netherlands. It is ethically approved by the Medical-Ethical Commit-
tee of Arnhem-Nijmegen and registered in the Central Committee on Re-
search Involving Human Subjects (CCMO) Register by as NL51648.091.14. 
Twenty patients with (recurrent) non-invasive vulvar Paget disease will be 
treated with topical 5% imiquimod cream three times a week for 16 weeks. 
The primary efficacy outcome is the reduction in lesion size at 12 weeks 
after end of treatment. Secondary outcomes are safety, immunological re-
sponse, and quality of life. Safety will be assessed by evaluation of adverse 
events and tolerability of treatment. To evaluate the immunological re-
sponse, various immunological markers will be tested on biopsy specimens 
taken before, during, and after treatment. Quality of life will be assessed 
with three questionnaires taken before, during, and after treatment.
Results: First results are expected in the summer of 2018.
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Introduction
Cutaneous Paget disease was first described in a series of patients with 
nipple ulceration and an underlying breast carcinoma. This became 
known as mammary Paget disease (MPD).1 When the same condition was 
reported on the scrotum and vulva, these were named extramammary 
Paget disease (EMPD).2, 3 
The presence of so-called Paget cells in the basal layers of the epitheli-
um is pathognomonic for this rare disease. The origin of these large cells 
with abundant clear, pale cytoplasm, which often contain mucin, remains 
unclear. The most common hypothesis is that Paget cells originate from 
adnexal structures, such as apocrine glands or multipotent stem cells in 
the basal layer of the epidermis.4, 5 Other theories suggest the anogenital 
area contains mammary- like glands, or that Toker cells, also seen in the 
nipple in mammary Paget disease, are precursor cells for EMPD.6-8
The incidence rate of EMPD is 0.11 per 100,000 person-years, based on an 
epidemiological study with data of the Netherlands Cancer Registry.9 Vul-
var Paget disease (VPD) causes pain, itching or a burning sensation, and 
a skin lesion which can be described as a scaling, erythematous plaque 
which sometimes shows ulceration. VPD typically presents in postmeno-
pausal Caucasian women.8
Vulvar Paget disease can be divided in primary VPD, which is cutaneous 
and secondary VPD, which is non-cutaneous. Table 1 illustrates the dif-
ferent types of VPD.10.
Primary EMPD  
(cutaneous)
Type 1a Associated with non-invasive, intraepithelial disease
Type 1b Associated with invasive disease
Type 1c Associated with an underlying adenocarcinoma
Secondary EMPD  
(non-cutaneous)
Type 2 EMPD originates from intestinal adenocarcinoma
Type 3 EMPD originates from urothelial carcinoma
Table 1  Different types of vulvar Paget disease
VPD is associated with different malignancies, mainly an underlying vulvar, in-
testinal or urological malignancy, and breast cancer. About 20% of patients are 
THE PAGET TRIAL
145 
reported to have an associated malignancy in their history. Therefore screening 
for underlying carcinoma is advised, although there is no evidence for screen-
ing, and no consensus on the extent of the additional diagnostic procedures.11,12
Historically, the treatment of choice for VPD is wide local excision with 
clear margins, which is not always easy to realise on the vulva. Because 
Paget cells are found widely spread throughout the anogenital area, it is 
almost impossible to obtain clear surgical margins.13,14 The recurrence 
rates of VPD are high: 15 to 70%, independent of margin status. The risk 
of recurrence is highest in the first year after treatment.15 To improve ob-
taining clear surgical margins, Moh’s Microsurgery (MMS) has been eval-
uated for treatment of VPD. In MMS, the lesion is excised and the entire 
margin is examined immediately.16 In case the margin is not clear the 
excision is repeated, enlarging the circumference until the margins are 
clear. This technique may lead to lower recurrence rates.17 However, large 
vulvar excisions may require plastic reconstruction. 
Extensive vulvar surgery can cause permanent mutilation and functional 
impairment.18-22 To address this problem, alternative treatment options 
such as photodynamic therapy, radiotherapy, chemotherapy, laser treat-
ment and recently topical 5% imiquimod cream have been used in pa-
tients with VPD, with varying degrees of success.23-30 
Topical 5% imiquimod cream is an immune response modifier. It binds 
to toll-like receptor 7, inducing an innate and cell-mediated immune re-
sponse.31 It has antiviral and antitumour properties and is registered for 
the treatment of condylomata acuminata, actinic keratosis and superficial 
basal cell carcinomas. Also Imiquimod has shown to be effective for hu-
man papilloma virus (HPV) induced usual vulvar intraepithelial neoplasia 
(uVIN).32, 33 The mechanism of action of imiquimod and local immunity in 
VPD are not known.
More recently, a number of case reports, case series and one observa-
tional trial that reported on the use of topical 5% imiquimod cream for 
VPD, showed that imiquimod may be an effective treatment option.34, 35 A 
systematic review also concluded it is an effective alternative for VPD.36 
However, most studies described limited numbers of patients, various 
treatment schedules and short follow-up periods. Therefore, it is imposs-
ible to pool data from previous study to make final conclusions about the 
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efficacy. The authors of the systematic review also mentioned the risk of 
publication bias: only positive results may be published retrospectively.36 
Objective
The objective of this study is to assess the clinical efficacy, safety, and 
local immunity of topical 5% imiquimod cream in patients with non-inva-
sive vulvar Paget disease. 
Methods/design
Study design
This study is a multi-centre, prospective, open-label observational cohort 
study in patients with histologically proven, non-invasive VPD. Patients 
will be treated with topical 5% imiquimod cream three times a week for 16 
weeks, with follow-up of one year after the end of treatment.
Study setting
As VPD is rare, with an estimated incidence of 4 to 7 cases per year in 
the Netherlands, the trial will be carried out in 7 tertiary referral hospitals 
with a vulvar clinic in the Netherlands. Vulvar clinics are outpatient mul-
tidisciplinary clinics with participation of both gynaecologists and derma-
tologists who are specialised in disorders of the vulva.
Participating centres are: 
• Antoni van Leeuwenhoek, Netherlands Cancer Institute, Amsterdam; 
• Catharina Ziekenhuis, Eindhoven;
• Erasmus Medical Center, Rotterdam;
• Leiden University Medical Center;
• Radboudumc, Nijmegen;
• University Medical Center Groningen;
• University Medical Center Utrecht.
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Participants
All patients with histologically proven non-invasive cutaneous VPD visit-
ing or referred to a participating clinic will be asked to participate in this 
study. We estimate to include one patient per centre per year because of 
the rarity of the disease.
Inclusion criteria are: non-invasive VPD (primary or recurrence after ear-
lier surgery or imiquimod treatment more than 6 months ago), age 18 and 
older, willing and able to comply with the protocol and provide informed 
consent in accordance with institutional and regulatory guidelines. Most 
patients are expected to be elderly, postmenopausal women, who may 
suffer from co-morbidities. All patients are instructed on how to apply the 
imiquimod cream by their clinician, according to the leaflet provided by 
the manufacturer, and using a mirror. In cases the patient is physically 
unable to apply the cream, a health care provider (for example a nurse of 
the nursing home, or via domiciliary care) will receive written instructions. 
If the patient consents, a printed photograph in which the affected skin 
is marked will be provided. Main exclusion criteria are: current invasive 
VPD, underlying adenocarcinoma and treatment of the vulva with topical 
5% imiquimod cream during the last 6 months.
Sample size
Based on the estimated incidence of VPD in the Netherlands, viability is 
set at 20 inclusions. Our sample size considerations are based on the 
response rate. The primary outcome variable is the response at 12 weeks 
after end of treatment with topical 5% imiquimod cream. The only obser-
vational study on this topic, at time of conception of this trial, reported a 
response in 9 out of 10 women.35 Assuming a complete response rate of 
80%, a cohort size of 20 patients is sufficient to estimate the complete re-
sponse rate with a standard error of 9%, using the normal approximation 
for the binomial distribution. As we presume that the dropout rate will not 
exceed 20%, a maximum of 25 patients will be included. When 20 patients 
have been treated with topical 5% imiquimod cream for at least 8 weeks, 
we will stop recruitment. 
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Study intervention
All patients will be treated with topical 5% imiquimod cream 3 times a 
week for 16 weeks. This treatment schedule is based on the treatment 
schedule for condylomata acuminata and on a previous randomised con-
trolled trial of imiquimod 5% for usual vulvar intraepithelial neoplasia.31, 
33 The healthy skin around the visible lesion can be protected with an in-
different basic ointment. Patients are allowed to use topical 3% lidocaine 
in vaseline ointment if they experience pain at the application site. There 
must be a one hour interval between the application of different topical 
agents. Patients are also allowed to use paracetamol. In case of severe 
pain, when paracetamol and 3% lidocaine ointment are insufficient, it is 
permitted after consultation with the clinician to stop the treatment with 
topical 5% imiquimod cream for one week at a time. Patients are allowed 
to stop/delay treatment for a total of 3 weeks within the assigned treat-
ment period.
In case of a suspected secondary bacterial infection, fucidin cream or 
ointment 20 mg/g will be prescribed. The patient will apply the fucidin 
cream or ointment 3 times a day, according to the prescription. No other 
local products than imiquimod cream, lidocaine, indifferent moisturisers 
or fucidin are allowed to be applied at the lesion site. On individual basis, 
other topical products will be considered as a protocol violation.
Study schedule
Patients will visit the clinic 7 times during the study; the final visit will be 
one year after the end of treatment (Table 2). One consultation will take 
place by telephone. During these consultations, pain will be measured 
by means of the visual analog scale (VAS) score for pain. Pain, burning 
and itching will be asked on a four-point likert scale. During the visits, 
the clinical response will be evaluated by vulvar examination and bi-di-
mensional measurement of the visible lesions. The histological effect will 
be assessed by pathological assessment of the presence of Paget cells in 
the biopsy sample(s) taken 12 weeks after the end of treatment. All biopsy 
samples, taken before, during and after treatment, will be taken around 
the same location. The site of the first biopsy is most likely the most evi-
dent lesion, causing a clinically visible lesion. The site of this biopsy will 
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be recorded in the Case Report File, to ensure other biopsies will be taken 
at the same area. Quality of life will be assessed before, during and after 
treatment, using 3 questionnaires on general health (EQ5D), dermato-
logical quality of life (DLQI) and (if applicable) sexual functioning (FSDS).
Safety will be evaluated by documentation of all adverse effects, recorded 
by the clinician, and by the patient in the patient diary. 
The immunological effect will be assessed by comparing the results of an 
additional immunohistochemistry stains performed on all 3 samples ta-
ken around the same location at baseline, 4 weeks after start of treatment 
and 12 weeks after end of treatment. All biopsies will be taken at about 
the same location, to ensure the local microenvironment is as similar as 
possible in all samples. There are limited data on the tumour microen-
vironment in VPD; currently we perform a pilot study to investigate the 
parameters in the immune infiltrate in VPD. We are investigating which 
immune cells are present in VPD, and will use this knowledge to further 
explore which immune cells respond to the topical imiquimod cream, and 
which role they play in the origin and treatment of VPD.
0 w Baseline 4 w 10 w 16 w 28 w 40 w 52 w 68 w
Mapping and mammography X
Written informed consent X
Require histological samples 
(incl. mapping) and mammog-
raphy results from referring 
hospital
X
Imiquimod 5% cream Start Stop
Consultation by phone X
Consultation at outpatient 
clinic of involved research 
clinic, containing:
X X X X X X X
• Vulvar examination, 
measurement and photo 
documentation
X X X X
• VAS score X X X X X X X X
• Tolerability questionnaire X X X
• Biopsy X X X
• EQ5D X X X
• DLQI X X X
• FSDS X X X
• Review patient diary X X X
Table 2 Study schedule presenting an overview of all study activities.
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Study endpoints
The main study outcome is the clinical response. This will be assessed 
by determination of the reduction in lesion size 12 weeks after the end of 
treatment. This will ensure any local skin effects caused by treatment will 
be healed at time of examination. All measurements during the study will 
be conducted by the same trained and experienced local clinician. Photo-
graphs for documentation will be taken with a ruler alongside the lesions. 
The comparison between the lesion size at the start of treatment and 12 
weeks after the end of treatment can lead to the following outcome:
• Complete response (CR): defined as disappearance of the lesion and 
histological confirmation of disappearance;
• Partial response (PR): defined as decrease by ≥50% of total lesion size;
• No response: defined as <50% decrease of total lesion size; 
• Progressive disease: defined as ≥25% increase of total lesion size or 
progression into invasive disease and/or adenocarcinoma.
Secondary outcomes are the safety, quality of life and the assessment of 
local immunological response. These outcomes will be assessed according 
to the following criteria:
• Safety: all adverse events that occur during the study will be collected 
by the clinician at every consultation (at the clinic or via telephone) and 
by the patient using a standardised patient diary.
• Quality of life: results of the 3 questionnaires (EQ5D, DLQI and, if ap-
plicable, FSDS) taken before, during and after treatment will be com-
pared.
• Local immunological response will be assessed by a set of markers, 
to be determined, in tissue samples obtained by vulvar biopsy before, 
during and after treatment. 
Statistical analysis
An intention-to-treat (ITT) and per protocol (PP) analysis will be performed. 
The population included in the ITT analysis is defined as all patients that 
have started treatment with topical 5% imiquimod cream. PP analysis will 
include patients that have completed treatment with topical 5% imiquim-
od cream according to protocol: during 8 weeks. Two-tailed P values <0.05 
will be considered statistically significant. Our primary study parameter 
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is the clinical response to topical 5% imiquimod cream. Twelve weeks 
after the end of treatment the clinician will examine the vulva of the pa-
tient, and assign the patient in one of the response categories as defined 
above. Estimates of the percentage responders per response category will 
be presented, with corresponding 95% confidence intervals. The relation 
between treatment duration and dose versus response will be explored. 
Safety will be analysed in a descriptive manner, presenting all adverse 
events (local and systemic) in all subjects treated with topical 5% imiqui-
mod cream. Also the use of painkillers, lidocaine ointment and discontin-
uation of treatment will be reported.
Quality of life will be assessed by three questionnaires. The EQ5D results 
will be converted to the crosswalk index values, using the Crosswalk In-
dex Value Calculator.37 The DLQI results will be categorised according to 
the instruction manual, ranging from ‘no effect at all at patients life’ to 
‘extremely large effect on patients life’.38 The result of the FSDS is the sum 
of the answers. Descriptive statistics will be used to present the changes 
outcomes during treatment versus before treatment, and after treatment 
versus before treatment. A sub-analysis of responders and non-respond-
ers will be conducted.
The immunological results will be counted and compared between the 
different biopsy samples. These data will be reported in a descriptive man-
ner. 
Ethics
This study will be conducted according to the principles of the Declaration 
of Helsinki (2008) and the Medical Research Involving Human Subjects 
Act (Dutch: WMO). The protocol has been medical-ethically approved by 
the Medical-Ethical Committee of Arnhem-Nijmegen to be conducted in 
all 8 centres (NL51648.091.14). Before enrolment to the study, written 
informed consent will be obtained from all patients. 
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Results
The study opened for enrolment in January 2015. Currently, 17 patients 
are participating in this trial. The first results are expected in the summer 
of 2018.
Discussion
Currently, this study is the first prospective study examining the clinical 
efficacy of topical 5% imiquimod cream in patient with non-invasive VPD 
using a standardised treatment schedule during 16 weeks. In addition, 
this study will also be the first to investigate the safety, quality of life and 
immunological response of 5% imiquimod cream therapy in patients with 
VPD. 
Until now, about 25 retrospective case series have been published on this 
topic. These studies show high success rates. The effectiveness of topical 
5% imiquimod cream for VPD in these cases might be overrated due to 
publication bias in these retrospective cases. Most of the retrospective 
series have used different treatment schedules. The prospective trial of 
Marchitelli et al. used a different treatment schedule per patient.35 In most 
case studies, treatment was continued until the patient obtained a com-
plete response. The pilot study by Cowan et al. investigated the clinical 
response after 12 weeks of treatment in eight patients with non-invasive 
VPD.34 Patients applied the cream three times a week. Six patients had a 
clinical and histological complete response; the other two had a partial 
response with histological persistence. In our study, all 20 consecutive 
patients will be treated according to the same treatment schedule: 3 times 
a week for 16 weeks. Currently, there are no guidelines for topical 5% 
imiquimod treatment for VPD. We based the treatment schedule on the 
treatment schedule for condylomata acuminata, as this is a registered 
indication and therefore we consider this treatment schedule to be safe 
for the genital skin.31 Furthermore, VPD may be considered a vulvar pre-
malignancy, and the same treatment schedule is used in a previous ran-
domised controlled trial of imiquimod 5% for usual vulvar intraepithelial 
neoplasia.33 
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There are very limited data concerning the influence of VPD on everyday 
life of the patient. It is reported that vulvar surgery may contribute to 
decreased quality of life and sexual functioning compared to healthy pa-
tients. As VPD has high recurrence rates, we assume (repetitive) surgical 
treatment may have significant psychosexual effects on the patients. Top-
ical treatment with 5% imiquimod cream will not induce scarring, nor will 
it alter the anatomy of the vulva. Because there is a lack of data on this 
specific topic, we will investigate the quality of life with 3 different ques-
tionnaires before, during and after treatment. 
The mechanism of action and immunological effects of 5% imiquimod 
cream in vulvar Paget disease are uncertain. It is likely that imiquimods’ 
immune modulating effect induces a local immune response resulting in 
clearance of the Paget cells. Investigating the immunological response in 
biopsy specimen taken before, during and after treatment will provide 
insight in the local effects of imiquimod in the skin and also in the under-
lying mechanisms of action. Unfortunately, there is no current literature 
on this topic. Therefore we are conducting a pilot study, investigating the 
microenvironment of VPD, to assess which markers may be valuable in 
understanding the immunological response in VPD.
In conclusion, VPD remains an elusive disease. Surgery has been the 
treatment of choice over a century. Due to high recurrence rates and the 
vulnerable patient population affected by the disease, there is a need for 
other, less invasive treatment options. Topical 5% imiquimod cream may 
be an attractive alternative. Our trial will investigate the clinical efficacy 
of topical 5% imiquimod cream in 20 patients with a standardised treat-
ment schedule. This study will also evaluate the safety, quality of life and 
immunological response while using 5% imiquimod cream. 
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General discussion
Chapter 9
This thesis focuses on glandular lesions of the vulva, with a special interest 
in vulvar Paget disease (VPD). Due to its’ rarity there is limited knowledge on 
VPD. Worldwide there are few available guidelines on VPD: two guidelines 
from the Royal College of Obstetricians and Gynaecologists include VPD and 
several local guidelines, generally based on expert opinion and general prac-
tice. The aim of this thesis was to improve care for patients with VPD and im-
proving the knowledge on this disease by studying some clinical challenges.
In the Netherlands (population ~ 17 million), each year 10 to 15 women are 
diagnosed with any type of VPD. Due to the rarity of VPD, many clinicians 
are not familiar with this disease and may not recognise it. Fortunately the 
histopathological signs of VPD are very typical, so once a biopsy has been 
taken and the pathologist is familiar with vulvar pathology, the diagnosis 
VPD can be made rather quickly. 
However, the risks and consequences of VPD are unclear. This means most 
patients get limited information on the diagnosis VPD, and what to expect. 
For a long time, clinicians have been convinced that VPD is a life threaten-
ing malignant disease which may either metastasise to, or should be con-
sidered as a metastasis of malignancies of the breast, intestinal or urolog-
ical tract. Mostly, extensive locoregional surgery is advised to women who 
present with VPD. These statements are the main topics in this thesis, and 
are all rebutted to some extent. 
This leads us to the final conclusions which are important for all clini-
cians who may encounter VPD patients:
• Non-invasive VPD is a chronic skin disorder with a limited malignant 
potential;
• The risk of having a concurrent malignancy is very small;
• Treatment can be less invasive than extensive (perpetual) locoregional 
surgery.
Pathogenesis
VPD is considered to be an adenocarcinoma in situ of the vulvar skin. 
Little is known about the exact pathogenesis of VPD. The diagnosis is con-
firmed when typical Paget cells are seen in the vulvar skin but the origin 
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of these cells remains elusive. We are now almost 150 years after VPD was 
first described. And still, no-one has ever proven the origin of this disease. 
In the previous century, the skin adnexa were reported as the possible 
origin of Paget cells.1,2 A relatively recent study from 2006 investigated 
twelve cases of VPD or anal extramammary Paget disease (EMPD, i.e. 
 Paget disease located elsewhere than the breast).3 All cases showed Paget 
cells in the interfollicular epidermis, hair follicles, sebaceous and apocrine 
glands. In all cases, the Paget cells expressed CK19, a marker for follicular 
stem cells. 
A Russian study from 2016 investigated 178 specimens of 146 patients 
with primary anogenital EMPD.4 In more than 90% of the cases the skin 
adnexa were affected with disease, ranging from 3% of the apocrine secre-
tory coils to 82% of the hair follicles. 
The above mentioned studies suggest that the skin appendages of the 
vulva are a relatively common location for Paget cells. In mammary Paget 
disease (MPD) Paget cells are also suggested to have a glandular origin.5 
In MPD, the origin of the Paget cells is also unknown: the main hypothe-
sis is that Paget cells arise from ductal carcinoma cells, either invasive or 
not invasive, which migrated to the epidermis of the nipple. This is called 
the epidermotropic theory.6 A second theory is the transformation theory, 
in which keratinocytes transform in a malignant manner into Paget cells, 
suggesting VPD has a malignant potential. A third theory is the Toker cells 
theory7. Toker cells, which are polygonal, rather large, pale epithelial cells 
that may look like Paget cells. These cells are especially present in the nip-
ple region, and are seen as precursor cells that may transform into Paget 
cells. The origin of Toker cells is unclear; these cells were first described 
in the nipple and later on also suggested as precursor cells for VPD.8,9 The 
difference between Toker cells and Paget cells is defined as ‘the lack of cy-
tological stigmata of malignancy’, such as cytologically atypia, which can 
be seen in Paget cells.7 Besides, Toker cells contain melatonin.
Paget cells were first described in the nipple of cancerous breasts. There 
has always been a close link between MPD and EMPD, though, limited re-
search compared the two diseases. The main findings are the great variety 
in the presence of Paget cells and their molecular profiles in both MPD as 
well as EMPD.2,10 
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However, the natural behaviour of Paget cells in both the breast and vulva 
seems to overlap. From a histological point of view, it is almost impossible 
to distinguish the vulvar skin from the skin of the nipple: the nipple and 
the vulva contain the same tissue, which led to the suggestion of breast-
like tissue in the vulva. Mammary-like glands (MLG) are first described by 
Hartung in 1872 in a case of a patient who lactated from a vulvar lesion.11 
In 1994 van der Putte was the first to suggest EMPD originated from the 
MLG.12 
In another study, the previously mentioned Russian study group investi-
gated 181 cases of EMPD and found that all 4 cases with EMPD and an 
invasive carcinoma showed alterations in the MLG.13 MLG showed ductal 
carcinoma in situ, columnar cell change and columnar cell hyperplasia. 
In 6 cases the authors saw colonization of the MLG by Paget cells. The 
authors concluded that rare cases of primary EMPD may originate in the 
MLG, where the neoplastic Paget cells migrate into the epidermis and later 
may breach through the basal membrane. 
A different research group recently investigated whether MLG adenocarci-
nomas are immunohistochemically comparable to breast cancer.14 There 
are five different molecular types of breast cancer, see table 1. The author 
investigated whether four subtypes of breast cancer (luminal A, luminal 
B, HER2 and basal-like) were present in the MLG adenocarcinomas. This 
study reported it is impossible to distinguish a MLG adenocarcinoma from 
VPD, solely based on immunohistochemistry (IHC). Most cases of non-in-
vasive VPD were luminal A (70%), whereas only 29% of invasive VPD and 
14% of MLG adenocarcinoma were of this subtype. HER2 overexpression 
was more common in invasive VPD than in the non-invasive VPD: 43% 
versus 30%, which may trigger more aggressive tumour behaviour. The 
authors suggest this may be the reason why non-invasive VPD has a low 
malignant potential. And in cases of HER2 overexpression in invasive 
VPD, patients may respond to trastuzumab therapy. Previous studies re-
ported HER2 overexpression in non-invasive EMPD also,15-19 and two case 
reports include patients with HER2 positive EMPD with good responses to 
trastuzumab in combination with paclitaxel chemotherapy.20,21
As reported in chapter 3 of this thesis, studies that report on HER2 over-
expression in VPD show various results.23 Only one study investigated the 
presence of Ki67 in VPD, and found it was highly expressed (defined as 
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more than 5%) in about 30% of cases, but did not appear to correlate to 
the prognosis of the disease.24 VPD also seems to lack the hormone recep-
tors.25 This seems to strengthen the hypothesis that VPD is indeed most 
comparable to the breast cancer type Luminal A.
It is evident that Paget cells are related to glands. To truly understand the 
course of disease, it is necessary to understand where these cells originate 
and how they migrate and cause a skin lesion. One of the main issues in 
clarifying the pathogenesis is that, even though the vulva seems to be a 
small part of the female body, many theories are believed within differ-
ent groups of clinicians, pathologists and researchers. For example, some 
consider MLG to be the answer, whereas others deny the existence of such 
glands. From a pathological point of view, it can be very interesting to 
differentiate all separately involved glands and discuss whether these are 
involved. This causes the literature on this topic to become more and more 
divided into believers of separate types of glands. Whereas from a more 
pragmatic clinical point of view, it doesn’t matter which type of gland the 
cells come from as long as their malignant potential is clear, and how the 
symptoms they cause can be optimally cured. 
Molecular type Characteristics
Luminal A • Hormone receptor positive, and
• HER2 negative, and
• Low levels of Ki-67
• Low-grade malignancy, relatively good prognosis
Luminal B • Hormone receptor positive, and
• HER2 positive, or
• HER2 negative with high levels of Ki-67
• Slightly worse prognosis.
Basal-like (triple-negative) • Hormone receptor negative, and
• HER2 negative, and
• More common in BRCA1 gene mutation carriers.
HER2-enriched • Hormone receptor negative, and
• HER2 positive,
• High-grade malignancy, worse prognosis
• Targeted therapy possible.
Normal-like • Like Luminal A, but with slightly worse prognosis.
Table 1 Molecular types of breast cancer22
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Over the last several years, tumour immunology became an important 
topic within oncology. In many tumours the local microenvironment is 
investigated. For VPD little is known about the microenvironment. Chap-
ter 7 describes the study we conducted to explore the immune infiltrate 
in non-invasive VPD. We found a mixed-cell immune infiltrate main-
ly consisting of T-cells, macrophages and natural killer (NK)-cells were 
also present. We compared our findings to the immune infiltrate found in 
healthy controls and high-grade squamous intraepithelial lesions (H-SIL) 
of the vulva. The immune infiltrate in VPD differs from healthy controls, 
suggesting the presence of Paget cells either influences, or is influenced 
by the immune infiltrate. Another recent study investigated the immune 
checkpoint inhibitors CTLA4 and PD-L1 in both EMPD and MPD.26 PD-L1 
was not expressed in any of the tissue samples. CTLA4 was expressed 
occasionally in both mammary as well as extramammary tissue samples. 
The influence and role of the tumour microenvironment in VPD is yet to 
be determined. Understanding the tumour microenvironment will help to 
improve treatment and may enlighten the pathogenesis of the disease.
Clinical practice
Any doctor can perform a vulvar biopsy in a patient with a vulvar lesion. 
In case the pathology report comes back with the conclusion: “Non-in-
vasive primary/cutaneous Paget disease” the patient should be referred 
to an experienced gynaecologic oncologist, gynaecologist or dermatologist 
with a special interest for vulvar disease. The flowchart in figure 1 will aid 
clinicians in which diagnostics and treatment options can be considered. 
However, the patient needs to be informed of the diagnosis, which will lead 
her to asking questions:
Q: What is vulvar Paget disease?
A: Vulvar Paget disease is a chronic skin disease that causes an irritated, 
itching, scaling redness of the vulva. We don’t know how it originates. We 
found typical cells, called Paget cells in the skin of the vulva. 
Q: My family and I googled Paget and found something with bone disease, 
is that the same?
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A: No, both diseases are first described by an English doctor, James Paget, 
in the late 19th century, but there is no relation between VPD and the bone 
disease.
Q: My family and I googled Paget and found breast cancer, do I have can-
cer?
A: No, in the late 19th century a doctor called James Paget had 15 patients 
with a red, scaling nipple who all turned out to have breast cancer. A couple 
of years later, a French doctor called Dubreuilh, had a patient with a vul-
var lesion comparable to the nipple lesion Paget described. That’s where the 
name comes from. However, one in seven women will develop breast cancer 
in their live –unrelated to vulvar disease. Have you recently been checked? 
Otherwise I will examine you and order a mammogram to be sure.
Q: Can VPD be related to other cancers? Intestinal cancer runs in my 
family?
A: We used to think VPD is related to intestinal or urological cancer. We 
found that there are 3 types of VPD: VPD as a presentation of intestinal 
cancer, VPD as a presentation of urological cancer and strict cutaneous 
VPD. The pathologist, who microscopically examined the biopsy sample, 
has run additional tests on the tissue. We found that in your case, the le-
sion originates from the skin only. So we do not have to check for intestinal 
or urological disease. Unless you have other symptoms of these diseases? 
In that case we should evaluate to be sure. There is no information on VPD 
being hereditary. 
Q: Am I going to die from this disease?
A: The risk that you will die from non-invasive VPD is extremely low. Inva-
sive VPD, which is cancer, does influence survival severely. We know that 
+/- 8% of the patients with non-invasive VPD may develop invasion over 
several years; 92% does not. Therefore it is important we monitor the lesion 
very closely.
Q: Why did I get this disease?
A: We don’t know why certain patients get VPD, we also have not been able 
to identify risk factors for developing VPD. We know the disease is most com-
monly seen in elderly, postmenopausal patients. However, younger patients 
may also be affected. In general, VPD is extremely rare; each year about 10-
15 new patients are diagnosed in the Netherlands (~17 million inhabitants).
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Q: Are my children or sisters at risk?
A: This has not been a topic of research because the disease is extremely 
rare, but we have never found a report of different family members with 
VPD.
Q: Why are you referring me to another hospital?
A: Because each year, only 10-15 patients in the Netherlands are diagnosed 
with VPD. For such rare disease, we think it is important you see doctors 
who are experienced with treating and monitoring it. For sure, referring you 
to an oncology centre has no relation with a poor prognosis but is related to 
a very low incidence and the premalignant character of the disease.
Q: How is it treated?
A: That depends on the severity of your symptoms, the location and size of 
the lesion, your overall health and preference. There are different treatment 
options: a wait-and-see policy (not all lesions should be treated), it may be 
treated with a somewhat aggressive cream called topical 5% imiquimod 
cream, or surgery.
Future research
Research so far has proven that Paget cells are generally located in the epi-
dermis, close by the basal membrane and in the glands and hair follicles 
of the vulvar skin. The main challenge in VPD remains the clarification 
of the pathogenesis. Once the true origin of Paget cells is discovered, the 
natural course of disease can be evaluated. The main theories so far have 
focused on which part of the skin Paget cells arise from: skin appendages, 
Mammary-like glands, Toker cells. However, the effect Paget cells have on 
their surrounding cells is unknown. Maybe Paget cells originate in sub-
tracting hair follicles in the degenerating vulvar skin, and spread through 
the epidermis, being part of a natural development in the skin, with other 
factors causing the irritative symptoms? 
Pathologists faced with diagnosing VPD have no specific guidelines for re-
porting their findings regarding this disease. The pathologist’s conclusions 
have an enormous impact on the patient’s diagnosis and treatment. We ad-
vise the pathological report should at least describe whether the disease is 
invasive, and a immunohistochemistry panel to define the origin of disease.
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Still, a lot of debate is going on about the natural behaviour of Paget cells. 
They are thought to originate in the basal membrane of the skin or skin 
appendages, and migrate to the surface of the skin. But what happens in 
cases with invasive disease: how do they migrate the other way, and sud-
denly be able to invade through the basal membrane to the dermis and 
cause cancer? And what is the difference between ‘invasive VPD’ and ‘VPD 
with an underlying adenocarcinoma’? If the adenocarcinoma originates in 
the deeper layers or glands of the skin, and extends to the epidermis, are 
surrounding epidermal Paget cells part of that malignancy? Or does the 
patient have two diagnoses: a vulvar adenocarcinoma and non-invasive 
VPD?
Further research should be focussed on bringing the pathological and 
clinical implications together. Ideally combining clinical data and tissue 
samples from different countries, from both MPD and EMPD patients to-
gether. As long as case series are the highest level of evidence, we are 
unable to solve the mysteries of Paget cells. An important step in resolving 
the origin of Paget cells may be their genetic makeup. The techniques to 
evaluate the genetics of different tumours and diseases are improving, 
which will reveal the origin of Paget cells and their correlations to the sur-
rounding healthy tissue and cancerous tissue. 
Also the tumour microenvironment can provide knowledge about the ori-
gin and natural behaviour of Paget cells. This will be further investigated 
in the Paget Trial, where the microenvironment in biopsy samples taken 
before, during and after treatment with 5% imiquimod cream for non-in-
vasive VPD.27 
When the origin of Paget cells is discovered, the true nature of the disease 
can be further explored and care for the few patients who suffer from this 
rare disease can be really improved. Moreover, the effectiveness of topical 
5% imiquimod cream may be better understood and treatment schedules 
can be improved. 
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Patientsuspected for VPD
Consultation:
Medical history including symptoms of breast, intestinal
and urological malignancies
Examination:
Complete physical examination including representative
vulvar biopsy of skin lesion
Histopathological examination of tissue:
Including IHC to distinguish cutaneous origin from non-
cutaneous origin. Suggestion: CK7/CK20/Uroplakin-III
Cutaneous VPD Non-cutaneous VPD
Vulvar mapping
Further examination:
Cystoscopy and/or
colonoscopy
Screening
negative
Screening
positive
Invasive
cutaneous VPD
Non-invasive
cutaneous VPD
Treatment:
According to
protocol for vulvar
adenocarcinoma
Treatment:
Topical 5% imiquimod cream
(off-label), watchfull waiting,
surgery
Individualised therapy, taking into account:
Location and extent of malignancy,
location and extent of vulvar lesions,
patient factors
Follow-up vulva:
Consultation every 3-6 months
In case of changes of the residual lesion or development of new
lesion:
Vulvar punch biopsy
Follow-up malignancy:
According to guidelines for individual case
Figure 1 Flow-chart for the work-up for patients with VPD
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Summary/Samenvatting
Chapter 10
Summary
Vulvar Paget disease (VPD) is a rare skin lesion most commonly seen in 
postmenopausal Caucasian women. It causes pain, itching or a burning 
sensation and presents as a scaling erythematous plaque. The symptoms 
resemble the nipple ulceration called mammary Paget disease, which is 
associated with breast cancer. Both types of Paget disease are confirmed 
when typical Paget cells are seen in a histological biopsy sample. Chapter 
1 describes the history of the disease and explains the anatomy of the 
vulva, followed by the pathogenesis and treatment of vulvar malignancies.
The incidence and survival of different glandular vulvar malignancies is 
described in chapter 2. Data of PALGA, a nation-wide database register-
ing all histo- and cytopathology in the Netherlands, was used to identify 
all cases of glandular vulvar malignancies between 2000 and 2015. Ad-
ditional data were retrieved via the Netherlands Cancer Registry. A total 
of 197 patients with a glandular vulvar malignancy were identified. Of 
these patients 55% had a primary malignancy while 45% had secondary 
malignancies: expansion of another tumour in 17% and metastases or 
recurrences of another malignancy in 28%. There is a great variety of 
different diagnoses of primary glandular vulvar malignancies: 11 different 
types were identified. VPD was most common, 30% of primary glandular 
vulvar malignancies was (micro-)invasive VPD. We found an overall inci-
dence rate of glandular vulvar malignancies of 0.9 – 2.5 per 1,000,000 
women per year. Five-year survival for patients with a primary glandular 
vulvar malignancy was 68.5%, which is comparable to patients with a vul-
var squamous cell carcinoma. Most of the secondary vulvar malignancies 
originated from (ano-) rectal malignancies. The great variety in diagnoses 
combined with the low incidence should lead to routine pathologic revi-
sion of these lesions and treatment in specialised gynaecologic oncology 
centres.
Chapter 3 presents an overview of the clinical aspects, histopathology, 
molecular genetics, and treatment options for VPD. Historically, surgi-
cal excision has been the treatment of choice. Recent studies show that 
imiquimod cream may be an effective and safe alternative.
In chapter 4 the current treatment schedules, recurrence rates and sur-
vival of patients with VPD were studied in a retrospective cohort study. 
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Data was collected in eight tertiary clinics throughout the Netherlands 
about 113 patients diagnosed with VPD between 1991 and 2016. The 
median age at time of diagnosis was 73 years. Non-invasive VPD was the 
most common diagnosis (77%). Most women were surgically treated (65%) 
while about 25% of the women with non-invasive disease used topical 
treatment. Almost 40% of women had one or more recurrences. Of wom-
en with non-invasive VPD 8% developed invasion during follow-up. There 
were no disease specific deaths reported in women with non-invasive VPD. 
The 5 year DSS was over 98% in non-invasive and microinvasive VPD, 
and significantly worse in invasive VPD: 50%. This study concludes that 
non-invasive VPD does not seem to affect survival of patients, and should 
be considered as a chronic vulvar skin disorder with a limited invasive po-
tential. In case of invasive disease survival decreases significantly. Based 
on the high recurrence rate lifelong surveillance of all VPD women is ad-
vised.
VPD has always been associated with mammary Paget disease. The ori-
gin of both diseases is still unknown. However, many clinicians consider 
patients with VPD at risk for different other malignancies, such as breast 
cancer, intestinal or urological malignancies. The aim of chapter 5 was 
to evaluate the risk of developing breast, intestinal, and urological ma-
lignancies in patients with VPD compared with the general population, 
and in particular with the focus on the risk of malignancy in patients 
with cutaneous non-invasive VPD. Data on the oncologic history of pa-
tients with any type of VPD between 2000 and 2015 were obtained from 
PALGA; follow-up data and a control group from the general population 
were obtained from the Netherlands Cancer Registry. After correction for 
age and calendar year at time of diagnosis, standardised incidence ratios 
(SIR) for the first three years after VPD diagnosis were estimated with 95% 
confidence intervals (95%CI). A total of 199 patients with a first diagnosis 
of VPD (164 non-invasive, 35 (micro-)invasive) between 2000 and 2015 
were identified. The SIR of developing an associated malignancy in the 
first 3 years after diagnosis was 4.67 (95%CI 2.66-7.64). This was mainly 
due to the high incidence of intestinal malignancies among patients with 
secondary VPD. Subgroup analysis for cutaneous non-invasive VPD did 
not reveal a significantly increased risk for associated malignancies i.e., 
SIR 2.08 (95%CI 0.76-4.62). In conclusion, of patients with VPD 76.9% 
is diagnosed with cutaneous non-invasive VPD, and this group has no 
increased risk for developing malignancies of the breast, intestinal or uro-
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logical tract. This study suggests that routine screening for these malig-
nancies in patients diagnosed with cutaneous non-invasive VPD may not 
be necessary. 
The association of VPD with intestinal malignancies is further explored 
in chapter 6. This chapter reports the first case of retrograde pagetoid 
spread from a rectal adenocarcinoma to the vulva and cervix. A 66-year-
old woman presented with postmenopausal bleeding and a history of 
Crohn disease. Gynaecological workup revealed vulvar and endocervical 
lesions consisting of Paget cells and adenocarcinoma, respectively. A rec-
tal adenocarcinoma with in situ adenocarcinoma was diagnosed. The sur-
gical specimen demonstrated Paget cells in the squamous epithelium of 
the anus and vulva. Immunohistochemistry demonstrated an intestinal 
phenotype of these cells. Genetic testing revealed the same TP53 mutation 
in tumour cells of the rectal adenocarcinoma and vulvar and endocervical 
lesions, demonstrating that the Paget cells originated from the same in-
testinal tumour.
The origin of Paget cells remains elusive. New effective treatment ther-
apies such as immunotherapy with topical Imiquimod cream suggests 
the microenvironment in VPD may play an important role in the origin. 
Chapter 7 describes the immune cell infiltrate in the microenvironment 
of vulvar Paget disease. The basic characteristics of the immune infiltrate 
in VPD were reported in samples of 10 patients; moreover the influence 
of imiquimod was studied in 6 patients. Immunohistochemistry for CD4, 
CD8, CD14, CD20, CD56 and FoxP3 was performed. The infiltrates of VPD 
were compared to vulvar high-grade squamous cell intraepithelial lesions 
(HSIL) (n=43), a HPV induced vulvar premalignancy with known response 
to imiquimod cream, and healthy controls (n=30). Immune cell counts in 
samples taken before and after treatment were compared. The microenvi-
ronment in VPD differs from the healthy vulvar skin and vulvar HSIL. VPD 
is characterised by less immune cells in the epithelium and an abundant 
number of immune cells in the stroma, consisting predominantly of T 
cells. The intraepithelial CD8+/Foxp3+ ratio and number of CD56+ in-
creased after imiquimod therapy, whereas the numbers of CD14+ cells de-
creased which may point to a treatment-induced type 1 immune response. 
Changes in immune cell counts after immune modulation in relation to 
clinical responses should be further investigated.
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Chapter 8 describes the study protocol of an ongoing study on topical 5% 
imiquimod cream for vulvar Paget disease, the Paget Trial (NCT02385188). 
This trial investigates the clinical efficacy, safety and immunological re-
sponse. The challenge of obtaining clear surgical margins may lead to 
extensive and mutilating surgery in patients with VPD. Even then, recur-
rence rates are high, ranging from 15% to 70%, which emphasised the 
need for new treatment options. A number of case reports, retrospective 
case series, and one observational study have shown promising results 
using the topical immune response modifier imiquimod. This multicenter 
observational cohort study includes eight tertiary referral hospitals in the 
Netherlands. Twenty patients with (recurrent) non-invasive vulvar Paget 
disease are treated with topical 5% imiquimod cream three times a week 
for 16 weeks. The primary efficacy outcome is the reduction in lesion size 
at 12 weeks after end of treatment. Secondary outcomes are safety, im-
munological response, and quality of life. Safety will be assessed by eva-
luation of adverse events and tolerability of treatment. To evaluate the 
immunological response, various immunological markers will be tested 
on biopsy specimens taken before, during, and after treatment. Quality of 
life will be assessed with three questionnaires taken before, during, and 
after treatment.
At last, chapter 9 hypothesises on the origin of Paget cells and the com-
parison with breast cancer and mammary Paget disease. It also includes 
a section to assist clinicians with counselling patients and a work-up for 
diagnostics and treatment. Finally, suggestions for future research are 
made.
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Samenvatting
Vulvaire morbus Paget (VPD), ofwel de ‘ziekte van Paget aan de schaam-
lippen’, is een zeldzame huidaandoening die vooral bij postmenopausale 
vrouwen van het Kaukasische ras voorkomt. Het veroorzaakt pijn, jeuk en 
branderigheid, en op de vulva is een schilferend erytheem te zien. De symp-
tomen lijken op die van de tepelafwijking ‘ziekte van Paget’, ofwel mammaire 
morbus Paget. Als deze afwijking wordt gezien is er vaak sprake van borst-
kanker. Beide types van de ziekte van Paget worden vastgesteld indien er 
typische Paget cellen zichtbaar zijn in een weefselbiopt. Hoofdstuk 1 be-
schrijft de geschiedenis van de ziekte van Paget, de anatomie van de vulva, 
gevolgd door de pathogenese en behandeling van vulvaire maligniteiten.
De incidentie en overleving van verschillende typen maligniteiten van 
de klieren van de vulva wordt in hoofdstuk 2 beschreven. Hiervoor is 
data gebruikt van PALGA: een nationale database waarin alle histo- en 
cytologische onderzoeken in Nederland worden geregistreerd. Alle casus 
van maligniteiten van vulvaklieren tussen 2000 en 2015 zijn geïdenti-
ficeerd. Aanvullende gegevens zijn opgezocht in de Nederlandse Kanker 
Registratie. Totaal zijn er 197 patiënten gediagnosticeerd met een ma-
ligniteit van de vulvaire klieren. Van deze patiënten had 55% een pri-
maire vulva maligniteit, en 45% secundair aan een andere maligniteit: 
doorgroei van een andere tumor in 17%, en een metastase of recidief van 
een andere tumor in 28%. Er is een groot aantal verschillende typen pri-
maire maligniteiten van de vulvaire klieren: er werden 11 verschillende 
types beschreven. VPD was het meest voorkomend: 30% van de primaire 
maligniteiten was (micro-)invasieve VPD. De incidentie van maligniteiten 
van de vulvaire klieren was 0,9 – 2,5 per 1.000.000 vrouwen per jaar. 
De vijfjaarsoverleving voor patiënten met een primaire maligniteit van de 
vulvaire klieren was 68,5%, vergelijkbaar als de overleving van patiënten 
met een plaveiselcelcarcinoom van de vulva. De meeste secundaire vulva 
maligniteiten hadden een intestinale origine: een (ano-)rectaal carcinoom. 
Gezien de grote verscheidenheid aan diagnoses, en de lage incidentie van 
deze aandoeningen zou revisie van de pathologie routinematig moeten 
plaats vinden, behandeling dienst plaats te vinden in gespecialiseerde gy-
naecologische oncologie centra.
Hoofdstuk 3 geeft een overzicht van de klinische aspecten, histopathologie, 
moleculaire genetica en behandeling van VPD. Van oudsher is chirurgie de 
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eerste keus behandeling. Recente literatuur laat echter goede resultaten 
zien van imiquimod crème, wat een effectief en veilig alternatief kan zijn.
In hoofdstuk 4 wordt een retrospectieve studie naar de huidige behan-
delschema’s, recidiefkansen en overleving van patiënten met VPD be-
schreven. In acht Nederlandse tertiaire centra werd data over 113 patiënt-
en die tussen 1991 en 2016 met VPD zijn gediagnosticeerd verzameld. De 
mediane leeftijd ten tijde van diagnose was 73 jaar. Niet-invasieve Paget 
was de meest voorkomende diagnose (77%). De meeste patiënten werden 
chirurgisch behandeld (65%), 25% van de vrouwen die niet-invasieve Paget 
had kreeg een topicale behandeling. Bijna 40% van de patiënten had één 
of meer recidieven. Van de vrouwen met niet-invasieve VPD ontwikkelde 
8% invasieve ziekte gedurende de follow-up periode. Er werden geen over-
lijdens veroorzaakt door niet-invasieve VPD gevonden. De ziekte specifieke 
vijfjaarsoverleving was groter dan 98% in niet-invasieve en microinvasieve 
VPD, maar significant slechter in de invasieve groep met een overleving 
van 50%. Dit onderzoek concludeert dat niet-invasieve VPD de overleving 
niet lijkt te beïnvloeden, en beschouwd kan worden als een chronische 
vulvaire huidaandoening met een beperkte maligne potentie. In het geval 
van invasieve ziekte is de overleving significant slechter. Op basis van de 
hoge recidiefkansen wordt geadviseerd alle patiënten met VPD levenslang 
te controleren.
VPD werd altijd geassocieerd met mammaire Paget. De origine van beide 
aandoeningen is nog altijd onbekend. Desondanks worden patiënten 
met VPD beschouwd als patiënten met een hoger risico op andere malig-
niteiten, zoals borstkanker, of maligniteiten van het maagdarm- of urogen-
itale kanaal. Het doel van hoofdstuk 5 was om het risico op geassocieerde 
maligniteiten van de borst, intestinaal of urologisch, te onderzoeken bij 
patiënten met primaire, vanuit de huid ontstane, niet-invasieve VPD. Ge-
gevens van de oncologische voorgeschiedenis van alle patiënten gediag-
nosticeerd tussen 2000 en 2015 met alle typen VPD werden opgezocht in 
PALGA; follow-up data en een controle groep uit de algemene populatie 
werden samengesteld uit data van de Nederlandse Kanker Registratie. Na 
correctie van leeftijd en kalenderjaar ten tijde van diagnose werden ge-
standaardiseerde incidentie ratio’s (SIR) berekend met een 95% betrouw-
baarheidsinter val (95% BI) voor de eerste drie jaar na de diagnose VPD. 
In totaal werden 199 patiënten met een eerste diagnose van VPD (164 
niet-invasief, 35 (micro-)invasief) tussen 2000 en 2015 geïdentificeerd. De 
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SIR voor het ontwikkelen van een geassocieerde maligniteit in de eerste 
drie jaar na de diagnose VPD was 4,67 (95% BI 2,66-7,64). Dit werd voor-
namelijk veroorzaakt door de hoge incidentie van darmmaligniteiten bij pa-
tiënten met secundaire VPD. Subgroep analyse voor patiënten met cutane, 
niet-invasieve VPD liet geen significant verhoogd risico op geassocieerde 
maligniteiten zien: SIR 2,08 (95% BI 0,76-4,62). Concluderend heeft 76,9% 
van de patiënten met VPD de cutane, niet-invasieve variant. Deze groep 
heeft geen verhoogd risico op het ontwikkelen van maligniteiten van de 
borst, maagdarm- of urogenitale kanaal. Deze studie suggereert dat het 
standaard verrichten van aanvullend onderzoek naar geassocieerde malig-
niteiten ten tijde van de diagnose cutane, niet-invasieve VPD niet zinvol is.
De associatie van VPD met darmmaligniteiten wordt in hoofdstuk 6 verder 
onderzocht. Dit hoofdstuk beschrijft de eerste casus van een retrograde 
pagetoïde spread van een rectaal adenocarcinoom naar de vulva en cer-
vix. Een 66 jarige vrouw meldde zich met klachten van postmenopauzaal 
bloedverlies en een voorgeschiedenis van de ziekte van Crohn. Gynaecolo-
gisch onderzoek toonde vulvaire en endocervicale afwijkingen met respec-
tievelijk Paget cellen en een adenocarcinoom. Een rectaal adenocarcinoom 
met adenocarcinoma in situ werd vastgesteld. Het chirurgisch verwijderde 
weefsel bevatte Paget cellen in het plaveiselepitheel van de anus en vul-
va. Immunohistochemie toonde een intestinaal fenotype aan. Genetisch 
onderzoek liet dezelfde TP53 mutatie zien in de tumor cellen van het rect-
aal adenocarcinoom, de vulvaire en de endocervicale weefsels. Dit bevestigt 
dat de darmtumor de oorsprong van de Paget cellen is.
De origine van Paget cellen blijft dubieus. Nieuwe behandelmethodes zoals 
immunotherapie met topicale Imiquimod crème suggereert dat de het mi-
cromilieu van de cellen een belangrijke rol kan spelen in het ontstaan. 
Hoofdstuk 7 beschrijft het immuuncel infiltraat in het micromilieu van 
VPD. De basale kenmerken van het infiltraat als gezien in de weefselbiop-
ten van 10 patiënten met VPD worden beschreven. Tevens wordt de invloed 
van imiquimod op het immuun infiltraat bestudeerd in de weefsels van 
6 van deze patiënten. Immunohistochemie werd verricht voor CD4, CD8, 
CD14, CD20, CD56 en FoxP3. Het infiltraat bij patiënten met VPD werd 
vergeleken met het infiltraat gezien bij patiënten met vulvaire hooggradige 
squameuze intraepitheliale laesies (HSIL) (n=43), een HPV geïnduceerde 
vulvaire premaligniteit met een bekende respons op imiquimod behandel-
ing, en gezonde controle weefsels (n=30). Immuuncel aantallen in weefsels 
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genomen voor en na behandeling werden vergeleken. Het micromilieu in 
VPD verschilt van de gezonde vulvaire huid en van vulvaire HSIL. VPD 
wordt gekarakteriseerd door een immuungecompromitteerd epitheel en 
immuunrijk stroma, voornamelijk bestaand uit T cellen. De intraepithe-
liale CD8+/FoxP3+ ratio en het aantal CD56+ cellen zijn verhoogd na be-
handeling met imiquimod, terwijl het aantal CD14+ cellen afgenomen was. 
Dit kan duiden op een door de behandeling geïnduceerde type 1 immuun-
respons. Veranderingen in de aantallen immuuncellen na immunotherapie 
in relatie tot de klinische respons zullen verder onderzocht moeten worden.
Hoofdstuk 8 beschrijft het studie protocol van een lopen onderzoek naar 
topicale 5% imiquimod crème voor vulvaire morbus Paget, de Paget Tri-
al (NCT02385188). Deze trial onderzoekt de klinische effectiviteit, de vei-
ligheid en immunologische respons. Het is zeer moeilijk om bij de chirurg-
ische behandeling van VPD vrije snijvlakken te verkrijgen, dit kan leiden 
tot herhaaldelijke en mutilerende ingrepen. Zelfs als het lukt, worden 
recidiefkansen beschreven variërend van 15% tot 70%. Dit benadrukt 
de noodzaak voor nieuwe behandelopties. Een aantal case reports, ret-
rospectieve case series en een observationele studie hebben veelbeloven-
de resultaten van het topicale immuunmodulerende middel imiquimod 
beschreven. Deze multicenter observationele cohort studie loopt in acht 
tertiaire centra in Nederland. Twintig patiënten met (een recidief) niet-in-
vasieve VPD worden met topicale 5% imiquimod behandeld, 3 maal per 
week, gedurende 16 weken. De primaire uitkomstmaat is de effectiviteit, 
gemeten als afname van omvang van de laesie 12 weken na het eind van 
de behandeling. Secundaire uitkomstmaten zijn veiligheid, immunolo-
gische respons, en kwaliteit van leven. Veiligheid wordt onderzicht met het 
evalueren van bijwerkingen en verdraagbaarheid van de behandeling. De 
immunologische respons wordt onderzocht door verschillende immunolo-
gische markers te testen op weefselbiopten die zijn genomen voor, tijdens 
en na behandeling. Kwaliteit van leven wordt onderzocht met behulp van 
een drietal vragenlijsten, ingevuld voor, tijdens en na behandeling.
Ten slotte wordt in hoofdstuk 9 verder in gegaan op de mogelijke origine 
van Paget cellen en de vergelijking met borstkanker en mammaire morbus 
Paget. Het omvat ook een ondersteuning voor artsen om patiënten met 
VPD te counselen, en een flowchart voor de diagnostiek en behandeling 
van de aandoening. Afsluitend worden er suggesties voor verder onder-
zoek gedaan.
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Abbreviations
BCC Basal cell carcinoma
CEA Carcinoembryonic antigen
CI Confidence Interval
CK Cytokeratin
DCIS Ductal carcinoma in situ
DFS Disease free survival
DSS Disease specific survival
EMPD Extramammary Paget disease
FIGO International Federation of Gynecology and Obstetrics
HE Haematoxylin and Eosin staining
HPV Human papilloma virus
HSIL High grade squamous intraepithelial lesion
ICD-O International Classification of Disease for Oncology
IFL Inguinofemoral lymphadenectomy
IHC Immunohistochemistry
IKNL Netherlands Comprehensive Cancer Centre  
(in Dutch: Integraal Kankercentrum Nederland)
ISSVD International Society for the Study of Vulvovaginal Disease
ITT Intention to treat; statistical analysis
MLG Mammary-like-glands
MMS Moh’s microsurgery
MPD Mammary Paget disease
NCR Netherland Cancer Registry  
(in Dutch: Nederlandse Kankerregistratie, NKR)
NOS Not otherwise specified
PDT Photodynamic therapy
PP Per protocol; statistical analysis
SCC Squamous cell carcinoma
SIR Standardised Incidence Ratios
SLN Sentinel lymph node
TNM Tumour Node Metastasis
VIN Vulvar intraepithelial neoplasia
VPD Vulvar Paget disease
VSCC Vulvar squamous cell carcinoma
WHO World Health Organisation
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Dankwoord
Eenieder die mij kent weet dat kort & bondig niet aan mij is besteed. In de 
wetenschappelijke wereld bestaat er (gelukkig) zoiets als word counts, en 
daarom zijn mijn stukken tot redelijk leesbare lengtes geredigeerd. Gelukkig is 
er in mijn proefschrift ook één plaats waar less is more niet hoeft te gelden, en 
dat is hier. Ik ben namelijk ontzettend dankbaar voor iedereen die, op welke 
manier dan ook, heeft bijgedragen aan de totstandkoming van dit proefschrift.
Op de eerste plaats het promotieteam, prof. dr. Leon Massuger, dr.  Joanne 
de Hullu en dr. Johan Bulten.
Beste Leon, tijdens een onderzoeksoverleg zoals zo velen sprak je de -voor 
mij- legendarische woorden: “Misschien moeten we het gewoon doen… 
Een boek schrijven over Paget.” Vanaf dat moment kon ik eindelijk los om 
uit te gaan zoeken wat me al maanden bezig hield: wat is Paget? En als ik 
dan eindelijk had bedacht hoe het wel zou moeten zijn, kwam je met een 
kritische vraag, een nieuw idee of bleek er een gen gemuteerd. Hoe die rare 
cellen nou precies werken kan ik nog steeds niet uitleggen, maar dankzij 
jouw sturing lijken we toch een stap dichter in de buurt.
Beste Joanne, zonder jouw fantastische begeleiding was dit boekje er  nooit 
gekomen. Ik bewonder je ontzettend. Je bent een ontzettend fijne dokter 
voor je patiënten (ze komen niet voor niets vanuit heel het land), een en-
thousiaste wetenschapper met talloze ideeën, voorzitter en lid van zoveel 
verschillende aldanniet werkgerelateerde clubs en verenigingen. Maar 
vooral een heel erg fijn persoon, eerlijk en betrokken. En waarschijn lijk 
hebben de meest waardevolle dingen die ik van je heb geleerd niet eens 
met de wetenschap te maken.
Beste Hans, ik ben maar wat blij dat ik het (als een van de weinigen!) heb 
geschopt tot een hoekje op je tafel. Dank voor je kritische noten op alle 
stukken en je enthousiasme, en laten we niet vergeten dat ik tussen de 
coupes door dankzij jou toch ook weer wat soeprecepten en reisideeën 
rijker ben geworden.
Geachte leden van de manuscript commissie, professor de Jong, professor 
Amant en professor Hollema, dank voor jullie tijd en beoordeling van het 
manuscript.
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Dit proefschrift had nooit bestaan zonder de patiënten die er aan mee 
hebben gewerkt. Dankzij deze vrouwen, die zich aan een nieuwe behan-
delmethode durfde te wagen, kon ik mijn onderzoek doen. Dank voor al 
jullie vertrouwen en medewerking! Ik hoop dat er snel wél antwoord komt 
op al jullie vragen waar we tot nu toe nog geen informatie over hebben, en 
dat we de ultieme behandeling voor jullie vinden.
Onderzoek doen naar een aandoening die op basis van histologie gediag-
nosticeerd wordt, betekent dat ik ook veel tijd op de afdeling pathologie 
heb doorgebracht. Dr. Peter Bult, dank voor je frisse blik, secure werk en 
doordachte commentaren. Als ik na uitgebreide discussies eindelijk dacht 
te snappen hoe het zou kunnen werken met al die gekke celletjes, kwam 
er vanuit jouw expertise als mamma-patholoog toch weer iets waar we nog 
niet aan hadden gedacht. Jouw gegrinnik over de mogelijke noodzaak van 
mammografieën is de drijvende kracht achter hoofdstuk 5 geweest: als jij 
het niet zag moest het toch maar eens goed uitgezocht worden! Dr. Steven 
Bosch, dankzij jouw bijscholing in de vulvapathologie wist ik eindelijk 
waar ik naar keek. Het heeft me vooral geleerd dat het vak van de patho-
logie maar ingewikkeld is, en die cellen zich niet aan de boekjes hou den. 
Ik wens je veel succes met je verdere carrière, waar we elkaar hopelijk 
nog eens tegenkomen bij een tumorwerkgroep. Prof. dr. Iris Nagtegaal, 
dank voor uw bijdrage aan hoofdstuk 6. Dankzij de samenwerking tussen 
de gastrointestinale en gynaecologische pathologie hebben we een zeer 
bijzondere casus kunnen uitdiepen. Het secretariaat van de afdeling pa-
thologie, met in het bijzonder Els Schut, voor het opvragen en versturen 
van de materialen, het lab voor het maken van mijn blokjes, en uiteraard 
Beyhan die met stralende glimlach talloze coupes uit alle archiefkasten 
heeft weten te traceren!
Al vroeg in het traject begon de samenwerking met het LUMC. Dr. van 
Poelgeest, beste Mariëtte, dank voor al je hulp en enthousiaste begeleiding 
op afstand de afgelopen jaren. Waar het mij duizelde tussen alle immuun-
cellen werd jij alleen maar enthousiaster. Ik ben benieuwd waar de re-
sultaten van onze pilot studie toe zullen leiden. Dr. Bosse, beste Tjalling, 
dank voor de uren coupes kijken, beoordelen, bediscussiëren, en de gast-
vrijheid op jullie afdeling en lab. Enno Dreef, voor alle werkzaamheden op 
het lab. En natuurlijk heel veel dank aan alle Ellen’s en Inge’s (en de ander 
promovendi van de Leidse pathologie afdeling) voor de open ontvangst in 
jullie werkkamer, jullie wisten altijd weer een bureau vrij te maken, een 
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lege coupedoos te traceren of de coupe-scanner aan de praat te krijgen. Ik 
wens jullie allen veel succes met de afronding van jullie promotieonder-
zoek en verdere carrières.
Dr. van Esch, beste Edith, jouw proefschrift lag al standaard ter inspiratie 
op mijn bureau, en toen kwam je nog naar Nijmegen ook. Wat fijn dat je 
jouw expertise op mijn werk hebt laten schijnen en bereid was er aan mee 
te werken, je hebt mij wegwijs gemaakt in de wereld van de immunologie.
Beste Sophieke, dank voor je engelengeduld om urenlang celletjes te tel-
len! En natuurlijk alle onderzoekers-tuin-gezelligheid.
Beste Dr. Joanna in ’t Hout, het is heerlijk om met een statisticus als jij 
samen te werken. Je overziet meer dan alleen de cijfers, je denkt mee over 
de opzet, uitvoering, klinische relevantie en haalbaarheid. Iets wat voor 
een klinisch onderzoeker van onschatbare waarde is.
Dr. van der Aa en Dr. Schuurman, beste Maaike en Melinda, heel veel 
dank voor de samenwerking aan hoofdstukken 2 en 5. Dankzij jullie aan-
vullende data en analyses hebben we prachtige overzichten van zeldzame 
aandoeningen en casuïstiek kunnen maken. 
Mijn tijd als onderzoeker begon met het opzetten van de landelijke Paget 
Trial. Deze multicenter studie is van de grond gekomen dankzij de fijne 
samenwerking met alle hoofdonderzoekers: Dr. Marc van Beurden, drs. 
Colette van Hees, drs. Eleonora van Dorst, Dr. Manon van Seters, Dr. 
Brigitte Slangen en Dr. Dorry Boll. Maar later natuurlijk ook Dr. Maaike 
Oonk, drs. Lena van Doorn, drs. Iris Hendriks, Dr. Martha Esajas, Dr. 
Refika Yigit, Dr. Nienke van Trommel, Helma van Berkum, en alle andere 
verpleegkundig specialisten/research nurses. Allen zeer bedankt voor het 
meedenken over het protocol, het includeren van de patiënten, en steeds 
weer dat CRF faxen.
Dirk van den Brand, dank voor het maken van de blokjes, ze zijn goud 
waard!
Ook veel dank aan Dr. Guus Fons en Dr. Christianne Lok voor jullie 
medewerking aan de klinische serie.
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Dank aan alle gynaecologisch oncologen van het Radboudumc voor de 
interesse naar mijn onderzoek, support vanuit de zaal op congressen en 
gezelligheid op de Nijmeegse avonden.
Professor Jan Kremer, zonder u was ik waarschijnlijk nooit aan de weten-
schap begonnen. Dankzij uw begeleiding op afstand tijdens mijn weten-
schappelijke onderzoeksstage en mentorschap in de jaren daarna ben 
ik zo ver gekomen. Ik hoop de komende jaren nog regelmatig te mogen 
komen vertellen hoe het verder gaat.
In de loop der jaren heeft zich het fenomeen van de Nijmeegse Vulva-
meisjes ontwaard: ik mag mij nu als 6e aansluiten. Irene, Hedwig, Kim, 
Loes, en Floor, dankzij jullie lag er al een gebaand pad voor mij vrij. Anne-
Floor, succes met het voortzetten van deze traditie. En dat er nog maar 
velen mogen volgen!
Alle tuinbewoners, bedankt voor de gezelligheid, de publicatie- en ver-
jaardagstaarten, de kerstlunch, de vele, vele borrels, en de onderzoeks-
weekendjes. Dankzij jullie ben ik altijd met veel plezier naar de tuin ge-
komen. Special shout out aan de betrokkenen van de FrESGO Vissenkom 
in Nice, de vulvameisjes in Torino, de Portuganzen, en de Weense dele-
gatie.
Janneke Hoogstad, uiteindelijk is het échte begin van dit proefschrift aan 
jou te danken. Een rustige nachtdienst als co-assistent waarin je het idee 
had om mijn PICO misschien daadwerkelijk op te schrijven en te publi-
ceren. Het duurde een paar jaar, en van het een kwam het ander. Ik hoop 
je nog vaak tegen te komen in de komende jaren, en ben heel benieuwd 
naar jouw boekje. 
En natuurlijk de dames van het secretariaat, in het bijzonder Yvonne, die 
altijd de meest onmogelijke agendaverzoeken van me kreeg. En natuurlijk 
Wilma, meestal was mijn net gehaalde thee alweer op eer we uitgekletst 
waren over de vierdaagse, ouderdom, en wat nog meer...
Heel veel dank aan alle gynaecologen, assistenten, verloskundigen en ver-
pleegkundigen op de afdeling Verloskunde en Gynaecologie van het Rijnstate 
Ziekenhuis. Ik werd door jullie in een warm (beval)bad ontvangen, en heb 
dankzij jullie geleerd wat er nog meer is dan zeldzame vulva-aandoeningen. 
Appendices
191 
En dan de Roeimeisjes! Heerlijk om iedere zaterdag na het (onmeunig 
vroege) roeien met jullie koffie te drinken op Arnhems mooiste terras. 
Ongelofelijk hoeveel appgroepen we in het leven hebben geblazen. Lieve 
coaches, ik snap niet hoe jullie het volhouden met al dat geklets over de 
snit van het roeipakje, wenkbrauwen, zwangerschapskwaaltjes, etcetera. 
Dank voor jullie verwoedde pogingen ons tussendoor harder te laten roei-
en: het werkt nog ook! Speciale dank aan de DDS, Voga Longa en Elf-
steden equippe, waaruit maar weer blijkt dat marathonroeien tot legen-
darische stellingen kan leiden.
Ploeg Pils, dankzij jullie is het wonen in Arnhem écht leuk. Altijd iemand 
in voor een borrel, koffie, serieus gesprek, ijsje, film, (disco)dansen, foute 
kattenplaatjes, en laten we onze (nu al!) legendarische BBQ’s niet ver-
geten.
En natuurlijk ook aan mijn medebestuursleden, Richard, Kees,  Diederik 
en Lous (en natuurlijk ook Erik, Monique en haar voorganger). Iedere 
maand proberen we allemaal het reilen en zeilen van onze mooie vereni-
ging nóg mooier te maken, elk met een andere achtergrond en andere 
roeidoelen, en daar geniet ik enorm van. 
Lieve Ignatia, Tosti en Polletje: wanneer gaan we nou eindelijk eens een 
weekendje weg om onze artsenbul te vieren? Deze keer ergens waar ze wel 
wc-deuren hebben in plaats van gordijnen?
Lieve Ninke, hoe veel kilometers hebben wij (lopend of rijdend) zij aan zij 
afgelegd? I would walk 500 miles, and I would walk 500 more, want ik heb 
je lief, 14 bloemencorso’s lang...
Lieve Marieke, wat kan ik heerlijk met je eten, wijn drinken en goede 
gesprekken voeren. Maar goed dat we toen naast elkaar zijn gaan zitten 
bij wiskunde. Al is dat vrees ik ook wel de oorzaak dat ik niet zo goed was 
in wiskunde…
Lieve Willemijn en Maya (en ook Coen, Fred, Floor, Otto, en de volgende 
mini die precies voor vandaag gepland is), al 10 jaar lang eten we samen. 
Ondertussen lukt het niet meer om dit íedere maandag te doen, en is 
Grey’s volgens mij ook al lang niet meer op tv… We delen lief en leed 
met elkaar. Jullie enthousiasme en oprechte trots voor mijn wetenschap-
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pelijke triomfen, en de spiegel die jullie me voor houden als ik weer eens 
te kort door de bocht ga betekenen veel voor me. Ik ben apetrots op hoe 
jullie werk, man, huis en babies weten te managen, en dat jullie dan ook 
nog tijd voor mij vrij weten te maken…
Lieve Joske, mijn belastingadviseur, bouwkundig ingenieur, afstands-
roei-coach, poezen-mattie, IKEA-mede-fanaat en paranimf. Ergens tus-
sen Marokko en Volendam was het wel duidelijk dat we niet zomaar 
co-groepgenootjes waren. Ik vind het super dat je nu naast me staat, want 
met zo’n rots in de branding moet het goed komen! 
Lieve Marline, dankzij jou heb ik: een bureau toegewezen gekregen in de 
tuin, altijd kunnen navragen hoe je precies alle CMO papierwerkjes in 
moest vullen, geleerd hoe je officieel een studie zou moeten monitoren, 
gemiddeld 25 mailtjes per dag aan onzin geschreven, een dubieuze vermel-
ding als bedpartner in jouw proefschrift, een jaarlijkse chocolade-peper-
notentraditie, de ghetto van Colombia bezocht, Sri Lanka’s belangrijkste 
chefkok ontmoet, nooit –d/-t foutjes in mijn teksten, een superleuke col-
lega, en nu ook nog eens een fantastische paranimf. De afgelopen jaren 
waren lang niet zo leuk zijn geweest zonder jou!
Mijn lieve oma’s, waarvan ik er drie mocht hebben, die allen op hun eigen 
manier hebben meegeleefd met mijn onderzoek. 
En natuurlijk mijn ouders, van wie ik hou en zonder wie ik niet zou bestaan. 
Lieve Els, ik was een jaar of 6 toen jij in mijn leven kwam en ik vond het 
meteen leuk. Zo leuk, dat ik 7 jaar later -ietwat onverwacht- mijzelf full-
time in jouw leven uitnodigde. Ik waardeer enorm hoe je daar mee bent 
omgegaan en hoe je sinds het begin voor mij klaar hebt gestaan en alles 
wat je mij hebt meegegeven.
En dan, Meines Paps. Ik heb het geprobeerd hoor, achter de worst bij de 
Hema. Maar het werd tóch iets anders. Ik ben je enorm dankbaar voor hoe 
jij je altijd (en nog steeds) hebt ingespannen om te zorgen dat ik kon doen 
wat nodig was om mijn doelen te bereiken. Ik heb niet alleen mijn lengte 
van jou, we kunnen allebei verhalen vertellen met een introductie die zo 
lang is dat niemand meer naar de clou luistert, en als ik een gevatte op-
merking maak ben jij de eerste die ‘m doorheeft. Ik ben trots om je dochter 
te mogen zijn. 
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